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Summary 
In the present study a novel metabolic pathway for 4-and 5-chlorosalicylate degradation in 
Pseudomonas sp. strain MT1, a bacterial isolate derived from a  four-membered 4-chlorosalicylate 
degrading community, was elucidated.  
4-chlorocatechol, 3-chloromuconate and maleylacetate were identified to be metabolites of the 
pathway. Transformation of 4- and 5-chlorosalicylate was shown to be catalyzed by a salicylate 
1-hydroxy-lase. The reaction product 4-chlorocatechol was subject to intradiol cleavage by a  
catechol 1,2-dioxygenase with substrate specificity similar to enzymes of the  3-oxoadipate 
pathway. Thus MT1 is the first strain described  to mineralize chloroaromatics without the 
involvement of a dioxygenase specialized for chloroaromatic ring-cleavage. 
 
Transformation of 3-chloromuconate constitutes the core of the novel pathway and the responsible 
enzymes were identified and purified. Muconate cycloisomerase (MCI) catalyzed 3-chloromuconate 
transformation to mainly protoanemonin and minor amounts of cis-dienelactone and maleylacetate. 
Protoanemonin and cis-dienelactone are dead-end products of MT1 metabolism. A second 
muconate cycloisomerase (MCIB), transforms 3-chloromuconate to protoanemonin and cis-
dienelactone in equal amounts and is assumed to be an evolutionary intermediate  between 
muconate and chloromuconate cycloisomerases. Even though purified trans-dienelactone hydrolase 
(trans-DLH) acts neither on 3-chloromuconate, nor on protoanemonin, it was found that 
simultaneous presence of trans-DLH and one of the cycloisomerases yielded considerately less 
protoanemonin and more maleylacetate than when 3-chloromuconate was transformed by MCI or 
MCIB alone. As trans-DLH converts 4-fluoromuconolactone to maleylacetate, it is suggested that 
this enzyme hydrolizes 4-chloromuconolactone, the assumed intermediate of 3-chloromuconate 
cycloisomerization, and thus prevents protoanemonin formation in favor of maleylacetate 
formation. cis-Dienelactone formation was not effected by the presence of trans-DLH, indicating 
that its production does not necessitate the intermediate formation of 4-chloromuconolactone. 
Maleylacetate is channeled to the 3-oxoadipate pathway by a maleylacetate reductase (MAR). 
 
Detailed analysis of 3-chloromuconate transformation by the concomitant action of purified MCI 
(or MCIB) and trans-DLH revealed that product formation was not only dependent on the ratio of 
enzymes, but that higher protein concentrations favored maleylacetate formation over 
protoanemonin formation. Such a behavior can be explained by kinetic models describing the 
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reaction mechanism with a spontaneous degradation of 4-chloromuconolactone to protoanemonin 
competing with a trans-DLH catalyzed hydrolization of 4-chloromuconolactone to maleylacetate.  
 
MCI was induced to high activity during growth on salicylate and to a much lower extent during 
growth on chlorosalicylate. This indicates that MCI, despite its extraordinary high activity with 
3-chloromuconate is part of the 3-oxoadipate pathway of MT1. In contrast, MCIB and trans-DLH 
were predominantly induced during growth on chlorosalicylate. This suggests that MCI and MCIB 
belong to independent regulons. 
 
trans-DLH differs from previously described cis/trans-dienelactone hydrolases not only by 
substrate specificity, but also by its susceptibility to reducing and chelating agents. Partial protein 
sequences revealed no homology to previously described proteins. Thus, trans-DLH seems to be a 
member of a previously undescribed protein family. 
 
The MAR encoding gene is not localized in a chlorocatechol gene cluster, as none of the other 
typical enzymes forming such clusters was coinduced. MAR of MT1 was shown to differ from 
MAR TfdFI of JMP134 by its substrate specificity, being capable to transform cis-acetylacrylate. 
This activity could explain the previous observation of cis-acetylacrylate being a growth substrate 
for MT1, which had been misinterpreted as an indication for cis-acetylacrylate as a pathway 
intermediate in an earlier study (106). 
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1. Introduction 
1.1 Natural and xenobiotic aromatic compounds in the environment 
Aromatic compounds form a large class of organic molecules which contain one or more aromatic 
rings. They can be substituted and combined into large polyaromatic molecules, giving millions of 
possible different compounds (167). Aromatic compounds play an important role in natural carbon 
cycles as they are indispensable constituents of proteins and electron transport chains and important 
plant constituents such as hydroquinones, flavonoids or lignin (53, 156). Though, a wide variety of 
naturally occurring halogenated aromatics have been identified (5), most haloaromatic compounds 
present in the environment are products of human activity. The use of chloroaromatic compounds 
(eg. polychlorinated biphenyls (PCB) or  polychlorinated naphthalenes (PCN)) became popular in 
the beginning of the last century. Due to their high stability they found large application as 
inflammables, insulators, and preservative additives in coatings, colours, and organic solvents (96, 
166). Other chlorinated aromatics such as chlorinated dibenzofurans and dibenzodioxins were 
formed as by-products during production processes or incineration. Among others, polychlorinated 
naphthalenes have been identified as priority pollutants by the U.S. Environmental Protection 
Agency (57). It is the same chemical inertness that made chloroaromatics popular for many modern 
applications, now responsible for their persistence in the environment. Even though substantial 
progress has been made to reduce industrial pollution, also by limiting the number of applications, 
major accidents still occur and a considerable number of polluted sites exist. A prominent example 
is the industrial waste site near Bitterfeld, Germany, comprising a 25 km2 area and 2·108 m3 of 
groundwater contaminated predominantly with chlorobenzene, resulting in significantly increased 
atmospheric concentrations of chlorobenzenes  (11, 87, 117). Some of the contaminated sites are a 
high risk for contamination of drinking-water supplies and as such a substantial health hazard for 
current and future generations (160, 179).  
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1.2 Aerobic degradation of aromatic compounds by bacteria 
The degradation of aromatic compounds has been subject to intensive investigations (147). Under 
aerobic conditions a large variety of upper pathway reactions, which comprise only a few reaction 
types (121), most importantly mono- and dioxygenations (53), transform aromatics to a small 
number of central metabolites; dihydroxy derivatives, such as catechols or protocatechuate and 
gentisate which undergo oxygenolytic cleavage of the aromatic ring (50, 125) (Fig. 1). Gentisate is 
oxidized by gentisate 1,2-dioxygenases between the carboxyl-substituted carbon and the adjacent 
hydroxylated carbon to maleylpyruvate (44, 172, 186). Protocatechuate can either be cleaved in an 
introdiol (ortho-cleavage) or extradiol (meta-cleavage) fashion (50) and then be further metabolized 
to Krebs cycle intermediates (100, 101) (Fig. 1). 
 
Catechol           
OH
OH
COO-
COO- -COO-
CHO
OH
OH
OH
COO-
COO-
COO-
-OOC
OH
HO
COO-
HO
O
COO-
COO-
Protocatechuate           
ortho meta ortho meta
COO-
CHO-OOC
OH  
Figure 1: Catechol, protocatechuate and gentisate as central intermediates in aromatic degradative pathways. Modes 
of ring-cleavage of these intermediates are indicated. 
 
Catechols are the central intermediate of the degradation of aromatic hydrocarbons like benzoates, 
benzenes or phenols, amino acids and toluenes (50).  
Unsubstituted catechol can be readily degraded by the wide-spread catechol branch of the 3-
oxoadipate pathway (50, 100) (Fig. 4 A) which proceeds by ortho-cleavage of the aromatic ring by 
catechol 1,2-dioxygenase to cis,cis-muconate. Muconate is further transformed to muconolactone 
(4-carboxymethylbut-2-en-4-olide) by muconate cycloisomerase, followed by isomerization to 
enollactone (4-carboxymethylbut-3-en-4-olide) catalyzed by muconolactone isomerase. Enollactone 
hydrolase hydrolyzes enollactone to 3-oxoadipate. 3-Oxoadipate is further transformed by 
3-oxoadipate:succinyl-CoA transferase and 3-oxoadipyl-CoA thiolase to succinate and acetyl-CoA 
which can readily be mineralized in the Krebs cycle.  
Gentisate 
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Methylcatechols are generally metabolized via meta-cleavage. This reaction is catalyzed by a 
catechol 2,3-dioxygenase leading to 2-hydroxymuconic semialdehydes (6, 129, 176) which are 
further converted to the final pathway products, pyruvate and acetylaldehyde or their derivatives 
(161) (Fig. 2).  
 
O
O
OH
+
Pyruvate
Acetyl-
aldehyde
2-Hydroxymuconate 
semialdehyde
Catechol
catechol 2,3-
dioxygenase OH
CHO
COO-OH COO-
OH O
COO-
2-Oxopenta-4-ene acid
OH O
COO-
4-Hydroxy-2-oxohexanic acid
COO-H3C
 
 Figure 2: Degradation of catechols by the meta-cleavage pathway. 
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 Figure 3: Catechol as central intermediate in the aerobic degradation of aromatic compounds. 
 
Poly- and bicyclic aromatic compounds, such as naphthalenes, dibenzofurans and biphenyls, are 
transformed by so-called peripheral or “upper pathway” reactions, to central intermediates; 
naphthalenes and dibenzofurans are degraded via salicylates (32, 37, 182), biphenyls via benzoates 
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as intermediates (41) (Fig 3). Though direct ring fission of salicylate (59) has been described, the 
degradation of salicylate involves either transformation by a salicylate 5-hydroxylase to gentisate 
(40, 47) or by a salicylate 1-hydroxylase yielding catechol (121, 182, 184). 
 
 
1.3 Degradation of chlorocatechols by the specialized chlorocatechol pathway 
Various enzymes involved in the degradation of aromatic compounds such as toluene dioxygenase 
(43) benzoate dioxygenase (122) or salicylate hydroxylase (82) have been reported to be of 
relatively broad substrate specificity and to be capable to transform at least some lower chlorinated 
substrate analogues. Such activities usually result in the formation of chlorosubstituted catechols 
from chloroaromatics. Chlorocatechols, in most cases reported thus far, are degraded by enzymes of 
the chlorocatechol pathway, also called the modified ortho-cleavage pathway (30, 121, 124, 139). 
The chlorocatechol pathway (Fig. 4 B) involves ortho-cleavage by chlorocatechol 1,2-dioxygenase 
which is highly active with chlorocatechols (30), a chloromuconate cycloisomerase highly active 
with chloro-cis,cis-muconates (139), a dienelactone hydrolase active with cis- and trans-
dienelactone (4-carboxymethylenebut-2-en-4-olide) (139), and a maleylacetate reductase (70) that 
reduces the hydrolysis product, maleylacetate, to 3-oxoadipate. 3-Oxoadipate conversion into 
Krebs-cycle intermediates relies on the 3-oxoadipate:succinyl-CoA transferase and 3-oxoadipyl-
CoA thiolase of the 3-oxoadipate pathway. However, degradation of chlorocatechols  via a meta-
cleavage pathway has also recently been described (86). 
 
 
1.4 Comparison of the 3-oxoadipate and the chlorocatechol pathway 
1.4.1 Biochemistry of the 3-oxoadipate and the chlorocatechol pathway 
The first enzymes of the 3-oxoadipate pathway for catechol degradation and of the chlorocatechol 
pathway carry out identical reactions. Catechol 1,2-dioxygenase and chlorocatechol 
1,2-dioxygenase, respectively, cleave the aromatic ring of (chloro)catechols between the hydroxyl 
groups (ortho position) leading to the respective muconates (Fig. 4). However, these classes of 
enzymes differ significantly in their substrate specificity. Whereas chlorocatecol 1,2-dioxygenases 
from proteobacteria exhibit similar activities with catechol and 4- and 3-chlorocatechol activity of 
catechol 1,2-dioxygenases with 4-chlorocatechol and 3-chlorocatechol is low (10 % and 1 %) 
compared to its activity with catechol (13, 30, 121).  
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Figure 4: Transformation of catechol, 3-chloro-and 4-chlorocatechol by the proteobacterial 3-oxoadipate pathway 
(A) and chlorocatechol pathway (B). Postulated metabolites of hypothetical presence are embraced in brackets. 
 
Similarly, muconate cyloisomerases involved in the 3-oxoadipate pathway are reported to have a 
narrow substrate specificity being highly active with unchlorinated muconate, whereas their activity 
with 2- and 3-chloromuconate is very low (139, 169). In contrast, protobacterial chloromuconate 
cycloisomerases have a relaxed substrate specificity and thus can transform muconate, 2-chloro- 
and 3-chloromuconate with high activities (139). Whereas trans-dienelactone is the product formed 
from 2-chloromuconate by chloromuconate cycloisomerases, 3-chloromuconate yields cis-
dienelactone. However, whereas catechol- and chlorocatechol dioxygenases differ only in substrate 
specificity, muconate and chloromuconate cycloisomerases differ also in the reaction they catalyze 
(see 1.5).  
Muconolactone, the cycloisomerization product formed during catechol degradation via the 
3-oxoadipate pathway, is further transformed by muconolactone isomerase, a reaction which has no 
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counterpart in the chlorocatechol pathway. The enzyme shifts the double bond of muconolactone to 
form 3-oxoadipate enollactone (enollactone) and thus prepares the lactone for hydrolysis (103). In 
contrast, cis- or trans-dienelactone formed from chlorocatechols have a conjugated double bond 
adjacent to the lactone bond and can therefore be subject to direct hydrolysis. Hydrolysis of 
enollactone yields directly 3-oxoadipate, whereas hydrolization of dienelactones by cis-/trans-
dienelactone hydrolase release maleylacetate. It was already in 1980 described that the enollactone 
hydrolase of the 3-oxoadipate pathway and cis-/trans-dienelactone hydrolase of the chlorocatechol 
pathway show no cross-reactivity (132, 139). Reduction of maleylacetate to 3-oxoadipate by 
maleylacetate reductase in the chlorocatechol pathway has no analogous counterpart in the 
3-oxoadipate pathway.  
 
 
1.4.2 Genetics of the 3-oxoadipate and the chlorocatechol pathway 
The 3-oxoadipate pathway has been observed in a broad range of microorganisms. As it plays a key 
role in the catabolism of a wide variety of aromatic compounds, it is not surprising that this pathway 
is present in all four Pseudomonas species whose genome has been analyzed thus far (62). The two 
branches of the 3-oxoadipate pathway, i. e. the protocatechuate branch (pca genes) and the catechol 
branch (cat genes), converge at 3-oxoadipate enollactone in Pseudomonas. One set of enzymes 
(pcaDIJF gene products) complete the conversion of the latter to the Krebs cycle intermediates, 
succinyl-CoA and acetyl-CoA. In some other bacterial species such as Acinetobacter sp. ADP1, the 
catechol branch and the protocatechuate branch never converge and two independently regulated set 
of genes encode isofunctional enzymes for the last three steps of the pathway (62, 104).  In contrast 
to the chromosomally encoded 3-oxoadipate pathway, the chlorocatechol pathway is usually 
encoded on mobile genetic elements, often on plasmids (6, 32, 62, 161, 176) and generally  encoded 
by a single operon.  
Due to the biochemical analogies between the pathways, it was assumed that the chlorocatechol 
pathway had derived from the wide-spread 3-oxoadipate pathway (29). Indeed, proteobacterial 
catechol 1,2-dioxygenases and chlorocatechol 1,2-dioxygenases share 25 – 35 % amino acid 
identity, among catechol 1,2-dioxygenases the percentage of identical positions varies from 
27 - 58 %, and among chlorocatechol 1,2-dioxygenases from 55 - 66 % (34, 134, 162, 164). 
Muconate cycloisomerases and chloromuconate cycloisomerases share significant amino acid 
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identity of 40 -  45 % (133). In contrast, sequence similarities between enollactone and dienelactone 
hydrolases are not significant (133).  
 
 
1.5 Muconate and chloromuconate cycloisomerases 
Muconate cycloisomerase and chloromuconate cycloisomerase were first distinguished by their 
substrate specificity (139). Muconate cycloisomerases are active with unsubstituted muconate, but 
their activity with 2-chloromuconate, 3-chloromuconate and 2,4-dichloromuconate is very low. In 
contrast, chloromuconate cycloisomerases are highly active with chloromuconates, while their 
activity with muconate can be decreased (78, 139, 168, 169). 
Recent studies have demonstrated that chloromuconate cycloisomerases and muconate 
cycloisomerases also differ in the reactions they catalyze (8, 168, 171). Proteobacterial 
chloromuconate cycloisomerases transform 2-chloromuconate predominantly by 
3,6-cycloisomerization to 5-chloromuconolactone and by subsequent dehalogenation to trans-
dienelactone (78, 139, 140, 171) whereas proteobacterial muconate cycloisomerases catalyzes 
3,6- and 1,4-cycloisomerization with 2-chloro- and 5-chloromuconolactone as the final products 
(168) (Fig. 4) (168). 3-Chloromuconate is subject to cycloisomerization and dehalogenation by 
chloromuconate cycloisomerases with cis-dienelactone as product (139) whereas muconate 
cycloisomerases form toxic protoanemonin as product by an unknown mechanism (8) (Fig. 4). 
Chloromuconate cycloisomerases thus differ from muconate cycloisomerases in terms of: 
(i) increased turnover of 2-chloro-cis,cis-muconate, (ii) discrimination between the two possible 
cycloisomerization directions of this substrate, (iii) dehalogenation of (+)-5-chloromuconolactone, 
(iv) increased conversion  of (+)-5-chloromuconolactone, (v) increased conversion of 
3-chloromuconate and 2,4-dichloro-cis,cis-muconate and (vi) avoidance of protoanemonin 
formation during 3-chloro-cis,cis-muconate transformation (131, 169). Crystallization and studies 
of the three-dimensional structure of muconate cycloisomerase of Pseudomonas putida PRS2000 
(55) and chloromuconate cycloisomerase of Ralstonia eutropha JMP134 (49, 76) have provided 
new insights into substrate binding and catalytic mechanisms. Both muconate cycloisomerase and 
chloromuconate cycloisomerase consist of eight identical subunits, each containing an essential 
manganese ion at the active site (55, 76, 131). Comparisons of the reaction mechanisms of 
muconate cycloisomerase and mandelate racemase lead to postulation of an enol/enolate 
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intermediate formed during cycloisomerization (42, 55, 131). In the transformation of muconate, a 
proton is added to this intermediate resulting in the formation of muconolactone. 
Site-directed mutagenesis studies (72) showed that both, the formation of muconolactone from 
muconate or the formation of chloromuconolactones from 2-chloromuconate as well as the 
formation of  protoanemonin from 3-chloromuconate, as carried out by muconate cycloisomerases, 
requires protonation catalyzed by a lysine residue. In contrast, protonation is not necessary for the 
formation of cis-dienelactone as catalyzed by chloromuconate cycloisomerases (42, 72). Whereas 
dehalogenation of 3-chloromuconate seems to be a rather simple process, dehalogenation of 
2-chloromuconate is more complex. Structural studies on the wild-type and variants muconate 
cycloisomerase of PRS2000 suggested that dehalogenation necessitates the rotation of the lactone 
group of intermediary 5-chloromuconolactone, to give trans-dienelactone (131).  
However, even though site-directed mutagenesis studies had increased our knowledge on the 
reaction mechanisms of muconate and chloromuconate cycloisomerases, exchanges of specific 
amino acids at the active site of the muconate cycloisomerase of Pseudomonas putida PRS2000 
demonstrated that the putative evolution from muconate cycloisomerases to chloromuconate 
cycloisomerases of gram-negative bacteria cannot be mimicked by a single or double substitutions, 
but must be the result of a rather complex process (169).  
 
Contrary to information on proteobacterial muconate and chloromuconate cycloisomerases, there is 
only poor information on the respective enzymes from gram positive organisms. A muconate 
cycloisomerase and a chloromuconate cycloisomerase had been purified from the gram positive 
strain Rhodococcus opacus 1CP (33, 34). Like proteobacterial muconate cycloisomerases, 
muconate cycloisomerase of strain 1CP had only poor activity with chloromuconates. However, in 
contrast, this enzyme converted 2-chloromuconate to 5-chloromuconolactone as only products and 
was not capable to transform 2-chloromuconolactone. The 1CP derived chloromuconate 
cycloisomerase differed from the 1CP muconate cycloisomerase mainly by its capability to rapidly 
transform 3-chloromuconate and was as well neither capable to dehalogenate 2-chloromuconate nor 
to transform 2-cloromuconolactone (150). Recently, a second chloromuconate cycloisomerase was 
described from the same strain (90). Even though it exhibited higher turnover numbers with 
2-chloromuconate, this enzyme was as well not capable to dehalogenate 2-chloromuconate and 
5-chloromuconolactone was the only cycloisomerization product. None of the three protein 
sequences were highly related to muconate and chloromuconate cycloisomerases of gram negative 
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strains (34, 91). The metabolic diversity of (chloro)muconate cycloisomerases was further 
underlined by studies of Plumeier et al. who recently demonstrated that the chloromuconate 
cycloisomerase TfdDII  of the gram-negative bacterium Ralstonia eutropha JMP134 is also only 
distantly related to all other cycloisomerases characterized thus far and is unable to efficiently 
convert 2-chloro-cis,cis-muconate to trans-dienelactone (114). 
 
 
1.6 Enollactone hydrolases and dienelactone hydrolases 
Enollactone hydrolase and cis-/trans-dienelactone hydrolase (cis-/trans-DLH) catalyze hydrolysis 
of lactones in the 3-oxoadipate and the chlorocatechol pathway, respectively. The low sequence 
similarity (<12 % identical amino acid positions) (39, 133, 163) and the lack of cross-reactivity 
between enollactone hydrolases and cis-/trans-DLH with each others substrates (85, 95, 133, 139) 
disproves the hypothesis that cis-/trans-DLH of the chlorocatechol pathway was recruited from 
enollactone hydrolase of the 3-oxoadipate pathway (Fig. 4).  
Dienelactone hydrolases involved in the chlorocatechol pathway are usually active with both the 
cis- and the trans-isomer. Such a specificity is necessary as cis-dienelactone is the product formed 
during degradation of 4-chlorocatechol via 3-chloromuconate, and trans-dienelactone is formed 
during metabolism of 3-chlorocatechol via 2-chloromuconate by enzymes of the chlorocatechol 
pathway as described above. However, dienelactone hydrolases with more restricted substrate 
specificity  have been described by Schlömann et al. (137). The authors analyzed the degradation of 
4-fluorobenzoate by bacterial isolates and showed that various strains can mineralize this substrate 
without expressing chlorocatechol dioxygenase and chloromuconate cycloisomerase. Obviously 
enzymes of the 3-oxoadipate pathway capable to transform fluorosubstituted analogues were 
recruited. However, as described above, the metabolic routes of halocatechol and catechol 
metabolism diverge after cycloisomerization. It was thus expected, that growth on fluorobenzoate 
necessitates the induction of a dienelactone hydrolase and a maleylacetate reductase. The work of 
Schlömann et al. resulted in two new findings. Firstly, the authors observe 4-fluoromuconolactone 
but not cis-dienelactone as cycloisomerization product (135). Secondly, new types of dienelactone 
hydrolases were shown to be induced during growth on fluorobenzoate. Ralstonia eutropha 335, 
H16 and JMP222 (132, 137) induced a dienelactone hydrolase active only with trans-dienelactone. 
This enzyme was shown to be capable to transform 4-fluoromuconolactone and obviously together 
with a maleylacetate reductase recruited for 4-fluorobenzoate degradation.  
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Burkholderia cepacia was shown to harbor a dienelactone hydrolase exclusively active with cis-
dienelactone but the function of this enzyme in fluorobenzoate degradation was not evident.  
Rhodococcus opacus 1CP was recently reported to harbor a DLH with similar substrate specificity 
active only with cis-dienelactone (85) as part of a novel pathway for chlorocatechol degradation 
(89, 90, 91). This enzyme is obviously involved only in 4-chloro- and 3,5-dichlorocatechol 
degradation, which both are degraded via cis-dienelactones. Based on susceptibility to inhibition by 
p-chloromercuribenzoate, protein sequence comparison (about 20-30 % amino acid identity with 
proteobacterial cis-/trans-DLH) (34, 85) R. opacus DLH was suggested to be closer related to 
proteobacterial cis-/trans-DLH than to cis-DLH of B. cepacia indicating that substrate specificity is 
not necessarily a valid property for classification of the DLH (85, 133). 
Above mentioned results on Rhodococcus raised the question, how 3-chlorocatechol is degraded by 
this strain, as cycloisomerization gives rise to 5-chloromuconolactone as product, which is not 
further transformed by the cycloisomerases of this strain. Prucha et al. had shown, that 
5-chloromuconolactone can be transformed at high activity by muconolactone isomerases of the 
3-oxoadipate pathway (119). In contrast to proteobacterial chloromuconate cycloisomerases, which 
catalyze the formation of trans-dienelactone (as dehalogenation necessitates a rotation of the 
lactone ring in the active site of the enzyme), muconolactone isomerase catalyze the formation of 
cis-dienelactone (119). Moiseva could show, that Rhodococcus opacus recruits a muconolactone for 
3-chlorocatechol degradation, thereby forming cis-dienelactone rather than trans-dienelactone as 
intermediate of 3-chlorocatechol degradation (89).  
 
 
1.7 Maleylacetate reductases (MAR) 
MAR catalyze the last step of the chlorocatechol pathway, the NADH- dependent reduction of 
maleylacetate to 3-oxoadipate (Fig. 4). Various substituted maleylacetates have been shown to be 
substrates for the enzyme. As the enzyme obviously catalyze a hydrid transfer to the C2 carbon, 
2-chloromaleylacetate is converted into an instable intermediate, which spontaneously eliminate 
halide forming maleylacetate, which is subject to a second round of reduction forming 3-oxoadipate 
(70). 
Most MAR encoding genes investigated so far are located in the specialized metabolic gene clusters  
encoding enzymes involved in aromatic (4, 35, 65, 152), and especially, chlorocatechol degradation 
(38, 67, 68, 79, 114, 143, 163). MAR is also involved in the degradation of chloroaromatics via 
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hydroquinones or hydroxyhydroquinones. In Sphingobium chlorophenolicum, 2,6-dichloro-
hydroquinone as intermediate of pentachlorophenol degradation is directly cleaved by PcpA 
dioxygenase. Evidence for the formation of 2-chloromaleylacetate was given (99, 180), which 
should arise after hydrolysis of the direct ring-cleavage product. MAR, as shown for the 
degradation of chlorocatechols, is assumed to channel 2-chloromaleylacetate into the Krebs cycle, 
and a MAR encoding gene pcpE was localized upstream of pcpA (16) but not clustered with other 
genes of the pathway. Similarly, degradation of 2,4,5-trichlorophenoxyacetate via hydroxyquinol by 
B. cepacia AC1100 or of 2,4,6-trichlorophenol by Ralstonia eutropha JMP134 involves 
maleylacetate reductases and their genes are not clustered with genes of the chlorocatechol 
pathway. In addition MAR play a crucial role in aerobic bacterial degradation of multiple aromatic 
compounds, such as resorcinol, 2,4-dihydroxybenoate (21) or nitro- or sulfoaromatics (35, 65, 152). 
Maleylacetate reductases thus fulfill functions in various different aromatic degradative pathways. 
 
 
1.8 Misrouting of aromatic compounds to toxic protoanemonin as dead-end product 
It is generally accepted that metabolites formed during transformation of aromatic compounds can 
be more toxic than the original substrate (52, 83, 128, 148). Consequently mineralization rather than 
incomplete biotransformation is important for bioremediation. Yet, the majority of microorganisms 
capable to transform substituted aromatics by unspecific peripheric reactions often does not harbor 
the appropriate enzymes for a lower metabolic pathway – leading to metabolic misrouting and 
accumulation of dead-end products. Therefore it is not surprising that during metabolism of 
chloroaromatics, chlorocatechols often accumulate (48, 124) or are further transformed by enzymes 
of the wide-spread 3-oxoadipate pathway (8, 146), which leads to unproductive misrouting (Fig. 4).  
Blasco et. al described that catechol 1,2-dioxygenase transforms 4-chlorocatechol to 3-chloro-
cis,cis-muconate in analogy to the reaction catalyzed by chlorocatechol 1,2-dioxygenase. A toxic 
compound with antimicrobial activity, protoanemonin, is the product of 3-chloromuconate  
transformation by muconate cycloisomerase (8). Protoanemonin formation in turn was assumed to 
be the reason for the poor survival of PCB cometabolizing organisms in soil microcosms. Though 
the indigenous soil microflora was demonstrated to metabolize protoanemonin (7), no defined 
reaction or defined enzyme activity capable to transform protoanemonin has been characterized so 
far. As the only exception, protoanemonin has been observed to be a substrate, though a very poor 
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one, for cis-/trans-DLH of the chlorocatechol pathways (14) - no significant activity with 
protoanemonin has been detected for other DLHs. 
Protoanemonin formation has been shown to occur not only by misrouting of 4-chlorocatechol into 
the 3-oxoadipate pathway but also by misrouting of 3-chlorocatechol (146). As described above, 
muconate cycloisomerases catalyze cycloisomerization of 2-chloromuconate to form 2-chloro- and 
5-chloromuconolactone, which are both substrates for muconolactone isomerase. Whereas 
5-chloromuconolactone is transformed into cis-dienelactone, protoanemonin was shown to be 
formed from 2-chloromuconolactone, probably by elimination of CO2 and chloride from 
chlorosubstituted enollactone. Kinetic investigations of the reaction have shown high amounts of 
protoanemonin to be produced from 2-chloromuconate. Thus protoanemonin accumulation seems to 
be a general problem when organisms harboring a 3-oxoadipate pathway are confronted with 
chloroaromatics. 
 
 
1.9 Microbial communities 
The pioneering work by Louis Pasteur and the germ theory of disease presented by Robert Koch in 
1881 and 1884 describing the ability of pure cultures of microorganisms to cause disease, basically 
conceptualized the microbial research and until recently, most studies have been focused on pure 
cultures. However, in nature, microorganisms live in communities (18) and, even pure cultures 
grown for a considerable period of time tend to diversify (120). Despite competition with other 
species, there are several advantages for bacteria to reside in multispecies communities (145). Some 
of the benefits could be improved access to resources and niches that are not available for isolated 
cells. Problems resulting from accumulation of dead-end metabolites of a pathway of a single 
organism can be avoided in bacterial communities. Bacteria can interact metabolically by 
transformation of  “dead” metabolites of one strain by another strain (24, 51, 97, 106, 177). Thus, 
the metabolic potential of a community corresponds to the sum (or even more) of the metabolisms 
of the single cells in the system (145) and laboratory studies document increased biodegradation by 
mixed cultures (36). 
Enrichment culture techniques have traditionally been used to isolate single bacterial strains capable 
of metabolizing certain compounds, but recently the technique has been applied to isolate bacterial 
communities with special metabolic properties (6, 28, 45, 47, 77, 106, 137, 177). For example 
enrichment strategies by continuous culture techniques have allowed enrichment of a defined 
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bacterial community able to degrade 4-chlorosalicylate at GBF, Braunschweig, Germany, in a 
chemostat feed with 4-chlorosalicylate as only source of carbon and energy. The chemostat was 
inoculated with sediment from the aerobic zone of the creek Spittelwasser which flows into the 
river Elbe, sampled close to Bitterfeld, Germany, a site famous for its history of pollution by 
chemical industry (11, 87, 117, 179). A bacterial four strain community was enriched and the 
members Pseudomonas sp. MT1 , Empedobacter sp. MT2, Alcaligenes sp. MT3 and Pseudomonas 
sp. MT4 are present in stable relative amounts (84 ± 5% MT1, 8± 4%  MT3 and MT4 and 1 % 
MT2) (106). Inoculation of new chemostats with the four strains resulted reproducibly in 
reestablishment of the community with all four strains in the above described relative amounts. 
Though MT1 can grow in absence of the other strains on 4-chlorosalicylate as only carbon source, it 
never out-competes the others in the mixed culture indicating that their presence must be of benefit 
to MT1. For efficient substrate degradation via 4-chlorocatechol, as assumed for MT1 (106), 
metabolic fluxes must be well balanced to avoid accumulation of 4-chlorocatechol, which can be 
toxic to bacteria (108). The other strains might feed on misrouted and accumulated metabolites of 
MT1 and thus, enhance and stabilize growth of MT1. Supporting this view, it was demonstrated 
that the community could grow at higher dilution rates than MT1 as a monoculture (106).  
 
 
1.10 Strains of investigations 
1.10.1 Pseudomonas sp. strain MT1 
Pseudomonas sp. strain MT1 is the most abundant strain of the above mentioned 4-membered 
bacterial community (106). In addition, MT1 can grow on 4-chlorosalicylate, 5-chlorosalicylate, 
and non-substituted salicylate, but not on 3-chlorosalicylate in monoculture. As small amounts of 
4-chlorocatechol can be detected in the culture medium, 4-chlorosalicylate is assumed to be 
metabolized via the central intermediate 4-chlorocatechol (106). As only ortho-cleavage activity 
against catechol and 4-chlorocatechol, but no meta-cleavage activity has been described in MT1 cell 
extracts (106) and as transformation of catechol was more efficient than of 4-chlorocatechol, it was 
assumed that metabolism proceeds via the 3-oxoadipate pathway. Neither chlorocatechol 
1,2-dioxygenase nor maleylacetate reducing activity which are typical for the chlorocatechol 
pathway have been detected in cell extracts of MT1 (106). Blasco et al. have demonstrated earlier, 
(see 1.8, Fig. 4) that action of homogeneous catechol 1,2-dioxygenase and muconate 
cycloisomerase of the 3-oxoadipate pathway leads to quantitative transformation of 
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4-chlorocatechol to protoanemonin (8). Consequently Pelz et al. hypothesized that MT1 harbors a 
novel pathway of 4-chlorocatechol degradation including reactions of the 3-oxoadipate pathway via 
protoanemonin as intermediate (106). Earlier Brückmann et al. had described the capability of a cis-
/trans-DLH of the chlorocatechol pathway to convert protoanemonin to cis-acetylacrylate. In 
contrast, cis-DLH and trans-DLH were shown not to be active with protoanemonin (14). The fact 
that MT1 was able to grow on cis-acetylacrylate was claimed to support the hypothesis of 
protoanemonin as central intermediate of a new pathway which is hydrolyzed to cis-acetylacrylate. 
Unfortunately, Pelz et al. did not test for any dienelactone hydrolase activity, nor could they 
demonstrate any protoanemonin transforming activity in cell extracts. Neither was the fate of cis-
acetylacrylate investigated. Therefore, the metabolic pathway of chlorosalicylate degradation by 
MT1 remained highly speculative (106). However, the ability of MT1 to mineralize 
4-chlorocatechol without accumulation of bacterial-toxic protoanemonin, though it expresses 
enzymes of the 3-oxoadipate pathway, demands studying its novel metabolic properties. In addition, 
elucidation of the metabolic pathway of 4-chlorosalicylate degradation in MT1 will contribute 
essentially to understanding the metabolic network in the bacterial community MT1 was isolated 
from. 
 
The fact that MT1 is a Pseudomonas strain makes it an even more interesting study object. 
Pseudomonas is a very diverse genus belonging to the γ-subgroup of proteobacteria. Pseudomonas 
are rod shaped, gram negative bacteria which are found in large numbers in all major natural 
environments, in association with plants and animal, as well as human pathogens (154). Due to their 
remarkable physiological diversity (155) which are reflected at the genetic level (154), many 
Pseudomonas strains are able to metabolize or co-metabolize recalcitrant chemicals that are 
dangerous environmental pollutants or precursors to valuable products. Consequently, 
Pseudomonas is of outstanding interest for bioremediation or fine-chemical producing industry (31, 
138, 160, 173) and investigation of its metabolic potential and metabolic flux will lead to deeper 
understanding of bacterial metabolisms and novel applications. 
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1.10.2 Pseudomonas sp. strain RW10 
Similarly to Pseudomonas sp. strain MT1, Pseudomonas sp. strain RW10 is a member of a bacterial 
community, a two-strain consortium, which was enriched for growth on 3-chlorodibenzofuran from 
aerobic sediment samples of the Elbe river downstream of Hamburg harbor, Germany (177). 
Neither of the strains of the consortium can grow in pure culture on 3-chlorodibenzofuran. 
However, Pseudomonas sp. strain RW10 grows on 4-chloro and 5-chlorosalicylate, metabolites of 
chlorodibenzofurans degradation as well as on salicylate, as only source of carbon and energy, 
evidencing that the second strain, Sphingomonas sp. RW16, transforms 3-chlorodibenzofuran to 
4-chlorosalicylate which is used as growth substrate for RW10. Similar to cell extracts of MT1, 
RW10 cell extracts transform 4-chloro- and 5-chlorosalicylate in high yield (>70 %) to 
protoanemonin (8) and harbor activities of enzymes of the 3-oxoadipate pathway (catechol 
1,2-dioxygenase) (177), whereas degradative routes of (chloro)salicylate via catechol meta-
cleavage, chlorocatechol or the gentisate pathway have been excluded (177). In analogy to the 
hypothesized metabolic route in Pseudomonas sp. strain MT1 (106), Wittich et al. (177) 
hypothesized that RW10 mineralizes 4-chlorocatechol via protoanemonin as intermediate. During 
growth on chlorosalicylate, MT1 expresses a trans-dienelactone hydrolyzing activity at levels 
higher than those observed during growth on salicylate, indicative of its involvement in 
chlorosalicylate degradation. However, the authors could not detect any significant protoanemonin 
transforming activity in cell extracts. Moreover, purified trans-DLH of this strain had previously 
been shown not to exhibit any significant protoanemonin transforming activity (14). Despite this 
fact and due to the observation that  cis-acetylacrylate serves as carbon source for growth of MT1 
and RW10 it was speculated that protoanemonin might be transformed in RW10 and in MT1 by a 
hydrolase to cis-acetylacrylate (106). As trans-DLH evidently cannot fulfill this function it could be 
argued that the postulated protoanemonin transforming enzyme of RW10 is not active under in-
vitro assay conditions or becomes inactive by cell disruption and therefore has not been determined. 
Elucidation of the putative novel metabolic pathway in Pseudomonas sp. strain RW10 or MT1 will 
broaden our current knowledge on aerobic 4-chlorocatechol degradation. 
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1.11 State of the art and outline of the project 
Pseudomonas sp. strain MT1 and RW10 were assumed to both harbor a novel pathway of 
4-chlorocatechol degradation involving protoanemonin and cis-acetylacrylate as intermediates.  
Metabolic properties of the two strains were to be re-evaluated properly through analysis of 
metabolites and enzyme activities. As both strains contain a similar metabolic route, MT1 was 
chosen as type strain for more detailed analysis. It was observed that the pathway in MT1 is indeed 
novel, but that protoanemonin is rather a minor side-product and not a major metabolite of the 
pathway.  
The key enzymes of this metabolic route, two muconate cycloisomerases (MCI and MCIB) and a 
trans-dienelactone hydrolase (trans-DLH) were characterized in detail and the metabolism of 
4-chlorocatechol to 3-oxoadipate clarified.  
Maleylacetate reductase, which has its function in the new metabolic route by converting 
maleylacetate into 3-oxoadipate was observed to be active on  cis-acetylacrylate forming laevulinate 
as side activity, explaining previous misinterpretations of cis-acetylacrylate degradation as 
indication for its involvement in the pathway. 
Genetic analysis of the novel pathway was approached using degenerated primers deduced from the 
obtained protein sequences of the three key enzymes. A fragment of MT1 MCI was successfully 
cloned, sequenced and compared with other MCI and CMCI encoding genes. 
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2. Materials and Methods 
2.1 Bacterial strains 
The 5- and 4-chlorosalicylate degrading organism Pseudomonas sp. strain MT1 was isolated by 
continuous culture enrichment on 4-chlorosalicylate from sediment of the Elbe river (Germany) 
(106). Strain MT1 is the most abundant strain in a stable 4-membered community.  
Pseudomonas sp. strain RW10 (DSM 12647) and Sphingomonas sp. strain RW16 were enriched 
from aerobic sediment sample of the river Elbe downstream of Hamburg harbor (177, 178) based on 
their capability to degrade, as a two membered culture,  3-chlorodibenzofuran. Whereas RW16 
transforms 3-chlorodibenzofuran into 4-chloro and 5-chlorosalicylate as well as traces of salicylate,  
RW10, like MT1, can grow on salicylate, 4- and 5-chlorosalicylate as only source of carbon and 
energy. 
E. coli DH5ά containing the expression vector pTP20 (118) (for overexpression of chlorocatechol 
1,2-dioxygenase of RW71) and Ralstonia eutropha JMP222 containing pBBR1M-I (comprising the 
chlorocatechol gene module I of R. eutropha JMP134) (107) were used for partial purification of 
auxiliary enzymes.   
BL21-Gold(DE3)pLysS strain (Stratagene, La Jolla, CA, USA) was used for expression of wild-
type and mutant muconate cycloisomerases from P. putida PRS2000 which had been cloned into 
pET-11a*, a derivative of pET-11a vector containing Apr and PT7lac (157), by Vollmer et al. 
(169). 
E. coli JM109 was used for cloning of PCR fragments during the molecular part of this thesis (98). 
 
 
2.2 Culture conditions and preparation of cell extracts 
Liquid cultures of Pseudomonas sp. strain MT1 were grown in LB-medium (130) or in mineral salts 
medium (22, 28) using 50 mM phosphate buffer (pH 7.5). The medium was supplemented with the 
indicated carbon source, usually at 2.5 mM for chlorinated and 5 mM for unchlorinated carbon 
sources (salicylate or succinate). For growth curves, cultures were inoculated to an OD600 of 0.01-
0.015 with cells growing exponentially on the respective substrate. Cells were grown in fluted 
Erlenmeyer flasks, incubated at 30 oC on a rotary shaker at 150 rpm. Growth was monitored 
spectrophotometrically at 600 nm. Cells were harvested during late exponential growth by 
centrifugation with 9000 x g and resuspended in Tris/HCl buffer (50 mM, pH 7.5) supplemented 
with 2 mM MnCl2, and after addition of a trace of DNase I disrupted by passing twice through a 
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French press (Aminco, Silver Spring, MD, USA). Cell debris was removed by 30 minutes 
ultracentrifugation with 100,000 x g at 4 oC. 
 
 
2.3 Biochemical methods 
2.3.1 Enzyme assays 
All enzymatic assays were performed in 50 mM Tris/HCl, pH 7.5, 2 mM MnCl2 by following 
photometrical absorption changes upon enzyme addition if not stated otherwise. Assays were 
performed in a total volume of 1 ml (in 1 ml cuvettes) or 300 µl (in 500 µl cuvettes) in order to 
economize ingredients. 
Catechol 1,2-dioxygenase (EC 1.13.11.1) and chlorocatechol 1,2-dioxygenase (EC 1.13.11.1) 
were measured by determining the formation of muconic acid from catechol (ε260 = 16,800 l  M-1 
cm-1), 2-chloromuconic acid from 3-chlorocatechol (ε260 = 17,100 l  M-1 cm-1) and 3-chloromuconic 
acid from 4-chlorocatechol (ε260 = 12,400 M-1 cm-1), respectively (29). Here, 50 mM Tris/HCl, pH 
7.5 was used as buffer supplemented with 1 mM EDTA in order to deplete all present Mn2+ and 
thus preventing cycloisomerase activity. Substrates were supplied at 0.2 mM initial concentrations. 
Catechol 2,3-dioxygenase (EC 1.13.11.2) was measured by determining formation of 
2-hydroxymuconic semiladehyde from catechol (0.1 mM) (ε375 = 36,000 M-1 cm-1) (86) in 50 mM 
phosphate buffer, pH 8.0.  
Muconate and chloromuconate cycloisomerizing activities (EC 5.5.1.1)(EC 5.5.1.7)  Activities 
in cell extracts were determined by measuring the depletion of muconate or 2-chloromuconate 
which were added at 0.1 mM initial concentration with ε260 = 16,800 M-1 cm-1 and  
ε260 = 17,100 M-1 cm-1, respectively (29). 
  
When both 3-chloromuconate cycloisomerasing enzymes of Pseudomonas sp. strain MT1 were 
separated by FPLC, activity of partially purified MCIB could be detected photometrically by the 
formation rate of cis-dienelactone from 0.1 mM 3-chloromuconate. ε278 nm= 1505 M-1 cm-1 was 
calculated to be the reaction coefficient. 
Low activities of muconate cycloisomerases and MCIB with 2-chloro- and 2,4-dichloromuconate 
were determined by following incubation over up to 40 minutes with the photometer at 260 nm and 
HPLC analysis for substrate depletion. 
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Dienelactone hydrolase (DLH)  (EC 3.1.1.45) activity was determined by depletion of 0.05 mM 
cis- or trans-dienelactone (ε280= 17,000 (139) and ε280 nm= 15,625 M-1 cm-1, respectively) (137). In 
order to be capable to compare activities of different key enzymes in single and multi-enzyme 
assays (i), and as trans-DLH of MT1 was subject to a rapid inhibition during turnover in 10 mM 
histidine/HCl, pH 6.5 buffer (137) (ii), activity was determined in 50 mM Tris/HCl, pH 7.5, 2 mM 
MnCl2.  
Activities of trans-DLH with 3-chloromuconate (160 µM) or protoanemonin (100 µM) were 
determined by HPLC (Methanol-H2O (30:70)) using up to 80 U/ml (measured with trans-
dienelactone) of purified trans-DLH. 
3-oxoadipate enol-lactone hydrolase (Enollactone hydrolase), (EC 3.1.1.24) was assayed in 
50 mM Tris/HCl, pH 8.0 or 7.5 with 0.3 mM muconolactone and non-limiting excess of partially 
purified muconolactone isomerase (see below).  
Muconolactone isomerase (EC 5.3.3.4) activity in cell extracts or partially purified was 
determined in 50 mM Tris/HCl, pH 7.5 with 0.2 mM 5-chloro-3-methylmuconolactone as substrate 
following the formation of the respective dienelactone ε280 nm= 17,000 M-1 cm-1 (100). Combined 
activity of muconolactone isomerase and enollactone hydrolase in cell extracts was determined  by 
incubation in 50 mM Tris/HCl, pH 8 with 300 µM muconolactone and ε230 nm= 1,400 M-1 cm-1. 
Salicylate 1-hydroxylase (EC 1.14.13.1) (10, 185) was determined in 50 mMTris/HCl, pH 8.0 
supplemented with 1 mM EDTA and substrate concentrations of 0.2 mM salicylate, 4-chloro- and 
5-chlorosalicylate and NADH. Activities were measured by following the oxidation of NADH with 
ε340 nm= 6,220 M-1 cm-1.  The background activity of the cell extracts with NADH in the absence of 
substrate was determined and subtracted from the activity measured when substrate was present. 
Maleylacetate reductase (MAR) (EC 1.3.1.32) was measured in cell extracts or partially purified 
enzyme preparations in 50 mM Tris/HCl, pH 7.5 according to Seibert et al. (143), using 0.05 mM 
maleylacetate freshly prepared by alkaline hydrolysis of cis-dienelactone and 0.2 mM NADH. 
Activity was calculated from NADH oxidation was followed with ε340 nm= 6,220 M-1 cm-1. Assays 
without addition maleylacetate served as reference.   
Activities against cis-acetylacrylate or trans-acetylacrylate, respectively, were measured 
respectively using 0.05 mM cis-acetylacrylate and 0.1 mM NADH. Decrease of cis-acetylacrylate 
was also followed over time by HPLC analysis with Methanol-H2O (18:82).  
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Specific activities are expressed as µmol of substrate converted or product formed per minute per 
gram protein at 25 oC.  
 
 
2.3.2 Protein concentration 
Protein concentrations were determined by the Bradford procedure using the Bio-Rad (Hercules, 
CA, USA). Protein assay with bovine serum albumin as protein standard (12). Protein content of 
whole cells of MT1 grown on salicylate or 5-chlorosalicylate was estimated to be 
0.13 ± 0.03 g protein/l at an OD600 = 1 (this study). 
 
 
2.3.3 Resting cell assays 
Cells pre-grown on 5-chlorosalicylate were washed twice in phosphate buffer (50 mM, pH 7.4) and 
resuspended in 10 ml of the same buffer to give an OD600 = 1. After addition of substrate (1 mM), 
cells were incubated at 30 oC and 120 rpm for up to 5 hours. Samples of the supernatants were 
taken at different time points, cells were spinned down immediately in a Microcentrifuge 
(13000 rpm) and the supernatants were analyzed by HPLC. 
 
 
2.3.4 Transformation by cell extracts 
4-Chlorocatechol (200 µM) or 3-chloromuconate (0.055 – 0.43 mM) were incubated at room 
temperature in Tris/HCl buffer (50 mM, 2 mM MnCl2, pH 7.5) with extracts of 5-chlorosalicylate-
grown MT1 cells corresponding to final protein contents of 60 or 360 µg protein/ml. 
Transformation of 4- or 5-chlorosalicylate was followed in the presence of NADH (400 µM). 
Samples of the assays were taken over time and directly injected into an HPLC for identification 
and quantification of metabolites. 
 
 
2.3.5 In-situ transformation of 3-chloromuconate by partially purified enzymes of MT1 
Fractions eluted from chromatographic columns during partially protein purification were assayed 
for 3-chloromuconate transforming activity by HPLC analysis of assays containing 0.1 mM 
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3-chloromuconate and 1-5 µl of enzyme fraction in a total volume of 0.1 ml Tris/HCl (50 mM, 
2 mM MnCl2, pH 7.5).  
 
 
2.3.6 In-situ transformation of 3-chloromuconate by the combined action of a cycloisomerase 
and trans-DLH of MT1 
Product formation from 3-chloromuconate by purified MCI or MCIB in the presence of purified 
trans-DLH was analyzed by HPLC in assays performed at room temperature in 150 µl Tris/HCl 
(50 mM, 2 mM MnCl2, pH 7.5) with 40-300 µM 3-chloromuconate as substrate. In experiments 
with combined action of two enzymes, MCI was added to give an activity (determined by the 
transformation of 0.1 mM cis,cis-muconate) of 0.18 – 2.7 mU MCI/ml (determined with 0.1 mM 
cis,cis-muconate) and corresponding to 0.45 - 6.75 nM, whereas trans-DLH was added to those 
assays with increasing amounts ranging from 0.608 – 2523 mU trans-DLH (determined by the 
transformation of 0.05 mM trans-dienelactone) and corresponding to 0.041 – 168 nM.  
 
MCIB was added to 0.2 mM 3-chloromuconate to give an activity of 53 mU/ml (determined with 
0.1 mM 3-chloromuconate) (corresponding to 8.8 nM MCIB) throughout one set of mixing 
experiments, whereas the amount of simultaneously added trans-DLH varied from 1.3 - 
1302 mU/ml (determined with 0.05 mM trans-dienelactone and corresponding to 0.087 - 86.6 nM, 
respectively). In a second experiment 72 mU MCIB/ml (12 nM ) and 0.66 – 1980 mU trans-
DLH/ml (0.044 nM - 132 nM) were concomitantly added. 
 
0.1 mM 3-chloromuconate was incubated with MCI of Pseudomonas putida PRS2000 and trans-
DLH of strain MT1 or with MCIB of strain MT1 and cis-/trans-DLH (TfdEI) of Ralstonia eutropha 
JMP134 and products were quantified by HPLC analysis. Concentrations of the respective enzymes 
are given in the result’s part. 
 
 
2.3.7 Influence of enzyme inhibitors on trans-DLH activity 
5 mU/ml trans-DLH were incubated in the presence of EDTA (1 or 10 mM), o-phenanthroline 
(1 mM), HgCl2 (1 mM), ZnCl2 (1mM), CuCl2 (1 mM), or 4-chloromercurybenzoate (0.02 or 2 mM) 
in Tris/HCl (50 mM, pH 7.5). Samples of the incubation mixtures were tested for enzyme activity 
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with the standard photometrical assay as described above at various time points up to 24 hours. 
Specific inactivation was assessed by comparison of the remaining activity in those assays to a 
control incubated without inhibitor. For dissolving of p-chloromercuribenzoic acid (also named 
4-chloromercuribenzoate) in distilled water (20 mM), the pH was adjusted to pH 11. Before the 
experiments, it was confirmed that the pH of the Tris-buffer remained constant at 7.5 when 
p-chloromercuribenzoic acid solution was added to give a final concentration of 0.2 or 2 mM.  
 
 
2.3.8 HPLC-analysis 
Metabolites were analyzed by injection of 10 µl samples into a Shimadzu (Kyoto, Japan) HPLC 
system (LC-10AD liquid chromatograph, DGU-3A degasser, SPD-M10A diode array detector and 
FCV-10AL solvent mixer) equipped with a Lichrospher SC 100 RP8 reversed phase column (125 
by 4.6 mm, Bischoff, Leonberg, Germany). Methanol-H2O containing 0.1 % (vol/vol) H3PO4 was 
used as eluent at a flow rate of 1 ml/min. The column effluent was monitored simultaneously at 
210, 260, and 280 nm by the diode array detector.  
 
 Table 1. Peak areas of 1 mM standards recorded at the given wavelengths. 
Compound Wavelength (nm) Peak area 
salicylate 210 1130 × 104 
5-chlorosalicylate 210 1550 × 104 
4-chlorosalicylate 210 1510 × 104 
3-chlorosalicylate 210 1540 × 104 
4-chlorocatechol 210 730 × 104 
3-chlorocatechol 210 1140 × 104 
4-fluorocatechol 210 207 × 104 
cis-,cis-muconate 260 1360 × 104 
3-chloro cis-, cis-muconate 260 320 × 104 
2-chloro cis-, cis-muconate 270 918 × 104 
4-fluoromuconolatone 210 155 × 104 
protoanemonin 260 590 × 104 
cis-dienelactone 280 880 × 104 
trans-dienelactone 280 980 × 104 
maleylacetate 210 315 × 104 
cis-acetylacrylate 205 370 × 104 
trans-acetylacrylate 205 350 × 104 
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Typical retention volumes were as follows: Methanol-H2O (18:82): 3-chloro-cis,cis-muconate, 
9.6 ml; cis-dienelactone, 5.2 ml; trans-dienelactone, 1.9 ml; protoanemonin, 4.9 ml; maleylacetate, 
0.7 ml; cis-acetylacrylate, 2.3 ml; trans-acetylacrylate, 2.9 ml. Methanol-H2O (30:70): 2-chloro-cis-
dienelactone, 9.4 ml; 2,4-dichloromuconate, 5.0 ml; 4-fluorocatechol, 4.4 ml; 3-chloro-cis-cis-
muconate, 4.3 ml; cis-dienelactone, 2.6 ml; protoanemonin, 2.3 ml; 3-fluoro-cis-cis-muconate, 
1.8 ml; 4-fluoromuconolactone, 1.6 ml; trans-dienelactone, 1 ml. Methanol-H2O (66:34): 
5-chlorosalicylate, 3.2 ml; 4-chlorosalicylate, 3.6 ml; salicylate, 1.6 ml; 4-chlorocatechol, 1.0 ml; 
2-chloro-cis-cis-muconate, 0.5 ml.  
 
 
2.3.9 In-situ NMR-analysis 
One-dimensional 1H-NMR spectra were recorded at 300°K on a Bruker AVANCE DMX 600 NMR 
spectrometer (Bruker, Rheinstetten, Germany) locked to the deuterium resonance of D2O in the 
solution. Spectra were recorded using the standard Bruker 1D NOESY suppression sequence with 
280 scans each with a 1.8 s acquisition time and 1.3 s relaxation delay. The center of the suppressed 
water signal was used as internal reference (δ 4.80 ppm). 1H-NMR spectra are preferably taken with 
inorganic buffer systems such as phosphate or borate buffer systems (112, 116), as the protons of 
the often complex organic molecules of organic buffer systems are feared to overlap with the peaks 
of the compounds of interest. As MAR of Pseudomonas sp. MT1 was substantially inhibited in 
phosphate buffer, we performed in-situ 1H-NMR in a 5 mM Tris/HCl, pH 7.5 buffer system 
(TRIZMA®BASE, Sigma-Aldrich, St. Louis, MO, USA). It was important to re-adjust the pH for 
compound identification after completion of the reaction. 
1H-NMR spectra of the substrates cis-acetylacrylate and NADH, as well as its products, laevulinic 
acid and NAD at 1 mM concentrations, were recorded individually in 5 mM Tris/HCl, pH 7.5 and 
20 % (vol/vol) D2O to serve as standards for identification of all peaks. For in-situ NMR the 
spectrum of 1mM cis-acetylacrylate in 5 mM Tris/HCl, pH 7.5 and 20 % (vol/vol) D2O was 
recorded before and directly after addition of partially purified MAR to be able to exclude any 
artifacts by the introduction of the proteins. Substrate transformation and product formation was 
followed over time.   
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2.4 Enzyme purification and characterization 
2.4.1 Enzyme purification 
Proteins were purified using a Fast Protein Liquid Chromatography (FPLC) system (Amersham 
Biosciences, Uppsala, Sweden) from Pseudomonas sp. strain MT1. Cells were harvested during late 
exponential growth with 5-chlorosalicylate. Cell disruption and all protein elutions were performed 
in Tris/HCl (50 mM, pH 7.5, 2 mM MnCl2) and 0.5 ml fractions were collected if not stated 
otherwise.  
For partial purification, the cell extract (usually containing between 8 and 20 mg of protein per 
ml) was applied directly to a MonoQ HR5/5 (anionic exchange) column (Amersham Pharmacia 
Biotech) or mixed with 2 M (NH4)2SO4 to give a final concentration of 0.8 M (NH4)2SO4 and, after 
centrifugation, applied to a SOURCE 15PHE PE 4.6/100 (hydrophobic interaction) column 
(Amersham Pharmacia Biotech). At least three independent experiments were performed. Proteins 
were eluted from the MonoQ HR5/5 column by a linear gradient of 0 – 0.4 M NaCl over 25 ml with 
a flow of 0.2 ml/min (MCI, 0.23 ± 0.03 M; MCIB, 0.32 ± 0.01 M and trans-DLH, 0.19 ± 0.01 M 
NaCl). Proteins were eluted from the SOURCE column by a linear gradient of (NH4)2SO4 (0.8 M – 
0 M) over 25 ml with a flow of 0.25 ml/min. Hydrophobic interaction chromatography separated 
MCI (0.06 ± 0.04 M), a novel type of cycloisomerase MCIB (0.25 ± 0.04 M), MAR (0 mM) and 
trans-DLH (0.8 M (NH4)2SO4)) thus excluding interference between their activities.  
For purification of MCI, MCIB and trans-DLH up to 400 mg of protein were applied onto the 
MonoQ HR 10/10 (Amersham Pharmacia Biotech). A stepwise gradient of 0 – 60 mM NaCl over 
40 ml, 60 – 380 mM over 120 ml and 380 – 2000 mM NaCl over 40 ml was applied. The flow rate 
was 0.3 ml/min. The eluate was collected in fractions of 5 ml volume. All fractions eluting at NaCl 
concentrations of 90 – 330 mM (a total of 90 ml) containing the enzymes of interest were pooled 
and concentrated to a final volume of 4.25 ml using ultrafiltration by Centriprep YM-50 (Millipore, 
Billerica, Mass. USA) according to the protocol of the manufacturer. The protein solution was 
supplemented with 4 M (NH4)2SO4 solution to give a final concentration of 0.8 M (NH4)2SO4 and 
centrifuged directly before application of the soluble proteins to the SOURCE column. Aliquots 
comprising 40 mg of protein were separated as described for partial purification: 
MCI (0.06 ± 0.04 M),  MCIB (0.25 ± 0.04 M) and trans-DLH (0.8 M (NH4)2SO4)). Fractions 
containing MCI, MCIB or trans-DLH were combined separately and concentrated by Centricon 
YM-50 (Millipore). Further purification was achieved by gelfiltration using a Superose 12 HR10/10 
column (Amersham Pharmacia Biotech). Proteins were eluted with Tris/HCl (50 mM, 2 mM MnCl2 
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pH 7.5) over 15 ml (flow rate 0.2 ml/min, fraction volume 0.5 ml). The fractions containing MCI  
(eluting at 11-12 ml), MCIB (eluting at 10.5 – 11.5 ml) or trans-DLH  (eluting at 13-14 ml) were 
applied separately onto a MonoQ HR5/5 column, and eluted using a gradient described above. 
While MCI and MCIB were homogenous as judged by SDS-PAGE, the trans-DLH containing 
fractions still contained significant amounts of contaminating proteins. Thus, these fractions were 
desalted by gelfiltration, supplemented with 4 M (NH4)2SO4 to give a final concentration of 1.85 M 
(NH4)2SO4 and again applied onto a SOURCE 15PHE PE 4.6/100 column. Proteins were eluted 
with a stepwise gradient of 1.85 – 0.93 M over 5 ml and 0.93 – 0 M (NH4)2SO4 over 20 ml in 
Tris/HCl (50 mM, 2 mM MnCl2, pH 7.5). trans-DLH eluted at ammoniumsulfate concentrations of 
0.42 – 0.47 M. Homogeneity was verified by SDS-PAGE.  
Muconolactone isomerase was partially purified from cell extract of salicylate grown MT1 by 
hydrophobic chromatography with a SOURCE 15PHE PE 4.6/100 column. For elution a two-step 
gradient (1.85 – 1.48 M(NH4)2SO4over 25 ml  and (1.48 – 0 M (NH4)2SO4 over 3 ml ) was applied. 
MLI eluted at 0 M ammoniumsulfate After heat treatment of the fractions containing the enzyme 
for 20 min at 70 °C and separation from the precipitated proteins by centrifugation in a 
microcentrifuge, modified as described in (139). Muconolactone isomerase was stored at – 20 °C. 
Maleylacetate reductase (MAR) was partially purified from Pseudomonas sp. MT1 grown on 
5-chlorosalicylate, washed in 50 mM phosphate buffer, pH 7.5 prior to making cell extracts in that 
buffer.  About 6 – 8 mg of proteins were loaded on a MonoQ HR5/5 column and eluted at 0.2 ± 
0.01 M NaCl by a linear gradient of 0 – 0.4 M NaCl in phosphate buffer over 25 ml with a flow of 
0.2 ml/min.  For preparation of MAR to be used in in-situ-NMR assays 10 mM Tris/HCl, pH 7.5 
buffer instead of phosphate buffer was used throughout the experiment. Similarly, MAR was eluted 
at 0.2 ±  0.01 M NaCl with a linear gradient of 0 – 2.5 M NaCl over 25 ml, here.  
Recombinant TetC (chlorocatechol 1,2-dioxygenase of P. chlororaphis RW71) was partially 
purified by a DEAE Sepharose column as described by Potrawfke et al. (118). 
cis-/trans-DLH (TfdDI) and MAR (TfdFI) of R. eutropha JMP134 were available from previous 
partial purification by anion exchange chromatography from R. eutropha JMP222 containing 
expression vector pBBR1M-I as described by Plumeier et al. (114). 
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2.4.2 Determination of molecular mass 
The molecular mass of MCI, MCIB and trans-DLH were determined by gelfiltration using a 
Superose 12 column as described above. The column was calibrated for molecular mass 
determinations with ovalbumin (43 kDa), aldolase (158 kDa), catalase (232 kDa) and  Ferritin (440 
kDa) (Bio-Rad) as reference proteins. 
 
 
2.4.3 Protein electrophoresis 
10 % SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed on a Bio-Rad 
Miniprotein II essentially as previously described (80). The acrylamide (rotiphorese Gel 30, ROTH, 
Germany) concentration was 10 % (wt/vol). The proteins were stained with Coomassie brilliant 
blue (Serva, Heidelberg, Germany). Prestained low range protein marker from Bio-Rad and 
peqGOLD Protein MW Marker from Peqlab, Germany were used.  
 
 
2.4.4 Amino acid sequencing 
Highly purified protein fractions were separated from low amounts of contaminating proteins by 
SDS-PAGE and electroblotted onto a PVDF membrane (Millipore) which was stained with 
Coomassie brilliant blue R250 0.1 % in a methanol (40 % vol/vol), acetic acid (10 % vol/vol), H2O 
(50 % vol/vol) solution for 15-30 minutes. The membrane was destained in the solution without 
Coomassie and dried over night on Whatman paper. The protein bands were excised and N-terminal 
amino acid sequencing was performed with an Applied Biosystem model 494A Procise HT 
sequencer by Rita Getzlaff at the GBF. 
For internal MS/MS sequencing the gel after SDS-PAGE was stained with Coomassie brilliant blue 
G250 and bands containing the protein of interest were cut out, neutralized in fresh 10 mM 
ammoniumbicarbonate (15 min) and destained in acetonitril (50 % vol/vol ) / 10 mM 
ammoniumbicarbonate (50 % vol/vol) prior to drying in a speed vac. Gelpieces were soaked with  5 
– 10 µl of trypsine solution (2 µg/ml) for 30 minutes and the same amount of 50 mM 
ammoniumcarbonate was added. The digests were incubated at 37 °C over night. The peptides were 
extracted by addition of 50 µl of a fresh solution of 50 mM ammoniumbicarbonate and twice with 
100 µl of a solution consisting of acetonitril (60 % vol/vol), formic acid (0.5 % vol/vol) H2O 
(49.5 % vol/vol) solution. Extracts were combined and concentrated in a speed vac at 4 °C over 
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several hours. The dried peptides could be stored at -20 °C. Prior to sequencing, peptides were re-
dissolved in approx. 10 µl 5 % vol/vol formic acid and cleaned with Zip Tips (Millipore) according 
to the manufactures protocol in order to eliminate salts and detergents (54). Sequencing was 
performed by the structural department of GBF with a Quadropole Time Of Flight (Q-TOF) mass 
spectrometer. 
Obtained sequences were compared with GeneBank (USA), Protein database (PDB, USA), protein 
informative resource (PIR), reference sequence collection (RefSeq, NCBI, USA), protein research 
foundation (PRF, Japan) and SwissProt using FastA and tblastn (BLASTP 2.25 (Nov-16-2002)).  
 
 
2.4.5 Analysis of kinetic data 
Kinetic data of muconate cycloisomerase, MCIB and trans-DLH were determined with 
homogeneous proteins in 50 mM Tris/HCl, pH 7.5, 2 mM MnCl2. As the enzymes had to be stored 
until the performance of experiments, their actual activities were determined using the respective 
standard tests (see 2.3.1) and all given activities were normalized to the activity of the enzyme right 
after purification. At least two independent experiments were performed for each value. Km and 
Vmax were calculated by nonlinear regression to the Michaelis-Menten equation, using the Curve Fit 
feature of Sigma-Plot 2000, if not stated otherwise. Turnover numbers (kcat values) were calculated 
assuming a subunit molecular mass of 40 ± 2 kDa for MCI and of 39 ± 4 kDa for trans-DLH. 
Km and kcat of muconate cycloisomerase (MCI) for muconate were determined 
spectrophotometrically at substrate concentrations up to 1.3 mM. Muconate depletion was followed 
at λ=260 nm (ε = 16,800 M-1 cm-1 (30) substrate concentrations of 50 – 130 µM), λ=285 nm 
(ε = 3,800 M-1 cm-1, substrate concentrations of 130 – 350 µM) or λ=295 nm (ε = 1,100 M-1 cm-1 
substrate concentrations of 350 – 1300 µM). 
Transformation of 3-chloromuconate by MCI was followed by HPLC analysis at substrate 
concentrations of 75 µM – 1500 µM using 5 mU/ml (measured with 100 µM cis,cis-muconate 
initial concentration) of purified MCI. Samples were taken during the reaction and protoanemonin 
formation was directly analyzed by HPLC. Kinetic constants were calculated based on 
protoanemonin formation rates. 
Km and kcat of MCIB for 3-chloromuconate transformation was determined spectrophotometrically 
in the presence of an excess of partially purified cis-/trans-DLH from R. eutropha JMP134 (TfdDI). 
As confirmed by HPLC analysis, independent of the substrate concentration, MCIB catalyzed the 
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transformation of 3-chloromuconate into 48 ± 5 % cis-dienelactone and protoanemonin, 
respectively in a 1:1 ratio. Addition of cis-/trans-DLH resulted in the prevention of any significant 
cis-dienelactone accumulation by transforming it into maleylacetate, thus resulting in a decrease in 
absorption at 260 nm. The extinction coefficient of the reaction was determined by comparison of 
photometrical spectra and HPLC analysis of the same assay over time to be ε260 nm= 2,000 M-1 cm-1.   
Ki of MCIB for 4-methylmuconolactone resulting in a 50 % inhibition was calculated with the 
following equation describing the effects of inhibitor and substrate concentrations on competitive 
inhibition:  
[ ] [ ] i
m
K
K
SI 


 += 15.0   
; with  [I] = 1 mM (4-methylmuconolactone inhibitor concentration) 
 [S] = 0.1 (3-chloromuconate as substrate concentration) 
 Km = 0.105 mM (Km-value of MCIB with 3-chloromuconate) 
 
Kinetic data of trans-dienelactone hydrolase (trans-DLH) with trans-dienelactone as substrate 
were determined spectrophotometrically at substrate concentrations up to 0.5 mM and followed at 
λ=280 nm (substrate concentrations up to 130 µM) or λ=305 nm (ε =  4380 M-1 cm-1 substrate 
concentrations of 130 – 520 µM).  
The turnover of 4-fluoromuconolactone by trans-DLH was analyzed spectrophotometrically at 
λ=240 nm using a reaction coefficient of 4200 M-1 cm-1 (εmaleylacetate = 4700 M-1 cm-1, 
ε 4-fluoromuconolactone= 500 M-1 cm-1 )(123). 
Km of maleylacetate reductase (MAR) for maleylacetate and cis-acetylacrylate were determined 
by following NADH reduction photometrically as described above with initial substrate 
concentrations of 0.02 – 0.2 mM maleylacetate and 0.025 – 0.6 mM cis-acetylacrylate, respectively. 
Equations describing enzyme activities versus substrate concentrations. 
Michaelis-Menten equation [ ][ ] mKS
SVv += max  
Polynomial expression describing substrate inhibition [ ] ( )[ ] ( )[ ]2maxmax
max
/1/1/ SVKSV
V
KvS SSm •++=  
(2, 56). 
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2.5 Chemicals 
Chemicals were purchased from Riedel de Haen (Seelze, Germany), Baker (Philipsburg, NJ, USA), 
Sigma-Aldrich (St. Louis, MO, USA), Fluka AG (St. Gallen, Switzerland) and Merck AG 
(Darmstadt, Germany). 4-Chlorocatechol was obtained from Helix Biotech (USA).  
3-Chloro-cis,cis-muconate and 3-fluoro-cis,cis-muconate were freshly prepared from 
4-chlorocatechol or 4-fluorocatechol in Tris/HCl (50 mM, pH 7.5, 2 mM MnCl2) using partially 
purified chlorocatechol 1,2-dioxygenase TetC of P. chlororaphis RW71 overexpressed in E. coli 
(118). Completed substrate transformation was confirmed by HPLC analysis. 
4-Fluoromuconolactone was prepared in-situ from 3-fluoro-cis,cis-muconate by purified MCI. 
Complete substrate conversion was again verified by HPLC. Enzymes were removed from the 
preparation by filtration with Centricon YM-10 (Millipore).  
Maleylacetate was freshly prepared by alkaline hydrolysis of cis-dienelactone (143).  
cis-Dienelactone and 4-fluorocatechol were kindly provided by Walter Reineke (Bergische 
Universität – Gesamthochschule Wuppertal, Germany) and Stefan Kaschabeck (TU Bergakademie 
Freiberg, Germany).  
trans-Dienelactone and protoanemonin were prepared as described earlier (8, 123). 
Protoanemonin was also formed by addition of partially purified MCI to 3-chloromuconate 
preparation. 
cis-Acetylacrylate was obtained by isomerization of 5 mM trans-acetylacrylate (Lancaster 
Synthesis, Morecambe, UK) over night under UV irradiation (λ = 254 nm) (132). Efficiency of 
isomerization was checked by HPLC analysis.  
 
 
2.6 Molecular techniques 
2.6.1 Genomic DNA extraction 
Genomic DNA of Pseudomonas sp. strain MT1 was obtained by a modified protocol of Grimberg 
et al. (46). 25 ml of cells grown in LB OD600=1 were harvested and washed with TNE buffer 
(10 mM Tris/HCl, 10 mM NaCl, 10 mM EDTA, pH 8.0). The pellets could be stored thereafter at  
–20 °C. The pellet was resuspended in 5 ml TNEX-buffer (TNE buffer supplemented with 1 % 
Triton-X 100) and 270 µl fractions transferred in 2 ml tubes. To each tube 30 µl of lysozyme 
(10 mg/ml) and 7.5 µl of freshly prepared Proteinase K (20 mg/ml) were added. The tubes were 
incubated for 2 h at 37 °C, followed by incubation for 2-3 h at 65 °C. The DNA was precipitated by 
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addition of 15 µl of 5 M NaCl, gentle inverting the tubes and gentle addition of cold 96 % ethanol. 
After 2-3 minutes the tubes were gently inverted again prior to spinning down the DNA for 10 min 
with 15000 rpm at 4 °C. The supernatant was discharged and the pellet washed with 1 ml cold 96 % 
ethanol. The pellet was dried at 37 °C and resuspended in 100 µl MilliQ water over night at 4 °C. 
For preparation of the genomic walker libraries (Stratagene, La Jolla, CA, USA) DNA was 
restricted with SmaI, EcoRV, PvuII and StuI. DraI was found not to restrict genomic DNA of MT1 
under standard conditions. The digests were further purified by QIAprep Spins for Minipreps 
(QIAGEN, Hilden, Germany). In contrast to the protocol, solution P1, P2 and N3 were mixed prior 
to addition to the digest. Thereby large fragments of DNA were not precipitated and could be eluted 
from the column. 
 
 
2.6.2 PCR assays 
PCR reactions were performed with Taq polymerase (Amersham or Invitrogen (Carlsbad, CA, 
USA) in 1 x Taq-buffer of the respective supplier. The effect of the addition of different 
concentrations of  DMSO (0, 1, 5, 10 %) or Q-solution (QIAGEN) to the PCR assays was tested, as 
those agents modify the melting temperature of DNA and thereby often facilitate amplification of 
GC rich templates, as present in Pseudomonas genomes. The addition of 5 % dimethylsufoxide 
(DSMO) was shown to be optimal. MgCl2 (1.5 mM) was added when using Invitrogen polymerase. 
5 µl of 10 µM primers were added to 25 µl assay volume. The concentration of genomic DNA used 
in the assays seemed to be very crucial. If not stated otherwise 0.2 µl of an approximately 100 ng/µl 
genomic DNA preparation were added to the assays. PCR was performed in a Biometra 
Thermocycler T3 at a total volume of 25 µl with: 5 min initial denaturation at 95 °C followed by 30 
cycles of 30 seconds at 95 °C, 30 seconds at 40 °C and 90 seconds of 72 °C. After the last cycle 
elongation was prolonged for 10 more minutes and the samples were cooled at 4 °C until analysis. 
 
 
2.6.3 TA Cloning, electroporation 
PCR fragments were purified by electrophoresis on a 0.8 % agarose gel followed by extraction 
using the GFX PCR DNA and Gel Band Purification Kit (Amersham Biosciences). The purified 
fragment was cloned into the pCR®4-TOPO vector, provided linearized and topoisomerase I-
activated with 3’-T overhangs, with the TOPO TA Cloning® Kit for Sequencing (Invitrogen) 
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according to the manufacturer protocol. The vector has a minimized multiple cloning site and 
M13-priming sites notably close to the product insertion site for efficient sequencing. Immediately 
after ligation the plasmid was transferred into E. coli JM105 by electroporation (400 OHMs, 
2.5 kVolt). The transformants were incubated at 30 °C for 1 – 1.5 hours in LB without selective 
agent, before plated onto LB Amp100 agar and incubation over night at 37 °C.  
 
 
2.6.4 Preparation of electrocompetent cells 
Exponentially grown E. coli JM105 were made electrocompetent by washing them twice with 
sterile MilliQ water (130). Competent cells were stored in 10 % glycerol at –80 °C. 
 
 
2.6.5 Plasmid preparation 
Plasmids were extracted with the QIAprep® Miniprep Kit (Qiagen, Hilden, Germany) according to 
the protocol for Qiaprep Spin Minipreps and eluted in MilliQ water. 
 
 
2.6.6 Southern Blot 
Aliquots of genomic DNA of Pseudomonas sp. MT1 were restricted separately with four distinct 
6-basepair cutters SmaI, EcoRV, PvuII and StuI. The digests (1 µg) were loaded on a 0.7 % agarose 
gel and eletrophoresed The DNA fragments from the digest were fractionized to smaller pieces by 
incubating the gel for 10 min in 0.37 % (v/v) HCl. Subsequently the DNA was denatured by 
incubation in 0.5 M NaOH, 1.5 M NaCl denaturation-buffer for 40 min, neutralized in 0.5 M Tris, 
3 M NaCl, pH 7.2 for at least 60 min and rinsed with water. The DNA was blotted onto a Nylon 
membrane (Nytran N, Schleicher & Schuell, Germany) which was presoaked in 6x SSC buffer for 
10 sec just prior to placing it onto the gel. 10x SSC (1.5 M NaCl, 0.15 M sodiumcitrate, pH 7.0) 
was run by capillary forces passing from below the gel upwards through the membrane and ensured 
the transfer of DNA over night. The membrane was rinsed with 6x SSC placed between Whatman 
paper and dried at 80 °C  for 2 hours.  
The membrane was prehybridized by being gently shaken in hybridization buffer (5x SSC, 1 % 
(w/v) blocking reagent (Boehringer Mannheim, Mannheim, Germany), 0.1 % (w/v) 
lauroylsarcosine, 0.02 % (w/v) SDS)  at 60 °C  for 1 hour. The probes were denatured by boiling for 
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5 min and shocking on ice water to avoid re-annealing. The prehybridization buffer was discarded 
and preheated hybridization buffer (including 600 ng DIG labeled probe) was added in amounts 
sufficient to cover the membrane. Hybridization was performed at 60 °C over night in a closed box 
to prevent evaporation. The hybridizing buffer including the probe was decanted and stored for later 
experiments at 4 °C. Rinsing and detection of hybridized bands was performed according the 
protocol of DIG DNA Labeling and Detection Kit from Boehringer Mannheim.  
 
 
2.6.7 Expression of wild-type and mutant muconate cycloisomerase from P. putida PRS2000 
Plasmids pCATB1, pCATB51 and pCATB54 carrying the wild type and the mutant muconate 
cycloisomerases I54V-CatB and A271S-CatB of Pseudomonas putida PRS2000, respectively, were 
kindly provided by Schlömann (169). The plasmids were transferred into BL21-Gold-derived 
competent cells designed for high-level protein expression using T7 RNA polymerase-based 
expression systems. The BL21-Gold(DE3)pLysS competent cells which provide tight control for 
expression of toxic proteins, were transformed according to the protocol of chemocompetent cells. 
Clones harbouring the plasmid were selected on LB Amp100 plates and grown and induced in LB-
medium Amp100 (130), as described by Vollmer et al. (169). 
 
 
2.6.8 Alignment and phylogenetic tree of (chloro)muconate cycloisomerases 
Sequences for the alignment were obtained from the NCBI database detected by tblastn search with 
the available 159 amino acid long protein sequence of Pseudomonas sp. strain MT1 (this study). 
Well studied and putative muconate and chloromuconate cycloisomerases, as well as some reliable 
sequences from genome projects and other approaches were selected. Protein accession numbers are 
given in the figure of the alignment. The alignment was performed using CLUSTAL W (159) using 
default values and a 159 amino acid block containing the full sequence of muconate cycloisomerase 
of Pseudomonas sp. strain MT1 was cut out. A phylogenetic tree was generated using the neighbour 
joining method option of CLUSTAL W with 1000 bootstraps. 
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3. RESULTS 
3.1 Growth of Pseudomonas sp. strain MT1 and RW10 on chlorosalicylates  
Pseudomonas sp. strain MT1 can grow on 4-chloro- and 5-chlorosalicylate and on salicylate as only 
source of energy and carbon with growth rates of 0.05 h-1 (2.5 mM 4-chlorosalicylate as carbon 
source), 0.16 h-1 (2.5 mM 5-chlorosalicylate) and 0.38 h-1 (5 mM salicylate), respectively. The 
maximal OD600 obtained during growth were 0.2, 0.3 and 0.9, corresponding to yields of 10, 15.5 
and 23 mg protein per mmole substrate, respectively. MT1 was not able to use 3-chlorosalicylate as 
only source of carbon and energy. 
During growth on 2 mM 5-chlorosalicylate MT1 excreted cis-dienelactone and minor amounts of 
protoanemonin corresponding to 17 and 4 % of the initial substrate concentration, respectively.  
Pseudomonas sp. strain RW10 showed similar growth rates of 0.10 h-1 (2.5 mM 4-chlorosalicylate), 
0.12 h-1 (2.5 mM 5-chlorosalicylate) and 0.35 h-1 (5 mM salicylate) and grew to maximal OD600 of 
0.2, 0.3 and 1.0, respectively. 
 
 
3.2 Enzyme activities in cell extracts 
Cell extracts of MT1 grown on 5-chlorosalicylate (Table 2) exhibited a significant catechol 
1,2-dioxygenase activity, but neither catechol 2,3-dioxygenase nor gentisate dioxygenase activity, 
indicating a metabolism via salicylate 1-hydroxylase and chlorocatechol ortho-cleavage. This fact 
was supported by the observation of a NADH dependent salicylate and chlorosalicylate 
transforming activity in cell extracts. All mono-chlorinated salicylates were transformed at rates 25 
- 50 % that of salicylate, resembling substrate specificities of salicylate 1-hydroxylase encoded by 
the nahG gene (82). Transformation rates of 4-chlorocatechol by both salicylate and 
5-chlorosalicylate-grown cells were 13 – 21 % those of catechol, whereas activities with 
3-chlorocatechol were negligible (< 2 % that of catechol). Such a substrate specificity is indicative 
for the induction of a catechol 1,2-dioxygenase rather than a chlorocatechol 1,2-dioxygenase, which 
usually is highly active against 3-chlorocatechol (30, 121). In accordance with an induction of 
enzymes of the 3-oxoadipate pathway was the observation of a muconate transforming activity, 
whilst activity against 2-chloromuconate was absent (< 5 U/g), indicating expression of muconate 
cycloisomerase (MCI) (139).  
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Table 2. Specific activities in cell extracts of Pseudomonas sp. strain MT1 grown on 5-chlorosalicylate, 
salicylate and succinate. Activities are given in U/g protein. ND = not determined. 
Growth substrate  
Enzyme 
 
Substrate 5-chlorosalicylate salicylate succinate 
salicylate 460 120 < 5 
3-chlorosalicylate 120 ND ND 
4-chlorosalicylate 240 ND ND 
Salicylate 1-
hydroxylase 
5-chlorosalicylate 190 ND ND 
Catechol 2,3-
dioxygenase 
catechol < 1 < 1 ND 
 dihydroxybiphenyl < 1 < 1 ND 
catechol 740 390 < 10 
3-chlorocatechol 14 < 1 ND 
Catechol 1,2-
dioxygenase 
4-chlorocatechol 160 50 ND 
Cycloisomerase muconic acid 25 350 < 5 
Muconolactone 
isomerase 
5-chloro-3-
methylmuconolactone
< 2 10 ND 
MLI + enollactone 
hydrolase 
muconolactone < 70 400 ND 
cis-dienelactone < 5 < 5 ND Dienelactone 
hydrolase trans-dienelactone 600 100 < 5 
 protoanemonin < 5 < 5 ND 
Maleylacetate 
reductase 
maleylacetate 1120 510 ND 
 cis- acetylacrylate 60 20 ND 
 trans-acetylacrylate < 5 < 5 < 5 
 
Muconolactone was transformed with an activity of approximately 400 U/g protein by cell extracts 
of salicylate grown MT1, indicating the combined presence of muconolactone isomerase and enol-
lactone hydrolase. In contrast, muconolactone depletion by cell extracts of 5-chlorosalicylate grown 
cells was lower and never exceeded 20 % the rate observed in salicylate grown cells. 
Transformation of 5-chloro-3-methylmuconolactone, as a measure for muconolactone isomerase 
activity, by cell extracts of salicylate grown cells was much lower than it had been described for 
muconolactone isomerase activity of Ralstonia eutropha JMP134 cell extracts (307 U/g) (119). This 
might indicate that 5-chloro-3-methylmuconolactone was not a good substrate for the 
muconolactone isomerase of MT1 in contrast to the one of JMP134. Nevertheless, muconolactone 
isomerase activity with 5-chloro-3-methylmuconolactone in extracts of salicylate-grown cells was 
about 5 to 10 fold higher compared to extracts of 5-chlorosalicylate grown cells, similar to the 
expression pattern of muconate cycloisomerase (MCI). Both cell extracts exhibited a high activity 
with trans-dienelactone, but not with cis-dienelactone. As previously described, dienelactone 
hydrolases (DLH) involved in the chlorocatechol pathway are active with both, cis- and trans-
dienelactone (133, 137, 139) or only the cis-isomer (85). However, hydrolases only transforming 
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the trans-isomer (133, 136) have previously also been reported in Ralstonia strains capable to grow 
on 4-fluorobenzoate (137) and in Pseudomonas sp. strain RW10 growing on chlorosalicylate (177). 
As in Pseudomonas sp. strain RW10, trans-DLH activity in MT1 was higher in 5-chlorosalicylate-
grown compared to salicylate-grown cells. Activity with maleylacetate was remarkably high and 
unexpected, because maleylacetate reductase (MAR) is usually expressed together with other 
enzymes of the chlorocatechol pathway and there was almost no activity reported in MT1 by Pelz et 
al. (106).  
 
Enzyme activities observed in cell extracts of 5-chlorosalicylate or salicylate grown cells of strain 
RW10 were highly similar to those observed in MT1. Catechol 1,2-dioxygenase, MCI, trans-DLH 
and MAR were induced, but no catechol 2,3-dioxygenase (Table 3). Like in MT1 MCI activity was 
higher in salicylate grown cells, whereas the other enzyme activities were higher in 
5-chlorosalicylate grown cells. 
 
Table 3. Specific activities in cell extracts of Pseudomonas sp. strain RW10 grown on 
5-chlorosalicylate and salicylate. Activities are given in U/g protein.  
Growth substrate  
Enzyme 
 
Substrate 5-chlorosalicylate salicylate 
Catechol 2,3-
dioxygenase 
catechol < 1 < 1 
 dihydroxybiphenyl < 1 < 1 
catechol 500 200 
3-chlorocatechol < 1 < 1 
Catechol 1,2-
dioxygenase 
4-chlorocatechol 120 30 
Cycloisomerase muconic acid 10 450 
cis-dienelactone < 5 < 5 Dienelactone 
hydrolase* trans-dienelactone  600 100 
 protoanemonin < 5 < 5 
Maleylacetate reductase maleylacetate 500 100 
 cis- acetylacrylate 130 10 
 trans-acetylacrylate 90 < 5 
 * in Histidine buffer 
Despite of previous propositions that MT1 and RW10 harbor a new metabolic route for 
chlorosalicylate degradation with protoanemonin as a central intermediate (106, 177) formed from 
4-chlorocatechol by the successive action of catechol 1,2-dioxygenase and MCI (8) (Fig. 4 B), in 
none of these organisms significant protoanemonin transforming activities could be observed. 
Wittich et al. had postulated that protoanemonin could be hydrolyzed to give cis-acetylacrylate, 
possibly by the action of trans-DLH (177). However, as shown for the trans-DLH of RW10 (14), 
the activity of purified trans-DLH of MT1 with protoanemonin was < 1 % that with trans-
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dienelactone (see 3.4.3) raising doubts on the hypothesis of protoanemonin as intermediate. 
Nevertheless, there was a significant NADH dependent cis-acetylacrylate transforming activity in 
MT1. This activity was later shown to be due to a side activity of MAR (see 3.7.1). 
Cell extracts of succinate-grown MT1 did not exhibit salicylate 1-hydroxylase, catechol 1,2-
dioxygenase, MCI, DLH or MAR activities. Thus, all those activities are inducible and not 
constitutively expressed. 
 
 
3.3. Metabolites in the degradation of chlorosalicylates by Pseudomonas sp. strain MT1 
3.3.1. Metabolites formed during transformation of chlorosalicylates and 4-chlorocatechol by 
resting cells of Pseudomonas sp. strain MT1 
The enzymatic activities detected in cell extracts of MT1 (see 3.2) did not account for a continuous 
route of degradation. However, despite the absence of any protoanemonin transformation in cell 
extracts, such an activity can be missed by the assay conditions. To further analyze the metabolic 
route of chlorosalicylate degradation in MT1, the different chlorosalicylates as well as the probable 
pathway intermediate 4-chlorocatechol were transformed by 5-chlorosalicylate grown resting cells 
(Fig. 5). During transformation of 4- and 5-chlorosalicylate, 4-chlorocatechol and 
3-chloromuconate were excreted transiently in small amounts (< 10 % of applied substrate), 
indicating them to be intermediates of the metabolic pathway. Protoanemonin and cis-dienelactone 
accumulated in amounts corresponding to approximately 7 ± 3 % and 10 ± 5 % of the initial 
substrate concentration, respectively (Fig. 5 A, B). Further transformation of 4-chlorocatechol and 
3-chloromuconate was rapid compared to the minor decrease in cis-dienelactone concentration. In 
contrast 3-chlorosalicylate transformation lead to transient excretion of 3-chlorocatechol (< 50 %) 
which was further transformed into 2-chloromuconate as a dead-end product (Fig. 5 C). When 
resting cells were incubated with 4-chlorocatechol, the same metabolites were identified as for 4- 
and 5-chlorosalicylate incubation, though higher concentrations of 3-chloromuconate (up to 15 % of 
initial substrate concentration) were excreted (data not shown). 
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Figure 5. Transformation of (1 mM) 4-chlorosalicylate 
(A),  5-chlorosalicylate (B) and 3-chlorosalicylate (C) 
by 5-chlorosalicylate grown resting cells of 
Pseudomonas sp. strain MT1 of an OD600=1 (A; C)  
or OD600=5 (B).  
◊ 4- chlorosalicylate;        ♦ 5- and 3-chlorosalicylate;   
○ 4- and 3-chlorocatechol; ∆ 3-and 2-chloromuconate; 
▲cis-dienelactone; ● protoanemonin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.2. Metabolites formed during transformation of 4-chlorocatechol or 3-chloromuconate by 
cell extracts of Pseudomonas sp. strain MT1 
When 4-chlorocatechol was transformed by cell extracts of 5-chlorosalicylate-grown cells 
(corresponding to 60 µg of protein per ml), a fast depletion occurred with concomitant formation of 
3-chloromuconate. 3-Chloromuconate was only a transient intermediate, and both cis-dienelactone 
and protoanemonin were observed as transformation products (Fig. 6). Even though 40 ± 10 % of 
the substrate applied accumulated as protoanemonin (30 ± 5 %) and cis-dienelactone (10 ± 5 %), 
the transformation was not stoichiometric. In fact, the formation of a third product was observed, 
which, by HPLC analysis, was shown to co-elute with authentic maleylacetate and which exhibited 
an identical absorption spectrum. Assuming its identity with maleylacetate, this compound 
comprised 55 ± 10 % of the initial substrate concentration. It was further transformed when NADH 
was added to the reaction mixture. 
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Figure 6: Transformation of 4-chloro-
catechol by cell extract (60 µg of 
protein/ml) of 5-chlorosalicylate 
grown Pseudomonas sp. strain MT1.  
○ 4-chlorocatechol; ∆ 3-chloro-
muconate; ▲cis-dienelactone;  
● protoanemonin, □ maleylacetate. 
 
 
 
 
 
 
 
Similarly, all three products were produced (protoanemonin: 35 ± 20 %; cis-dienelactone: 20 ± 5 %; 
maleylacetate: 45 ± 20 %) when 3-chloromuconate was transformed by cell extracts (60 to 360 µg 
protein/ml). Transformation of both cis-dienelactone and protoanemonin was negligible in all 
experiments performed. 
Interestingly, the product ratios were only reproducible, if assays were repeated with a defined 
protein concentration. Increasing the concentration of cell extract resulted in a decrease in 
protoanemonin and an increase in maleylacetate formation (Table 4). cis-Dienelactone production 
was not affected. Assays performed with varying 3-chloromuconate concentrations, demonstrated 
that the ratio of products was independent of the initial substrate concentration. 
 
Table 4. Products formed from 4-chlorocatechol and 3-chloromuconate by cell extracts of 5-chlorosalicylate 
grown Pseudomonas sp. strain MT1 in dependence of protein and substrate  concentrations. 
Substrate Initial 
concentration 
[µM] 
Cell 
extract 
[µg/ml] 
Proto-
anemonin 
[%] 
cis-Diene-
lactone 
[%] 
Maleyl-
acetate 
[%] 
recovery 
[%] 
Maleylacetate: 
protoanemonin 
(ratio) 
4-chloro-
catechol 
200 60 30 ± 10 10 ± 5 55 ± 10 95 1.8 
110 60 56 ± 2 22 ± 3 33 ± 3 101 0.6 
55 360 10 ± 5 27 ± 5 52 ± 8 90 5.2 
110 360 15 ± 5 23 ± 5 65 ± 5 93 4.3 
3-chloro-
muconate 
430 360 15 ± 5 22 ± 5 52 ± 8 87 5 
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3.3.3. Metabolites formed during transformation of 3-chloromuconate by partially purified 
enzymes 
Experiments with cell extracts had shown that protoanemonin and cis-dienelactone were only 
formed as side products. The major metabolite in the degradative pathway of 4- and 
5-chlorosalicylate had been identified as maleylacetate. The catabolic pathway of chlorosalicylate 
degradation in MT1 thus seems to comprise salicylate 1-hydroxylase and catechol 1,2-dioxygenase, 
forming 4-chlorocatechol and 3-chloromuconate as reaction products, respectively (Fig. 7). The fate 
of 3-chloromuconate, however, remained unclear. Incubation of 3-chloromuconate with cell 
extracts had demonstrated the formation of maleylacetate, beside protoanemonin and cis-
dienelactone. This, however,  can not be explained with current knowledge.  
3-Chloromuconate, by MCI and chloromuconate cycloisomerases (CMCI) reported thus far, is 
transformed into protoanemonin (8) and cis-dienelactone (139), respectively. No cis-dienelactone or 
protoanemonin transforming activity was detected in cell extracts. The conversion of 
3-chloromuconate to trans-dienelactone has never been observed, but a trans-DLH converting 
trans-dienelactone to maleylacetate was detected in MT1 cell extracts (Fig. 8). 
 
Catechol
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COOH
Cl
5-Chlorosalicylate
 
 Figure 7: Pathway of 4-chloro and 5-chlorosalicylate degradation by Pseudomonas sp. strain MT1. 
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Figure 8: Transformation of 3-chloromuconate by MCI, (muconate cycloisomerase); 
CMCI, (chloromuconate cycloisomerase) and so far not observed transformation (X). 
 
In order to characterize enzymes involved in the formation of maleylacetate from 
3-chloromuconate, extracts of 5-chlorosalicylate-grown cells were fractioned by FPLC and 
fractions tested for 3-chloromuconate transforming activity by HPLC analysis (Fig. 9).  
 
Astonishingly, two distinct 3-chloromuconate transforming activities were observed after 
hydrophobic interaction chromatography. Fractions eluting at 0.05 ± 0.04 M (NH4)2SO4 converted 
3-chloromuconate dominantly into protoanemonin (80 ± 5 %) with minor amounts of maleylacetate 
being formed. The respective enzyme thus resembles a MCI and was later on used for detailed 
analysis. Fractions eluting at 0.25 ± 0.04 M (NH4)2SO4 formed approximately equal amounts of 
protoanemonin (48 ± 3 %) and cis-dienelactone (48 ± 5 %) and thus displayed a product spectrum 
intermediate to those of MCI and CMCI (Fig. 9 A,B).  The respective enzyme is termed MCIB 
thereafter.  
None of the 3-chloromuconate transforming enzymes formed any detectable amount of trans-
dienelactone, and both observed dominating reaction products, protoanemonin and cis-dienelactone, 
were dead-end metabolites for MT1 (see 3.3.1 and 3.3.2). In contrast to transformation by cell 
extracts, only negligible amounts of maleylacetate were observed. Thus, it was speculated, that in 
the cell extract another enzyme might convert an intermediate product of 3-chloromuconate 
conversion into maleylacetate. 
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To evaluate this possibility, cell extracts were fractioned by a different method, anion-exchange 
chromatography. Again two distinct activities against 3-chloromuconate were determined. Enzymes 
eluting at 0.3 ± 0.02 M NaCl converted 3-chloromuconate to an approximately equal mixture of 
protoanemonin and cis-dienelactone as described above. However, 3-chloromuconate was 
transformed into maleylacetate and protoanemonin by fractions eluting at 0.25 ± 0.04 M NaCl, 
demonstrating that those fractions contained all necessary proteins for maleylacetate formation 
(Fig. 9 D).  
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Figure 9: Separation of proteins from cell extracts of 5-chlorosalicylate grown Pseudomonas sp. strain MT1 by means 
of hydrophobic-interaction with a SOURCE 15PHE PE column (A) or anion-exchange with a MonoQ HR5/5 column 
(B). Cell extracts were either directly applied (B) or applied after addition of ammonium sulfate (final concentration of 
0.8 M) (A), and proteins were eluted with a linear gradient of (NH4)2SO4 (0.8 to 0 M) or NaCl (0 to 0.4 M). The eluted 
fractions (0.5 ml) were analyzed for activities with 0.1 mM muconate, 0.1 mM 3-chloromuconate and 0.05 mM trans-
dienelactone. Activities of MCIB and trans-DLH are given in µmole/min per fraction, activities of MCI in 
(µmole * 10)/min per fraction  (A, C). Products and substrates after incubation of 0.1 mM 3-chloromuconate with 
1 - 5 µl of the respective fraction for 10 - 30 min were quantified by HPLC. For in A and C shaded fractions the relative 
amount of products and substrate are given as stacked columns in B and C, respectively:    3-chloromuconate; 
     protoanemonin;       cis-dienelactone;          maleylacetate.  
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It has previously been assumed that conversion of 3-chloromuconate to protoanemonin should 
proceed via 4-chloromuconolactone as reaction intermediate (8) (Fig. 10) and it could be postulated 
that hydrolysis of 4-chloromuconolactone would lead to maleylacetate. 4-Fluoromuconolactone has 
previously been described as a rather stable product of 3-fluoromuconate cycloisomerization by 
MCI of Ralstonia eutropha 335, Burkholderia cepacia and R. eutropha JMP134 (135). 
Furthermore, Schlömann showed, that 4-fluoromuconolactone is converted by trans- and cis-/trans-
DLH of R. eutropha 335 and R. eutropha JMP134 (TfdEI) to maleylacetate (133) (Fig. 10 B). Thus, 
it could be speculated that trans-DLH of MT1 acts on 4-chloromuconolactone transiently formed 
during cycloisomerization of 3-chloromuconate, producing maleylacetate. In fact, analysis of the 
elution profiles  demonstrated that trans-DLH and MCI co-eluted during anionic exchange 
chromatography (trans-DLH 0.19 ± 0.01 M NaCl) (Fig. 9 C) but not during hydrophobic interaction 
chromatography (trans-DLH 0.8 M (NH4)2SO4) (Fig. 9 A).  
In order to substantiate that formation of maleylacetate was actually due to the activity of trans-
DLH and not to any other undefined protein co-eluting with MCI, partially purified trans-DLH 
obtained by hydrophobic interaction chromatography was used in combination with the respective 
partially purified MCI or MCIB . The respective trans-DLH containing fractions turned over neither 
3-chloromuconate, nor protoanemonin or cis-dienelactone. However, the addition of trans-DLH 
containing fractions to reactions containing partially purified MCI resulted in the formation of 
significantly increased amounts of maleylacetate from 3-chloromuconate. Similarly, maleylacetate 
was formed in high amounts when 3-chloromuconate was incubated with a combination of trans-
DLH and MCIB. This indicated that trans-DLH interacts with both cycloisomerizing activities and 
is responsible for the increased maleylacetate formation. Consequently trans-DLH, MCI and MCIB 
were defined as the key enzymes of a new metabolic pathway in MT1. 
 
 
 
 
Figure 10: Transformation of 
3-chloromuconate to protoanemonin 
catalyzed by muconate cycloisomerase 
(MCI) (8). Postulated reaction inter-
mediate given in brackets (A). 
Transformation of 3-fluromuconate by 
MCI to 4-fluoromuconolacton which 
can be hydrolized by different 
dienelactone hydrolases to 
maleylacetate (133) (B). 
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3.4. Characterization of key enzymes of the novel pathway 
3.4.1. Characterization of homogeneous muconate cycloisomerase (MCI) 
 MCI of MT1 was purified to homogeneity. The molecular mass of the native MCI was estimated 
by gelfiltration to be 255 ± 20 kDa and by SDS-PAGE a single band of 40 ± 2 kDa was observed 
(Table 5). It can thus be assumed, that this enzyme, like MCI of P. putida PRS2000 (55) or CMCI 
from R. eutropha JMP 134 (TfdDI) (60) is a homo-octamer.  
The N-terminal sequence of MCI from MT1 (TQAKIESIETILVDLPTVRPHKLAM) showed a 
significant similarity to the CatB protein (accession number Q43931) of Acinetobacter 
calcoaceticus (14 identical amino acids) and to CatB from Pseudomonas putida PRS2015 
(accession number P08310, 10 identical amino acids) which also shares significant similarity 
(amino acid 213 to 231) to an internal sequence of the MT1 MCI (ACKVLGDNGLDLLEKPLSR) 
(identical amino acids are marked in bold). 
 
 Table 5. Molecular characterization of MCI, MCIB and trans-DLH of Pseudomonas sp. strain MT1. 
 
The substrate spectrum and kinetic parameters of MCI at a glance, were only partially similar to 
those of previously described proteobacterial MCIs. As expected, both, 2-chloromuconate and 
2,4-dichloromuconate were only poor substrates for the enzyme (Table 6). However, both muconate 
and 3-chloromuconate were transformed at relatively high rates, in contrast to previous information 
Enzyme Molecular 
mass  
[kDa] 
Subunit 
mass 
[kDa] 
N-terminal amino 
acid sequence 
Inner protein sequences 
MCI 255 ± 20 40 ± 2 TQAKIESIETILVDL
PTVRPHKLAM 
 
    is_d: DLAEAEHFLDVR 
    is_c: ACKVLGDNGLDLLEKPLSR 
MCIB 350 ± 20 43 ± 3 SQGFVIGRVLAQR
LDIPFSQPIRMSFGT
LD 
 
    is_b: FGSGDPDAELLR 
    is_c: TLSTGSEGGDLAEGER 
    is_d: MLFQENGGLEG 
trans-
DLH 
85 ± 30 39 ± 4 TDTSKSLPTYKQLL
ERKDAPPGSSWGL
FGK 
 
    is_c: VSQGVTLEPGDAVLLR 
    is_d: AFSLDLLATSLYALLAGPSL 
    is_e: 
KLDLDAGASGKALSAKVLEAAR 
    is_f: VDVNGAYSVDEAQALR 
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obtained during analysis of other MCIs (139, 169), which indicated a poor activity of these enzymes 
with 3-chloromuconate. The Km-value for muconate (1.73 ± 0.35 mM) was significantly higher than 
those previously reported for MCI of P. putida PRS2000 (0.04 mM) (169), Acinetobacter 
calcoaceticus ADP1 (0.13 mM) (169) or Pseudomonas sp. strain B13 (0.056 mM) (139). However, 
maximal turnover numbers were in the same order of magnitude (169). Surprisingly, a comparison 
of kcat/Km values indicated 3-chloromuconate to be preferred over muconate as a substrate by MCI 
of MT1. At substrate concentrations of 0.1 mM the enzyme transformed 3-chloromuconate about 
3.5 times faster compared to muconate (Table 6). Activities slightly approaching the values reported 
here have only be given for two site-directed mutants of P. putida PRS2000 MCI (see 3.8.1.3) by 
Vollmer et al. (169). 
Purified MCI of MT1 transformed 3-chloromuconate into protoanemonin as dominant product, and 
HPLC analysis revealed, that cis-dienelactone and maleylacetate were formed as side products 
corresponding to 8 ± 4 % and 8 ± 5 %, respectively, of the initial substrate concentration. 
 
Besides muconate and 3-chloromuconate, MCI of MT1 was able to transform 3-fluoromuconate. 
The formation of a single product was observed which, as determined by HPLC analysis, exhibited 
only negligible absorbance at wavelengths > 240 nm. Similarly, under physiological conditions the 
product exhibited only an absorption maximum at 208 nm (Fig. 11). This absorption behavior is 
characteristic for 4-fluoromuconolactone which was identified as the product formed during 
cycloisomerization of 3-fluoromuconate by MCI of Ralstonia eutropha 335 and JMP134 (135).  
The identity of the product formed from 3-fluoromuconate by MCI of MT1 as 
4-fluoromuconolactone was further confirmed by its transformation into maleylacetate by trans-
DLH (see 3.4.3) (Fig. 10 B). 
 
Figure 11:  Overlay spectra during 
transformation of  3-fluoromunate 
to 4-fluromuconolactone by 
partially purified MCI and of 
4-fluoromuconolactone to maleyl-
acetate by purified trans-DLH. 
Spectral changes during incubation 
with MCI are indicated by ↓, those 
during transformation by trans-
DLH by ↑.  
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Muconate and chloromuconate cycloisomerases were demonstrated to catalyze the formation of an 
equilibrium between 2-chloromuconolactone, 5-chloromuconolactone and 2-chloromuconate when 
transforming 2-chloromuconate (168, 171).Thus muconolactones are known to be substrates to 
those enzymes (116), however, some, like 4-methylmuconolactone (111) are not transformed. In 
order to try to accumulate the hypothesized reaction intermediate, the structural analogue 
4-methylmuconolactone was incubated with MCI and it was tested, if it can be recognized as an 
inhibitor.  HPLC analysis showed that the substrate analogue 4-methylmuconolactone (1 mM) was 
not transformed by MCI (data not shown) and that its inhibition on 3-chloromuconate (0.1 mM) 
transformation or protoanemonin formation by MCI (0.8 mU/ml determined with 0.1 mM 
muconate; 0.2 nM MCI) was less than 4 %. Assuming competitive inhibition to take place, it can be 
calculated that the Ki value for 4-methylmuconolactone is less than 19 mM.   
 
 
3.4.2. Characterization of homogenous  MCIB 
Various reports analyzed the kinetic differences between muconate and chloromuconate 
cyloisomerases and their evolutionary relationships. However, attempts to identify amino acid 
residues responsible for the formation of different products from 3-chloromuconate failed thus far 
(72). As CMCI produces nearly exclusively cis-dienelactone, and MCI protoanemonin, MCIB can 
be regarded as a probably evolutionary intermediate between these two types of enzymes.  
Purified MCIB transformed 3-chloromuconate stoichiometrically to equal amounts of 
protoanemonin and cis-dienelactone (48 ± 5 % respectively). Only very minor amounts of 
maleylacetate could be detected (5 ± 3 %). Following 3-chloromuconate transformation over time 
showed that both major products were formed in a constant ratio, indicating that the reaction 
mechanism was independent of the substrate concentration. 
The native molecular mass of MCIB was estimated by gelfiltration to be 350 ± 20 kDa and a single 
band of 43 ± 3 kDa was observed on SDS-gels. Thus MCIB might be a homooctamer, just like MCI 
of P. putida PRS2000 (55) or CMCI from R. eutropha JMP134 (49) or as assumed for MCI of 
Pseudomonas sp. strain MT1. No significant similarity of neither the N-terminal nor inner protein 
sequences was observed when these sequences were compared  to sequences of  cycloisomerases 
available in  databases (Table 5). 
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Out of the substrates tested, only 3-chloromuconate was transformed with high activity by this 
enzyme. Thus the absence of a significant activity with muconate distinguishes MCIB from MCI 
reported thus far, and the absence of a significant activity against 2-chloromuconate distinguishes it 
from most proteobacterial CMCI (78, 168, 169, 170). However, MCIB resembles the CMCI of 
R. eutropha JMP134 (TfdDII)  which also exhibits negligible activity with muconate (114) and the 
CMCI of the gram-positive Rhodococcus opacus 1CP (ClcB) also having negligible activity with 
muconate and 2-chloromuconate, but in contrast to MCIB of MT1 exhibits significant activity with 
2,4-dichloromuconate (151). 
 
Like MCI, MCIB of MT1 (1.9 mU/ml; 0.3 nM MCIB) was not able to transform 
4-methylmuconolactone (data not shown). 4-Methylmuconolactone (1 mM), however, inhibited 
significantly 3-chloromuconate (0.1 mM) transformation and protoanemonin formation by 50 %. 
Thus, 4-methylmuconolactone was recognized as inhibitor, but not converted by MCIB. Assuming 
competitive inhibition to take place a Ki value for 4-methylmuconolactone of 0.5 mM can be 
calculated. No accumulation of the hypothesized cycloisomerization intermediate could be detected 
– the sum of substrate (3-chloromuconate) and products (protoanemonin, cis-dienelactone and 
maleylacetate) remained constant throughout the experiment. 
 
 
 3.4.3. Characterization of homogeneous trans-dienelactone hydrolase (trans-DLH) 
Dienelactone hydrolases (DLH) have been divided into three classes according to their substrate 
specificities by Schlömann. Type I DLH transform trans-dienelactone much more efficient than cis-
dienelactone, type II DLH have an inverse substrate preference and type III transform both isomers 
with similar efficiencies (132). 
The molecular mass of native trans-DLH was determined to be 85 ± 30 kDa by gelfiltration. As a 
single band at 39 ± 4 kDa was visible on SDS-PAGE it can be assumed that trans-DLH of 
Pseudomonas sp. strain MT1 is a monomeric or dimeric enzyme (Table 5). In comparison, DLH 
involved in the chlorocatechol pathway and active with both cis- and trans-dienelactone, such as 
cis-/trans-DLH of Pseudomonas sp. strain B13 (105), P. putida strain 87 (149) and Rhodococcus 
opacus 1CP (85) as well as cis-DLH of Burkholderia cepacia (136) had been shown to be 
monomeric proteins. Similarly,  trans-DLH of Ralstonia eutropha 335  was assumed to be  a 
monomeric enzyme (132). Partial trans-DLH protein sequences (Table 5) were compared with 
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databases, but no significant similarity was obtained. Also no significant similarity was found when 
21 selected DLH protein sequences from SwissProt and the unpublished N-terminal sequence of 
trans-DLH of Ralstonia eutropha 335 (58) were compared with the N-terminal sequence of MT1 
trans-DLH. The activity of trans-DLH in 10 mM Histidine /HCl, pH 6.5 (137) was characterized by 
a rapid initial reaction followed by a drastic decrease in rate when 10 – 15 % of the substrates was 
converted, indicating that the enzyme was not acting as a typical catalyst, but that it was inhibited 
during transformation as previously observed for catechol 2,3-dioxygenase (69). However, when 
transformation was performed in 50 mM Tris/HCl, pH 7.5 no inactivation was observed. 
 
Table 7:  trans-Dienelactone hydrolase (trans-DLH) of Pseudomonas sp. strain MT1 in comparison to other DLH. 
Strain Enzyme Substrate Activity at 0.1 mM 
substrate (U/mg) 
Km (min-1) kcat 
(min-1) 
kcat/ Km  
(min-1 µM-1) 
trans-DLH cis-dienelactone < 1    
 trans-dienelactone 710 ± 37 480 ± 20 159000 
± 8500 
330 
 4-fluoromuconolactone 190 ± 4 1200 ± 20 98000 ± 
2200 
82 
Pseudomonas 
sp. strain 
MT1 
 enollactone 20 ± 10    
trans-DLH cis-dienelactone -    
 trans-dienelactone +    
 4-fluoromuconolactone +    
Alcaligenes 
eutrophus 335 
 enollactone +    
trans-DLH cis-dienelactone -    
 trans-dienelactone +    
 4-fluoromuconolactone (+)    
Alcaligenes 
eutrophus 
JMP 222 
 enollactone (+)    
cis-dienelactone + 400   
trans-dienelactone + 15   
4-fluoromuconolactone +    
Pseudomonas 
sp. strain B13 
cis-/trans-
DLH 
enollactone -    
cis-dienelactone + 140 *   
trans-dienelactone + 110 *   
4-fluoromuconolactone +    
Alcaligenes 
eutrophus 
JMP 134 
cis-/trans-
DLH 
enollactone -    
cis-DLH cis-dienelactone 24 28 923 33 
 trans-dienelactone < 0.2    
 4-fluoromuconolactone < 0.5    
Rhodococcus 
erythropolos 
1CP 
 enollactone -    
cis-DLH cis-dienelactone 220 ± 75 590 ± 240 49000 ± 
17000 
83 
 trans-dienelactone < 0.9    
 4-fluoromuconolactone < 0.5    
Burkholderia 
cepacia 
 enollactone < 4.5    
(*) determined in cell extracts. Data taken from following references: Alcaligenes eutrophus 335 (133, 132); 
A. eutrophus JMP222, (133); Pseudomonas sp. strain B13 (133); A. eutrophus JMP134 (133, 132); Rhodococcus 
erythropolis 1CP (133, 85); Burkholderia cepacia (136, 132). 
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The Km for trans-dienelactone (480 µM) (Table 7) was higher than those reported for cis-/trans-
DLH of the chlorocatechol pathway (133, 139) for this substrate. trans-DLH also exhibited 
significantly higher turnover numbers than cis-/trans-DLH of Pseudomonas sp. strain B13 
(1800 min-1, (95)) and even a higher turnover number compared to cis-DLH of B. cepacia with cis-
dienelactone (49.000 min-1 (136)). Activities of trans-DLH with 3-chloromuconate, protoanemonin 
and cis-dienelactone were negligible (< 0.1 % of the activity with 0.1 mM trans-dienelactone). 
Thus, while trans-DLH obviously interferes with the reaction catalyzed by MCI and MCIB, 
presumably preventing the formation of protoanemonin and supporting the formation of 
maleylacetate (see 3.5), the enzyme neither acts on the substrate (3-chloromuconate) nor on the 
product (protoanemonin) of this reaction.  
As, 4-chloromuconolactone, the postulated intermediate of 3-chloromuconate cycloisomerization 
(8, 72) was not available, transformation of the rather stable analogue 4-fluoromuconolactone (135) 
by trans-DLH was tested. HPLC revealed the quantitative transformation of 4-fluromuconolactone 
into a single product with a retention behavior and absorption spectrum identical to that of 
maleylacetate. Spectrophotometric analysis showed the product to exhibit an absorption maximum 
under physiological conditions of 243 nm, in accordance with its identity as maleylacetate (112, 
143) (Fig. 11). According to the kcat/Km-values, trans-dienelactone was the preferred substrate, 
being transformed approximately 4 times more efficiently than 4-fluoromuconolactone (Table 7). 
Similarly, trans-DLH of Ralstonia eutropha 335 and JMP222, as well as cis-/trans-DLH of 
Pseudomonas sp. B13 induced during growth on 4-fluorobenzoate (137) were reported to convert 
4--fluoromuconolactone. Only cis-DLH of Burkholderia cepacia did not transform 
4-fluoromuconolactone (133). 
Like the trans-DLH of Ralstonia eutropha 335 and JMP222, also the trans-DLH of Pseudomonas 
sp. strain MT1 exhibit a reasonable activity with enollactone. However, this activity, at a substrate 
concentration of 0.1 mM corresponds to only 4 ± 2 % the activity with trans-dienelactone, whereas 
activity of trans-DLH of R. eutropha 335 with enollactone was  40 ± 10 % the activity with trans-
dienelactone (132). Nevertheless, trans-DLHs seem to differ from cis-DLH and cis-/trans-DLH, 
which have no detectable activity with enollactone (133, 137).  
 
Organic mercurial substances like 4-chloromercurybenzoate have a high affinity for sulfhydryl 
groups in proteins and can be used for binding and inactivation studies. trans-DLH of MT1 was not 
inhibited by 4-chloromercurybenzoate, a characteristic shared with cis-DLH of B. cepacia (136). In 
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contrast, all cis-/trans DLH and even trans-DLH of JMP222 and 335 were reported to be 
inactivated by 4-chloromercurybenzoate (85, 95, 132). However, heavy metals had strong effects on 
trans-DLH activity (Table 8).  
 
Table 8. Effects of inhibitors on trans-dienelactone hydrolase (trans-DLH) activity of Pseudomonas 
sp. strain MT1. 
Enzyme inhibitor 
 
Concentration 
(mM) 
Relative enzyme activity (% )a after 
incubation for 
  5 min 60 min 240 min 
1 27 ± 3 17 ± 3 NDb EDTA  
 
 
10 13 ± 3 7 ± 3 ND 
o-Phenanthroline  
 
1 55 ± 4 18 ± 3 ND 
0.02 > 90 > 90 > 90 4-Chloromercuribenzoate  
 
 
2 > 90 > 90 > 90 
HgCl2   
 
1 6 ± 3 ND ND 
ZnCl2  
 
1 < 5 ND ND 
CuCl2  
 
1 34 ± 5 26 ± 4 ND 
 a Activity of purified trans-DLH is given compared to a control incubated without inhibitor. 
 b ND, not determined 
 
 
Schlömann stated that trans-DLHs need Mn2+ for efficient activity in contrast to cis- and cis-/trans-
DLH (132, 133). In order to test whether ions were necessary for catalysis, trans-DLH was 
incubated with the chelating agents EDTA and o-phenanthroline. Both agents significantly inhibited 
trans-DLH of MT1 (Table 8). Thus, with respect to inhibition by EDTA, trans-DLH of MT1 
resembles trans-DLH of JMP222 and 335, and contrasts cis-/trans-DLH of Ralstonia eutropha 
JMP134 (133) and cis-DLH of P. cepacia (78) which were not susceptible to EDTA. 
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3.5. In-situ transformation of 3-chloromuconate by purified enzymes 
3.5.1 In-situ transformation of 3-chloromuconate by combined action of MCI and trans-DLH 
of MT1 
When purified MCI of MT1 was incubated with 3-chloromuconate, protoanemonin was the major 
reaction product (>75 %) and only minor amounts of cis-dienelactone (8 ± 4 %) and maleylacetate 
(8 ± 5 %) were detected as side products (Fig. 12 A). However, when trans-DLH of MT1 was 
added simultaneously to the reaction mixture, higher amounts of maleylacetate and less 
protoanemonin were detected. Formation of cis-dienelactone was not effected by the addition of 
trans-DLH (Fig. 12 B - C). Following the transformation of 3-chloromuconate over time with 
different enzyme ratios showed, that all the products were continuously formed and that 
3-chloromuconate was transformed quantitatively into protoanemonin, cis-dienelactone and 
maleylacetate. No other compounds were accumulating during the reaction.  
 
0
20
40
60
80
100
120
140
0 10 20 30 40 50 60
3-Chloromuconate
Protoanemonin
cis-Dienelactone
Maleylacetate
C
on
ce
nt
ra
tio
n 
(µM
) 
Time (min)
3-Chloromuconate
Protoanemonin
cis-Dienelactone
Maleylacetate
0
20
40
60
80
100
120
140
C
on
ce
nt
ra
tio
n 
(µM
) 
0 20 40 60 80
Time (min)
A B
0
20
40
60
80
100
120
140
0 20 40 60 80
C
on
ce
nt
ra
tio
n 
(µM
) 
Time (min)
3-Chloromuconate
Protoanemonin
cis-Dienelactone
Maleylacetate
C D
Pr
od
uc
t r
at
io
 (c
on
en
tr
at
io
n 
of
 
m
al
ey
la
ce
ta
te
/c
on
ce
nt
ra
tio
n 
of
 p
ro
to
an
em
on
in
0
0,5
1
1,5
2
2,5
3
0 2 4 6
Enz yme  ratio (molecule s of trans -DLH/molecule s of MC I)
C
on
ce
nt
ra
tio
n 
(µM
) 
C
on
ce
nt
ra
tio
n 
(µM
) 
C
on
ce
nt
ra
tio
n 
(µM
) 
Pr
od
uc
t r
at
io
 (c
on
en
tr
at
io
n 
of
 
m
al
ey
la
ce
ta
te
/c
on
ce
nt
ra
tio
n 
of
 p
ro
to
an
em
on
in
 
Figure 12: Transformation of 3-chloromuconate by purified MCI or MCI and trans-DLH. (A) Transformation by MCI 
(0.9 mU/ml, 2.25 nM; (B) Transformation by MCI (0.3 mU/ml, 0.75 nM ) and trans-DLH (2.7 mU/ml, 0.18 nM); (C) 
Transformation by MCI (0.9 mU/ml, 2.25 nM) and trans-DLH (81 mU/ml, 5.4 nM); (D) Distribution of products in 
dependence to the applied enzyme ratio. MCI was added in fixed concentrations of  6.75 nM (♦); 2.25 nM (●); 
0.75 nM (○) or 0.45 nM (∆) . 
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It could be demonstrated, that the product ratio was independent of the initial substrate 
concentration (Fig. 13). When different concentrations of 3-chloromuconate (43 µM, 130 µM and 
290 µM) were incubated with  2.25 nM MCI (0.9 mU/ml)  and 5.4 nM trans-DLH (81 mU/ml), 
maleylacetate and protoanemonin were produced in approx. equal amounts throughout the whole 
transformation process. In all those assays 42 ± 2 % of the substrate was transformed into 
maleylacetate, 42 ± 5 % into protoanemonin and 12 ± 3 % into cis-dienelactone.   
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Figure 13: Transformation of different concentrations of 3-chloromuconate by a constant ratio of MCI (2.25 nM) and 
trans-DLH (5.4 nM). ∆ recovery (concentration of substrate plus concentration of products), ○ maleylacetate,  
● 3-chloromuconate, □ cis-dienelactone, ■ protoanemonin. 
 
Increasing the amount of trans-DLH at a fixed concentration of MCI resulted in an increase in 
maleylacetate formation. Different kinetic models were analyzed by Volker Hecht (GBF), if they 
could explain the observed enzyme kinetics and product shifts upon addition of enzyme mixtures. 
MCI was assumed to directly form cis-dienelactone without involving the intermediate formation of 
4-chloromuconolactone, whereas protoanemonin and maleylacetate formation was assumed to 
necessitate the intermediate formation of this compound. However, a simple competition between 
MCI catalyzing the formation of protoanemonin, and trans-DLH, catalyzing the formation of 
maleylacetate from 4-chloromuconolactone, could not explain the observed reaction kinetics. The 
kinetic data, however, could be explained by a rather improbable formation of a second reaction 
intermediate (I2) by trans-DLH, which spontaneously rearrange to form maleylacetate and a minor 
amount of protoanemonin (model 1), or by the enzymatic formation of both, maleylacetate and 
minor amounts of protoanemonin from 4-chloromuconolactone by trans-DLH (model 2) 
(Fig. 14 A). 
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Figure 14: (A) Kinetical models describing the formation of cis-dienelactone, protoanemonin and maleylacetate as 
products from 3-chloromuconate by MCI and trans-DLH catalyzed reactions or by spontaneous chemical reaction 
(chem.). Hypothesized intermediate 4-chloromuconolactone (4-ClML); hypothesized second reaction intermediate (I2).  
(B) Dependency of product ratio on the enzyme ratio and on the concentration of total proteins. Experimental data from 
data set with 0.45 nM with various concentrations of trans-DLH are indicated by symbols. Simulation of the 
composition of the formed product ratio using model 3 and model 4 with increasing total protein concentration (1.5, 2, 5 
and 10 fold). (B bottom) Product formation versus enzyme ratio with ♦ 2.7 mU/ml, 6.75 nM MCI; ● 0.9 mU/ml, 
2.25 nM MCI; ◦ 0.3 mU/ml, 0.75 nM; ∆ 0.18 mU/ml, 0.45 nM MCI with various concentrations trans-DLH as in 
Fig. 12 D. 
  
 
Both models were able to fit single data sets quite well. However, kinetic results from different data 
sets, where MCI was added in different fixed amounts (Fig. 12 D), could not be fitted by models 1 
and 2. As shown in Fig. 12 D the ratio of products formed was not only dependant on the ratio of 
trans-DLH/MCI. Experiments performed at constant concentrations of MCI of 0.45 nM, 0.75 nM, 
2.25 nM and 6.75 nM (corresponding to 0.18 mU MCI/ml, 0.3 mU MCI/ml, 0.9 mU MCI/ml and 
2,7 mU MCI/ml with 0.1 mM muconate, respectively) and increasing concentrations of trans-DLH 
showed, that at a constant ratio of trans-DLH/MCI, the formation of maleylacetate was favored by a 
high protein concentration.  
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The dependence of the product composition on the total protein concentration cannot be explained 
by the mechanisms used in models 1 and 2. It can, however, be explained if a spontaneous reaction 
competed with an enzyme catalyzed reaction.  Both models were therefore modified assuming 
chemical formation of protoanemonin from 4-chloromuconolactone.  
The two modified models (model 3 and model 4) were fitted to an experimental data set describing 
3-chloromuconate transformation in the presence of 0.45 nM MCI (0.18 mU MCI/ml) with various 
amounts of trans-DLH. Good agreement between model and experimental data were obtained for 
both models. The models were then used to simulate product formation using 1.5, 2.5, 5 and 10 fold 
total enzyme concentrations (Fig. 14 B). Even though both models not perfectly describe the 
increase in maleylacetate formation by increasing protein concentration, both models are in 
reasonably good agreement with the measured data. It should be noted, that measurements 
performed here, are highly dependent on the accuracy of protein activity determinations, 
determination of substrate and product formation, such that deviations to the model can easily be 
explained by experimental errors.  
Thus, the assumption that protoanemonin formation is a spontaneous reaction competing with an  
enzyme catalyzed transformation into maleylacetate is in accordance with the experimental data and 
explains the increase in maleylacetate formation upon increasing enzyme concentrations. 
In contrast to model 3, model 4 predicts accumulation of 4-chloromuconolactone at high total 
protein concentrations (5 – 20 fold). Experimentally we have never detected any misbalance of 
substrate and product concentrations, even when 3-chloromuconate (0.3 mM) was incubated with 
50 times MCI (22.5 nM, 9 mU MCI/ml). In addition there is no necessity to assume a second 
intermediate in model 3, so that model 3 obviously best describes the experimental findings.  
 
 
3.5.2. In-situ transformation of 3-chloromuconate by the combined action of MCIB and trans-
DLH of MT1 
Purified MCIB transformed 3-chloromuconate  into protoanemonin (48 ± 5 %) and cis-dienelactone 
(48 ± 5 %) in equal amounts. As observed during 3-chloromuconate transformation by MCI, only 
very minor amounts of maleylacetate (5 ± 3 %) were detected. To analyze, if the product 
composition, as shown above for MCI, can be influenced by co-incubation with trans-DLH, 
3-chloromuconate (0.1 mM) was transformed by enzyme mixtures. MCIB was added in activities 
corresponding to  53 mU/ml and 72 mU/ml (determined with 0.1 mM 3-chloromuconate, 
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(corresponding to 8.8 nM and 12 nM MCIB, respectively), whereas trans-DLH was applied with 
amounts ranging from 0.66 mU/ml – 1980 mU/ml (with 0.05 mM trans-dienelactone, 
corresponding to 0.044 nM – 132 nM trans-DLH), respectively. Addition of trans-DLH to the 
reaction mixture resulted in an increased formation of maleylacetate and decreased formation of 
protoanemonin, whereas the amount of cis-dienelactone produced remained constant (Fig. 15).  As 
observed for the combined action of MCI and trans-DLH, the product composition 
(maleylacetate/protoanemonin ratio) was also  dependent on the concentration of enzymes in the 
assays, whereas the amount of cis-dienelactone formed was independent of the presence of trans-
DLH and did not vary upon addition of different protein concentrations.   
 
 
Figure 15: Transformation of 3-chloro-
muconate by ● 8.8 nM MCIB, 53 mU/ml; 
◦ 12 nM MCIB, 72 mU/ml in the presence of 
increasing concentrations of trans-DLH. 
 
 
 
 
 
 
 
 
 
3.5.3. In-situ transformation of 3-chloromuconate by combined action of MCI of Pseudomonas 
putida PRS2000 and trans-dienelactone hydrolase of Pseudomonas sp. strain MT1 
In order to test whether intermediate 4-chloromuconolactone formation from  3-chloromuconate is a 
general capability of MCIs, and thus if protoanemonin formation can be generally prevented if a 
trans-DLH activity is present concomitantly, the archetype muconate cycloisomerase of 
Pseudomonas putida PRS2000 (CatB) was analyzed. This enzyme was previously reported by 
Vollmer to exhibit an only faint activity with 3-chloromuconate. According to Vollmer, the enzyme, 
when activities at substrate concentrations of 0.1 mM are compared, transforms muconate 590 times 
more rapidly than 3-chloromuconate and muconate was reported to be the by far preferred substrate 
with a Kcat/Km value more than 1000-fold that of 3-chloromuconate (Table 6).  In the following 
Enzyme ratio (molecules trans-DLH/molecules MCIB
Pr
od
uc
t r
at
io
 (c
on
ce
nt
ra
tio
n 
of
 
m
al
ey
la
ce
ta
te
/c
on
ce
nt
ra
tio
n 
of
pr
ot
oa
ne
m
on
in
)
0
2
4
6
8
10
12
14
16
18
0 2 4 6 8 10 12
Pr
od
uc
t r
at
io
 (c
on
ce
nt
ra
tio
n 
of
 
m
al
ey
la
ce
ta
te
/c
on
ce
nt
ra
tio
n 
of
pr
ot
oa
ne
m
on
in
)
Pr
od
uc
t r
at
io
 (c
on
ce
nt
ra
tio
n 
of
 
m
al
ey
la
ce
ta
te
/c
on
ce
nt
ra
tio
n 
of
pr
ot
oa
ne
m
on
in
)
 Results 56 
CatB was overexpressed from plasmid pCATB1 (kindly provided from Schlömann and 
Kaschabeck) containing catB of PRS2000, in a E. coli BL21 derivative. Transformation of 
3-chloromuconate and formation of products were evaluated by HPLC analysis. The reported kcat of 
12,600 min-1 mM-1 was used to calculate the concentration of protein molecules applied in the 
enzymatic tests. Activities were determined in at least 3 independent experiments. We observed, 
that 3-chloromuconate was a much better substrate to the CatB than Vollmer et. al had described 
(Table 12). In contrast to the 590 fold preference for muconate versus 3-chloromuconate (169), we 
determined an only 30 fold preference for muconate. Vollmer et al. have used a photometrical 
method to determine 3-chloromuconate transformation based on an initial decrease in absorption 
during 3-chloromuconate turnover (169). Such a method introduces not only a high error into the 
determined kinetic data (Table 6). Furthermore, it can be reasoned, that the decrease in absorption 
during the initial turnover is not due to transformation of 3-chloromuconate into protoanemonin, but 
due to the intermediate formation of 4-chloromuconolactone. Similarly, a slight decrease in 
absorption was also observed during transformation of 3-chloromuconate by MCI of MT1, 
however, 4-chloromuconolactone formation could never be observed by HPLC, and the initial 
decrease was too insensitive to base an enzymatic test on it. The common opinion, that MCI 
transform 3-chloromuconate with only a minor side-activity has therefore to be reconsidered.  
 
Similar to MCI of MT1, CatB transformed 3-chloromuconate to mainly protoanemonin (70 ± 8 %) 
and cis-dienelactone (17 ± 5 %). Again, all products were consistently formed over time . 
When 3-chloromuconate (0.15 mM) was incubated with  15.6 mU/ml of PRS2000 derived CatB 
(determined with 0.1 mM muconate and corresponding to 1.24 nM CatB) and an excess of 
190 mU/ml of trans-DLH of MT1 (determined with 0.05 mM trans-DLH, corresponding to 
12.6 nM trans-DLH). 22 ± 4 % of the substrate were transformed to protoanemonin, 22 ± 2 % to 
cis-dienelactone and the rest (55 ± 5 %) to maleylacetate. 
This experiment demonstrated successfully that the product formation from 3-chloromuconate 
transformation by a proteobacterial MCI is influenced by the concomitant action of MT1 trans-
DLH. Thus, it can be assumed to be a general phenomenon that the presence of trans-DLH can shift 
the product formation from toxic protoanemonin to maleylacetate for any proteobacterial MCI.  
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3.5.4. In-situ transformation of 3-chloromuconate by combined action of MCIB of MT1 and 
cis-/trans-DLH of Ralstonia eutropha JMP134 
Prevention of protoanemonin formation from 3-chloromuconate during muconate cycloisomerase 
catalyzed cycloisomerization by concomitant action of a trans-DLH, which is assumed to hydrolyze 
4-chloromuconolactone to maleylacetate, has not been observed previously. However, Schlömann 
analyzed the transformation of 4-fluoromuconolactone as an intermediate in the degradation of 
4-fluorobenzoate, and observed that both, trans-DLHs of Ralstonia strains, as well as cis-/trans-
DLHs of the chlorocatechol pathway are capable to transform 4-fluoromuconolactone (133). 
Therefore it was investigated, whether cis-/trans-DLH of the chlorocatechol pathway, like trans-
DLH of MT1, could act on 4-chloromuconolactone as the reaction intermediate of 
3-chloromuconate transformation and prevent protoanemonin production. TfdEI, a cis-/trans-DLH 
which was partially purified from R. eutropha JMP222 (pBBR1MI) (107) was used for this 
purpose. Thus, 3-chloromuconate (0.1 mM) was incubated with MCIB (21 mU/ml determined with 
0.1 mM 3-chloromuconate, corresponding to 3.5 nM MCIB) and TfdEI (62 mU/ml, determined with 
0.1 mM cis-dienelactone which corresponds to about 90 mU/ml DLH determined with 0.1 mM 
trans-DL (137)). Substrate conversion was monitored over time by HPLC analysis and 
spectrophotometrical analysis.  
In contrast to the previous experiment (see 3.5.2) where transformation of 3-chloromuconate by  
MCIB (53 mU/ml) and trans-DLH (65 mU/ml)  resulted in the formation of significant amounts of 
maleylacetate (maleylacetate : protoanemonin = 0.45 : 1) addition of cis-/trans-DLH only lead to 
formation of maleylacetate resulting from cis-dienelactone transformation. Protoanemonin 
formation was not reduced. Therefore it can be assumed that the ability of cis-/trans-DLH TfdEI to 
transform the  cycloisomerization intermediate 4-chloromuconolactone is at least not as pronounced 
as that of trans-DLH of MT1.  
 
Brückmann et al. have shown that cis-/trans-DLH of Pseudomonas sp. B13 transforms 
protoanemonin to cis-acetylacrylate with 0.8 % of its activity with cis-dienelactone (14). Thus we 
determined whether TfdEI is also capable to transform protoanemonin. However, we could not 
detect any significant decrease in protoanemonin concentration and therefore can state that activity 
of TfdEI  with 0.05 mM protoanemonin is < 0.10 % of its activity with 0.1 mM cis-dienelactone. 
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3.6. Quantification of the expression of MCI and MCIB during growth of Pseudomonas sp. 
strain MT1 on 5-chlorosalicylate and salicylate 
Based on the observation that MCIB does not exhibit any significant activity against muconate 
(Table 6), it is evident, that activities against muconate observed in cell extracts are exclusively due 
to induction of MCI. In contrast, activities against 3-chloromuconate can be due to both, induction 
of MCI or MCIB. 
In order to determine the activity of MCIB in cell extracts, both, the total activity against 0.1 mM 
3-chloromuconate as well as the activity against 0.1 mM muconate were determined. The activities 
with muconate were 25 U/g and 350 U/g, respectively, in extracts of 5-chlorosalicylate or salicylate 
grown cells, respectively, showing a significant higher induction of MCI in salicylate grown cells. 
As the activity of MCI with 0.1 mM 3-chloromuconate is 3.5 fold that with 0.1 mM (see 3.4.1), it 
can be estimated that the 3-chloromuconate transforming activity of MCI in 5-chlorosalicylate and 
salicylate grown cells should account for 85 and 1200 U/g, respectively. As the experimentally 
determined activity with 3-chloromuconate in salicylate-grown cells (1080 U/g) does not exceed 
above the calculated value (1200 U/g) it can be assumed, that MCIB activity is negligible under 
these conditions. In contrast, a high activity of 350 U/g observed in chlorosalicylate grown cells 
cannot be explained by induction of MCI only, but suggest 265 U/g to be due to MCIB induction 
(Table 9). Thus it can be assumed that MCIB is of minor importance for 3-chloromuconate 
transformation in salicylate grown cells and that MCIB is induced during growth on 
5-chlorosalicylate. When an extract of salicylate grown cells was applied to hydrophobic interaction 
chromatography, a method separating MCI and MCIB, only negligible activities of MCIB were 
observed, further evidencing, that this enzyme is specifically induced during growth on 
5-chlorosalicylate. 
 
Table 9. Specific activities of MCI and MCIB in cell extracts of Pseudomonas sp. strain MT1 grown on salicylate and 
5-chlorosalicylate. 
Growth substrate Test substrate Total activity 
measured (U/g) 
Activity of 
MCI (U/g) 
Activity of 
MCIB (U/g) 
Salicylate muconate 370 350 - 
 3-chloromuconate 1080 1225 - 
5-Chlorosalicylate muconate 25 25 - 
 3-chloromuconate 350 80 270 
 
 
 
 Results 59 
3.7. Maleylacetate reductase (MAR) of Pseudomonas sp. strain MT1 
3.7.1 MAR and its side activity with cis-acetylacrylate 
In cell extracts of MT1 grown on 5-chlorosalicylate or salicylate high activities against 
maleylacetate were detected, as well as significantly lower activities against cis-acetylacrylate. In 
both extracts the activity against cis-acetylacrylate corresponds to 4 – 5 % the activity with 
maleylacetate (at 0.05 mM concentration of the respective substrate). The capability to transform 
cis-acetylacrylate, the hydrolysis product of protoanemonin (14) was previously assumed to be an 
indication for a metabolic pathway of 4-chlorosalicylate degradation via protoanemonin (177). To 
analyze, if the activity against cis-acetylacrylate was due to cross-reactivity of MAR, an extract of 
5-chlorosalicylate grown cell was fractioned by ion exchange chromatography. In fact, both 
activities co-eluted, and the activity against cis-acetylacrylate in the partially purified fractions 
remained 4 % of the activity with maleylacetate. (Table 10). Thus, it can be assumed that MAR was 
responsible for transformation of both compounds. This assumption was feasible, as cis-
acetylacrylate resembles maleylacetate structurally apart from the missing carboxyl group 
(Fig. 16 A). In contrast to MAR of MT1, TfdFI MAR from R. eutropha JMP134 showed only 
negligible activity with cis-acetylacrylate (Table 10).  
 
Table 10. Activities in cell extracts and of partially purified maleylacetate reductases against maleylacetate,  cis- 
and trans-acetylacrylate. 
Substrate Cell extract Partially purified maleylacetate 
reductase 
 MT1 
salicylate grown 
MT1 
5-chlorosalicylate 
grown 
MT1 
5-chlorosalicylate 
grown 
TfdFI 
maleylacetate 100 % 100 % 100 % 100 % 
cis-acetylacrylate 4 ± 1 % 3 ± 1 % 4 ± 1 % 0.3 ± % 
trans-acetylacrylate < 1 % < 1 % < 1 % < 1 % 
a From Ralstonia eutropha JMP 222 (pBBR1MI) 3-chlorobenzoate grown. 
 
 
The applied photometrical test for determining MAR activity is based on measuring NADH 
oxidation over time. White-Stevens et al. had shown for salicylate hydroxylases that certain 
substrate analogues uncouple NADH oxidation from substrate reduction (174, 175). In order to 
exclude such an uncoupling to occur during incubation with cis-acetylacrylate, and to proof cis-
acetylacrylate to be a substrate for MAR, transformations were followed in parallel by HPLC and 
photometrical analysis. It could be demonstrated that the decrease of cis-acetylacrylate was 
stoichiometric to NADH oxidation and uncoupling was negligible.  
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As MAR of MT1 seemed to be special in terms of cis-acetylacrylate transformation, the kinetic 
parameters of transformation of both cis-acetylacrylate and maleylacetate were determined. 
Transformation of cis-acetylacrylate followed typical Michaelis-Menten kinetics and a Km of 640 ± 
135 µM was calculated. 
In contrast, maleylacetate transformation did not follow typical Michaelis-Menten kinetics. The 
curve could be fitted to a polynomial expression, earlier used for describing enzyme kinetics 
affected by substrate inhibition (2, 56). A Km value of 22 ± 5 µM and a KSS value (substrate 
inhibition constant) of 290 ± 110 µM were determined.  
As MAR was not purified to homogeneity, kcat values for maleylacetate or cis-acetylacrylate 
transformation could not be compared. However, comparison of Vmax values of partially purified 
MAR showed maximal turnover rates of cis-acetylacrylate to be 38 % those of maleylacetate.  
 
 
3.7.2. In-situ NMR-analysis of cis-acetylacrylate transformation 
In analogy to maleylacetate reduction by MAR, the product of cis-acetylacrylate transformation by 
MAR was assumed to be laevulinate. For identification of the product, transformation of cis-
acetylacrylate (1 mM) was followed in the presence of 1 mM NADH by 1H-NMR. cis-
Acetylacrylate exhibited signals at δ=2.35 ppm (methylfunction), δ=6.17 ppm and δ=6.52 ppm 
(olefinic protons) (Fig. 10 A).  
Upon addition of MAR (5 U/ml, determined with 0.05 mM cis-acetylacrylate) transformation of 
cis-acetylacrylate was monitored over time (Fig. 16 A, B, C). Samples of NADH and NAD+ were 
measured under identical conditions as references, such that the signals of all substrates and 
products of the reaction could be identified. A buffer concentration of  5 mM was chosen in order to 
keep the signals of the organic buffer (TRIZMA®BASE, Sigma (Tris[hydroxymethyl]-
aminomethane)) low. However, during the reaction, the pH decreased from 7.5 to 3.6. Chemical 
shifts of signals not arising from NADH or NAD and thus due to the reduction product formed from  
cis-acetylacrylate were detected at δ=2.27 ppm, δ=2.64 ppm (3J=17.2 Hz) and δ=2.92 ppm (3J=17.2 
Hz), respectively. The chemical shifts and the high coupling constants were indicative for the 
formation of a product with one methyl and two neighbored methylene groups (Fig. 16 F). Identical 
signals were observed when laevulinate was measured at pH 3.6 (Fig. 16 E). When the pH was 
readjusted to neutral conditions (pH 7.0), the signals of the two methylene groups of the reaction 
product shifted to δ=2.48 ppm (coupling constant 3J=13.8 Hz) and δ=2.82 ppm (3J=13.8 Hz). 
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Figure 16: Transformation of cis-acetylacrylate by partially purified MAR of Pseudomonas sp. strain MT1. cis-
Acetylacrylate (1 mM) was incubated in the presence of maleylacetate reductase (5 U/ml) and NADH (1 mM). 
Transformation was monitored over time (A: 3 h; B: 5.3 h; C: 20 h). If necessary the pH was manually adjusted to pH 
7.4. Arrows pointing downwards indicate peaks of the substrate (S), cis-acetylacrylate; arrows pointing upwards 
indicate peaks arising due to product (P) formed. All other signals were due to the presence of  NAD, NADH or D2O. 
Standards of laevulinic acid were measured at pH 7.0 (D) and pH 3.5 (E). cis-Acetylacrylate after incubation with 
maleylacetate reductase and  NADH for ca. 20 h at pH 3.6 (F) and after re-adjusting the pH to 7.0 (G). Chemical shifts 
of protons are given in ppm, coupling constants in brackets in Hz. 
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(Fig. 16 C and G), respectively. The resonance line of the methylfunction was not influenced by the 
pH. Similarly, the pH influenced the chemical shifts of the methylene groups of a laevulinate 
standard. At pH 7.0 (Fig. 16 D) signals at δ=2.27 ppm, δ=2.45 ppm (3J=13.5 Hz) and δ=2.82 ppm 
(3J=13.5 Hz) were observed. Thus, the product formed from cis-acetylacrylate and laevulinate 
showed identical NMR spectra and the product of cis-acetylacrylate reduction by MAR was 
identified as laevulinate. 
 
 
3.8. Genetic approach to identify gene sequences encoding key enzymes of the novel pathway 
The novel pathway for 4-chlorocatechol degradation by MT1 comprises enzymes known to be 
involved in the degradation of natural occurring aromatic compounds. However, the pathway 
specifically contains two distinct cycloisomerases and a trans-DLH. One cycloisomerase (MCI), 
from the product spectrum, is obviously highly related to proteobacterial MCIs, of the classical 
3-oxoadiate pathway for degradation of aromatics. The second cycloisomerase (MCIB), according 
to its product spectrum, seems to be intermediary to muconate and chloromuconate 
cycloisomerases. The trans-DLH resembles catalytical enzymes previously described in cell 
extracts of 4-fluorobenzoate degrading Ralstonia strains (137). Concomitant action of trans-DLH 
with one or the other cycloisomerase prevents the formation of the metabolic dead-end product 
protoanemonin which is formed when microorganisms harboring the wide-spread 3-oxoadipate 
pathway are confronted with 4-chlorocatechol. In order to clarify if the novel pathway is a 
physiological patchwork of enzymes encoded by genes in different operons or if it constitutes a 
novel genetic unit, part of this thesis project was aimed at the genetic description of the novel 
pathway. The genes encoding the three above mentioned key enzymes were attempted to be 
identified by PCR with degenerated primers derived from N-terminal and inner protein sequences 
and then to be localized.  
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3.8.1 Gene encoding muconate cycloisomerase (MCI) 
3.8.1.1 Sequencing of MCI 
PCR with primers N-term2 and Is D1 (Table 11) and DNA of MT1 as template amplified a 480 bp 
fragment which was visualized as dominant band on agarose gels (Fig. 17).  
 
Table 11. Amino acid sequences of the N-terminal and an internal tryptic peptide of Pseudomonas 
sp. strain MT1 muconate cycloisomerase (MCI) used for the development of degenerated primers. 
Peptide sequences underlined were used for the primer design. 
Peptide  Amino acid sequence Name and sequence of degenerated 
primers 
N-terminal TQAKIESIETILVDLPTVRPHKLAM N-term1 
GCAARATCGARWSCATCGA 
 TQAKIESIETILVDLPTVRPHKLAM N-term2 
GCATCGARACYATCCTDGTDGA
 TQAKIESIETILVDLPTVRPHKLAM N-term4 
CCNCAYAARCTDGCNATG 
Is d DLAEAEHFLDVR IS-D1 
GARCAYTTYCTDGAYGTGC 
 
Figure 17. PCR-amplification of a 480 bp 
gene fragment encoding part of the MCI 
gene using primers N-term2 and Is D1 and 
MT1 DNA as template. PCR reactions were 
performed with no additives (no), 
1 x Q-solution (Q) or DMSO at different 
final concentrations (1 %), (5 %), (10 %). 
Agarose gel loaded with PCR amplifications 
and λ DNA digested with HindIII and EcoRI 
as molecular weight marker (M). 
 
 
The extracted 480 bp fragment was cloned into pCR®4-TOPO and successful cloning was 
confirmed by plasmid extraction and excision of a 480 bp fragment with EcoRI restriction. PCR 
with the plasmid as template and the plasmid specific primers M13-F and M13-R (Invitrogen, 
Carlsbad, CA, USA) annealing adjacent to both sides of the insertion site resulted, as expected, in a 
ca. 650 bp amplification product. PCR with M13-F and N-term2 primers gave an amplification 
product of 560 bp, whereas PCR with M13-R and N-term2 primers failed to give amplification. 
This indicated that the MCI fragment was cloned with its N-terminal part adjacent to the M13-R 
site. The fragment was sequenced in both directions directly from the plasmid using M13-F and 
M13-R-primers. The obtained sequences were of high quality and allowed to recognize nucleotides 
of the plasmid and the earlier used protein deduced primers. The sequence was translated into 
protein sequence and complemented by amino acids identified by N-terminal protein sequencing to 
proceed the primer binding site. For further investigations residue 7 was defined as serine as 
M      no     Q    1%    5%   10% M
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determined by N-terminal sequencing, though DNA sequencing had indicated a cysteine instead. 
Database searches with that sequence using blastp showed highest homology to CatB of 
Pseudomonas putida CA10 (77 % identities, 88 % similarities), as already observed when the 
N-terminal sequence was compared with sequences from databases. High  similarities were also 
detected with various other muconate cycloisomerases. (CatB of P. putida KT2440, CatB of 
P. putida PRS2000 and CatB of P. putida SM25 (72 % identities, 87 % similarities) and CatB 
P. putida P111 and P. aeruginosa PAO1 (69 % identities, 86 % similarities)). CatB of 
Pseudomonas sp. MT1 shared less than 42 % identities and 62 % similarities with protein 
sequences of CMCI. 
 
 
3.8.1.2 Sequence alignment of MCI from MT1 with other (chloro)muconate cycloisomerases 
The phylogenetic tree of selected MCI and CMCI protein sequences demonstrates their relation in 
terms of homology (Fig. 19). MCI of Pseudomonas sp. strain MT1 clustered with CatBs of other 
Pseudomonads. CMCIs of proteobacteria formed a cluster distinct from that of proteobacterial 
MCIs. Interestingly CMCI (TfdDII) of Ralstonia eutropha JMP134 encoded on the degradative 
plasmid pJP4 could not be certainly assigned to the muconate or chloromuconate cycloisomerase 
cluster (bootstrap value only 53 out of 100), but was positioned between the two clusters. 
Both MCI and CMCI of Rhodococcus opacus 1CP did not cluster with any of the cycloisomerases 
of the proteobacteria indicating that those cycloisomerases of gram-positive and gram-negative 
bacteria evolved by functionally convergent evolution (34, 151).  
MCI of Pseudomonas sp. strain MT1 in contrast to all other proteobacterial MCI in the alignment 
carried instead of an isoleucine (I) a valine (V) at position 53 (numbering according to MCI 
sequence of MT1). All proteobacterial CMCI in the alignment had a valine at the respective 
position (except for TfdDII of R. eutropha JMP134 carrying a proline (P)). Vollmer et al. had 
created mutants of MCI of P. putida PRS2000 which they speculated to have increased 
transformation rates with 3-chloromuconate (169). According to their experiments, exchange of the 
above mentioned isoleucine with valine in mutant I54V lead to an increased kcat and increased 
affinity for 3-chloromuconate. According to our experiments (see chapter 3.8.1.3 Table 12) we 
assumed that the amino acid exchanges did not effect the rate of protoanemonin, but of 
4-chloromuconolactone formation. We further speculated that MCI of MT1 might have an 
increased 4-chloromuconolactone formation rate, because it carries a valine instead of an isoleucine.  
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P. putida PRS2000 CatB 1   TSALIERIDAIIVDLPTIRPHKLAMHTMQQQTLVVLRVRCSDGVEGIGEATTIGGLAYGY 60   
P. putida KT2440 CatB  1   TSVLIEHIDAIIVDLPTIRPHKLAMHTMQQQTLVVLRLRCSDGVEGIGEATTIGGLAYGY 60   
Pseudomonas sp. CA10 CatB 1   SQVLIESVETIIVDLPTIRPHKLAMHTMQHQTLVVIRLRCSDGIEGLGESTTIGGLAYGN 60   
Pseudomonas sp. MT1 CatB 1   TQAKIESIETILVDLPTVRPHKLAMHTISQQTLVIIRLRCSDGIEGLGESTTVGGLSYAN 60   
P. putida SM25 CatB 1   TSALIERIEAIIVDLPTIRPHKLAMHTMQQQTLVVLRVHCSDGVEGIGEATTIGGLAYGY 60   
P. putida P111 CatB 1   SQAVIQSLESIIVDLPTIRPHKLAMHTMNRQTLVILRLRCSDGIEGLGEATTIGGLAYGS 60   
P. aeruginosa PAO1 CatB 1   SQAVIQSLESIIVDLPTIRPHKLAMHTMNRQTLVILRLRCSDGIEGLGEATTIGGLAYGS 60   
R.metallidurans hypothetical 1   MTATISSIEAILVDLPTIRAHQLAMATMQQQTLVIVRLRCSDGIEGIGEATTIGGLSYGD 60   
R. eutropha. 335T CatB 1   SITAIESIEAILVDLPTIRPHQLAMATMQRQTLVIVRLRCADGIEGLGEATTIGGLSYGD 60   
Burkholderia sp. TH2 CatB1 1   MNAQITSVETVLVDLPTIRAHQLAMATMQQQTLVVVRLRSSDGIEGIGEATTIGGLSYGE 60   
Burkholderia sp. NK8 CatB 1   MNAQITSVEAILVDLPTIRAHQLAMATMQQQTLVIVRLRTSDGIEGIGEATTIGGLSHGD 60   
A. calcoaceticus ADP1 CatB 1   ---MYKSVETILVDIPTIRPHKLSVTTMQTQTLVLIKIITEDGIVGWGEATTIGGLNYGE 57   
Burkholderia sp. TH2 CatB2 1   SAVQIQAVETILVDVPTIRPHRLSVATMNCQALVLIRIQCADGITGWGEATTIGGLAYGE 60   
B.fungorum LB400 hypothetical 1   TPVKIESVETILVDVPTIRPHRLSVATMNCQTLVLVRIRCADGVVGVGEGTTIGGLAYGE 60   
A. lwoffii K24 CatB2 1   TPVKIESVETILVDVPTIRPHRLSVATMNCQTLVLVRIRCADGVVGVGEGTTIGGLAYGE 60   
Frateuria sp. ANA-18 CatB2 1   TPVKIESVETILVELPTIRPHRLSVATMNCQTLVLVRIRCADGVVGVGEGTTIGGLAYGE 60 
R. eutropha JMP134 TfdDII 1   KAAQIEAIETVIVDLPLRRIQQFARLGAKHQSSVLIRLHTKGGIVGIGESITPCGPWWSG 60 
Burkholderia sp. NK8 TfdD 1   --MKIDAIDALIVDVPTRRPIQMSMTTVHQQSYVIVRVR-AEGLVGVGEGGSVGGPVWSA 57   
B. cepacia CSV90 TfdD 1   --MKIDAIEAVIVDVPTKRPIQMSITTVHQQSYVIVRVY-SEGLVGVGEGGSVGGPVWSA 57   
R. eutropha JMP134 pJP4 TfdD 1   --MKIDAIEAVIVDVPTKRPIQMSITTVHQQSYVIVRVY-SEGLVGVGEGGSVGGPVWSA 57   
P. aeruginosa JB2 ClcB 1   --MKIEAIDVTLVDVPASRPIQMSFTTVQKQSYAIVQIR-AGGLVGIGEGSSVGGPTWSS 57  
P. putida pAC27 ClcB 1   --MKIEAIDVTLVDVPASRPIQMSFTTVQKQSYAIVQIR-AGGLVGIGEGSSVGGPTWSS 57   
P. aeruginosa 142 ClcB 1   --MKIEAIDVTLVDVPASRPIQMSFTTVQKQSYAIVQIR-AGGLVGIGEGSSVGGPTWSS 57   
B. cepacia 2a IjbD 1   --MRIESITATIVDVPTRGPLQMSFTTVDKQSYVIVEIK-AEGLVGIGEGGSVGGPTWSS 57   
Variovorax paradoxus TV1 TfdD 1   --MRIESITATIVDVPTRRPLQMSFTTVNKQSYVIVEIK-AEGLVGIGEGGSVGGPTWSS 57   
Pseudomonas sp. P51 TcbD 1   --MKIEAISTTIVDVPTRRPLQMSFTTVHKQSYVIVQVK-AGGLVGIGEGGSVGGPTWGS 57   
P. chlorophis RW71 TetD 1   --MKIEAISTTIVDVPTRRPLQMSFTTVHKQSYVIVQVT-AGGLVGIGEGGSVGGPTWGS 57   
R. eutropha NH9 CbnB 1   --MKIEAISTTIVDVPTRRPLQMSFTTVHKQSYVIVQVT-AGGLVGIGEGGSVGGPTWGS 57   
Rhodoferax sp. P230 TfdD 1   --MKIEAISTTIVDVPTRRPLQMSFTTVHKQSYVIVQVT-AGGLVGIGEGGSVGGPTWGS 57   
Delftia acidovorans TfdD     1   --MKIEAISTTIVDVPTRRPLQMSFTTVHKQSYVIVQVT-AGGLVGIGEGGSVGGPTWGS 57   
Rhodococcus opacus 1CP CatB 1   TDLSIVSVETTILDVPLVRPHKFATTSMTAQPLLLVAVTTAGGVTGYGEGVVPGGPWWGG 60   
Rhodococcus opacus 1CP ClcB2 1   T-TTITEMSATIVDLPSRRPHKFAATTMHHQSIVLVRVRDSDGGEGIGEAVTPGGPWWGG 59   
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P. putida PRS2000 CatB 61  ESPEGIKANIDAHLAPALIGLAADN-INAAMLKLDKLAKGNTFAKSGIESALLDAQGKRL 119 
P. putida SM25 CatB 61  ESPEGIKANIDAHLAPALIGLAADN-INAAMLRLEKLAKGNTFAKSGIESALLDAQGKRL 119  
P. putida KT2440 CatB 61  ESPEGIKANIDAYLAPALIGLPADN-INAAMLKLDKLAKGNTFAKSGIESALLDAQGKRL 119  
Pseudomonas sp. CA10 CatB 61  ESPESIKQNIDSHLAPLLIGQDAAN-INAAMLRLDKAAKGNTFAKSGLESALLDAQGKRL 119  
Pseudomonas sp. MT1 CatB 61  ESPESIKTNIDVHLAPALIGMDASN-FNAAMQRLDRIAKGNTFAKSGLESALLDAQGKRQ 119  
P. putida P111 CatB 61  ESPESIKSNLDAHFAPLLLGQPADN-VNAAMQRLDRHIRGNTFARSAVETALLDAHGKRL 119 
P. aeruginosa PAO1 CatB 61  ESPESIKSNLDAHFAPLLLGQPADN-VNAAMQRLDRHIRGNTFARSAVETALLDAHGKRL 119 
R.metallidurans hypothetical 61  ESPEGIKLTIDTYLAPALVGQDATN-VHAAMARLNKVARGNRFAKSALESAMLDAQGKRL 119 
R. eutropha. 335T CatB 61  ESPEGIKLTIDSYLAPALLGQDAAN-VHGAMARLGKVARGNRFAKSALETALLDAQGKRL 119 
Burkholderia sp. TH2 CatB1 61  ESPEGIKLTIDTYLAPALVGLDATN-VNGAMLKLNKVARGNRFAKCAIETALLDAQGKRL 119 
Burkholderia sp. NK8 CatB 61  ESPEGIKLTIDTYLAPALVGQDATN-INAAMLRLNKIARGNRFAKCAMETALLDAQGKRL 119 
A. calcoaceticus ADP1 CatB 58  ESPESVKANIDTYFKPLLLSIKAPLNVAQTLKLIRKSINGNRFAKCAIQTALLEIQAKRL 117 
Burkholderia sp. TH2 CatB2 61  ESPESIKTNIDTYFAPLLKGMDATR-PGQAMAKLRECFQGNRFAKCAIETALFDAQAQRF 119  
B.fungorum LB400 hypothetical 61  ESPESIKVNIDTYFAPLLKGLDATR-PGAAMAKLRELFQGNRFAKSALETALFDAQAQRL 119  
A. lwoffii K24 CatB2 61  ESPESIKVNIDTYFAPLLKGLDATR-PGAAMATLRGLFQGNRFARSAVETALFDAQAQRL 119  
Frateuria sp. ANA-18 CatB2   61  ESPESIKVNIDTYFAPLLKGLDATR-PGAAMATLRGLFQGNRFARSAVETALFDAHGAGL 119  
R. eutropha JMP134 TfdDII 61  DSVEAIQATINHYLAPLVVGEPALD-ASRIMAKLHGRVAGNAFAKAGIEMALLDAVGKIV 119  
Burkholderia sp. NK8 TfdD 58  ECAETIKTIVEQYLAPHLVGTDAFN-VSAALQTMARAVTGNASAKAALEMALLDLKARAL 116  
B. cepacia CSV90 TfdD 58  ECAETIKIIVERYLAPHLLGTDAFN-VSGALQTMARAVSGNASAKAAVEMALLDLKARAL 116  
R. eutropha JMP134 pJP4 TfdD 58  ECAETIKIIVERYLAPHLLGTDAFN-VSGALQTMARAVTGNASAKAAVEMALLDLKARAL 116  
P. aeruginosa JB2 ClcB 58  ECAETIKVIIETYLAPLLIGKDATN-LRELQHLMERAVTGNYSAKAAIDVALHDLKARSL 116  
P. putida pAC27 ClcB 58  ECAETIKVIIETYLAPLLIGKDATN-LRELQHLMERAVTGNYSAKAAIDVALHDLKARSL 116 
P. aeruginosa 142 ClcB 58  ECAETIKVIIETYLAPLLIGKDATN-LRELQHLMERAVTGNYSAKAAIDVALHDLKARSL 116  
B. cepacia 2a IjbD 58  ESAETIKTIIDTYLTPHLIGKDASN-LNVARILMDKAVTGNFSAKAAIDIALHDLKARAL 116  
Variovorax paradoxus TV1 TfdD 58  ESAETIKTIIDTYLTPHLIGKDASN-LNVARILMDKAVTGNFSAKAAIDIALHDLKARAL 116  
Pseudomonas sp. P51 TcbD 58  ESAETIKVIIDNYLAPLLVGKDASN-LSQARVLMDRAVTGNLSAKAAIDIALHDLKARAL 116  
P. chlorophis RW71 TetD 58  ESAETIKVIIDNYLAPLLIGKDASN-LSEARALMDRAVTGNLSAKAAIDIALHDLKARAL 116  
R. eutropha NH9 CbnB   58  ESAETIKVIIDNYLAPLLIGKDASN-LSEARALMDRAVTGNLSAKAAIDIALHDLKARAL 116  
Rhodoferax sp. P230 TfdD 58  ESAETIKVIIDNYLAPLLIGKDASN-LSEARALMDRAVTGNLSAKAAIDIALHDLKARAL 116  
Delftia acidovorans TfdD     58  ESAETIKVIIDNYLAPLLIGKDASN-LSEARALMDRAVTGNLSAKAAIDIALHDLKARAL 116  
Rhodococcus opacus 1CP CatB 61  ESVETMQAIVERYIVPVLLGRGVDE-ITGIMPDIERVVANARFAKAAVDVALHDAWARSL 119  
Rhodococcus opacus 1CP ClcB2 60  ESVETIKTIIDQYLAPVIIGRDPST-IGVASQSMDGLVFGNSVAKAAIETALWTSAERRS 118  
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P. putida PRS2000 CatB 120 GLPVSELLGGRVRDSLEVAWTLASGDTARDIAEARHMLEI 159  
P. putida SM25 CatB 120 GLPVSELLGGRVRESLEVAWTLASGDTARDIAEAQHMLEI 159  
P. putida KT2440 CatB 120 GLPVSELLGGRVRDSLEVAWTLASGDTARDIAEAQHMLDI 159  
Pseudomonas sp. CA10 CatB    120 GLPVSELLGGRVRDGLEVAWTLASGDTAKDIAEAQHMLEI 159  
Pseudomonas sp. MT1 CatB 120 GVAVSQLLGGRVRDSLEVGWVLASGNTARDIAKAEHFLDV 159  
P. putida P111 CatB 120 GLAVSELLGGRLHDSLEVAWTLASGDTGRDIEEAERMLDL 159  
P. aeruginosa PAO1 CatB 120 GLAVSELLGGRLHDSLEVAWTLASGDTGRDIEEAGRMLDL 159  
R.metallidurans hypothetical 120 DVPLATLLGGAVRDTLPVLWTLASGDTARDIEEAERFLEE 159  
R. eutropha. 335T CatB 120 GVPLATLLGGAVRDTLPVLWTLASGDTARDIDEAERLLAE 159  
Burkholderia sp. TH2 CatB1 120 GVPVSTLLGGAVRKTLPVLWTLASGDTQRDIEEAEMLLAE 159  
Burkholderia sp. NK8 CatB 120 GVPVCELLGGAVRKTLPVLWTLASGDTQRDIEEAEMLLAE 159  
A. calcoaceticus ADP1 CatB 118 NVPVSELLGGRIRDRLPVLWTLASGDTDKDIAEAKKMIEL 157  
Burkholderia sp. TH2 CatB2   120 GVPLSELFGGRVTDSVEVAWTLASGDTGRDIDEAHQMLEM 159  
B.fungorum LB400 hypothetical 120 GVPLSELFGGRVRDCVDVAWTLASGDTKRDIDEAGQVYET 159  
A. lwoffii K24 CatB2 120 GVPLSELFGGRIRDSVDVAWTLASGDTTRDIDEAERVFEA 159  
Frateuria sp. ANA-18 CatB2 120 GVPLSELFGGRIRDSVDVAWTLASGDTTRDIDEAERVFEA 159  
R. eutropha JMP134 TfdDII 120 DAPIHVLLGGRFRDRLSVAWPLATGDVNQEVDEAFRMLEA 159  
Burkholderia sp. NK8 TfdD 117 GVSIAELLGGRLRNSIPIAWTLASGDTKRDIDSAIEMIEK 156  
B. cepacia CSV90 TfdD 117 GVSIAELLGGPLRSAIPIAWTLASGDTKRDLDSAVEMIER 156  
R. eutropha JMP134 pJP4 TfdD 117 GVSIAELLGGPLRSAIPIAWTLASGDTKRDLDSAVEMIER 156  
P. aeruginosa JB2 ClcB 117 NLPLSDLIGGAIQQGIPIAWTLASGDTQRDIAIAEEMIER 156  
P. putida pAC27 ClcB 117 NLPLSDLIGGAIQQGIPIAWTLASGDTQRDIAIAEEMIER 156  
P. aeruginosa 142 ClcB 117 NLPLSDLIGGAIQQGIPIAWTLASGDTQRDIAIAEEMIER 156  
B. cepacia 2a IjbD 117 NLSVGDLIGGRTRDSIPIAWTLASGDTQRDIDSALEMIEA 156  
Variovorax paradoxus TV1 TfdD 117 NLSVGDLIGGRTRDSIPIAWTLASGDTQRDIDSALEMIEA 156  
Pseudomonas sp. P51 TcbD 117 NLSIADLIGGTMRTSIPIAWTLASGDTARDIDSALEMIET 156  
P. chlorophis RW71 TetD 117 NLSIADLIGGTMRKSIPIAWTLASGDTARDIDSALEMDRS 156  
R. eutropha NH9 CbnB 117 NLSIADLIGGTMRKSIPIAWTLASGDTARDIDSALEMIEA 156  
Rhodoferax sp. P230 TfdD 117 NLSIADLIGGTMRKSIPIAWTLASGDTARDIDSALEMIEA 156  
Delftia acidovorans TfdD     117 NLSIADLIGGTMRKSIPIAWTLASGDTARDIDSALEMIEA 156  
Rhodococcus opacus 1CP CatB 120 GVPVHTLLGGAFRKSVDVTWALGAAPAEEIIEEALDLVES 159  
Rhodococcus opacus 1CP ClcB2 119 RIPVSDLLGGLRRKRIPITWAFSAGSASDLIDEAAQKLDV 158  
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Figure 18: Alignment of protein sequences of muconate cycloisomerases (CatB), chloromuconate cycloisomerases 
(TfdD, ClcB, TetD, IjbD), TfdDII) and muconate cycloisomerase of Pseudomonas sp. strain MT1 based on 
CLUSTAL W alignment (159). Numbering of sequences are according to the sequence of muconate cycloisomerase of 
Pseudomonas sp. strain MT1. Amino acids conserved in muconate cycloisomerases are highlighted in light grey, those 
in chloromuconate cycloisomerases in and dark grey. Protein IDs are given in the tree in Figure 19. 
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R. opacus 1CP clcB2 CAD28144
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Figure 19: Phylogenetic tree of selected muconate and chloromuconate cycloisomerase protein 
sequences (indicated by abbreviated organism name, strain designation, name of gene and 
EMBL/GenBank/DDBJ gene accession number). Alignment of a 159 amino acid length block was 
performed with CLUSTAL W using default values (159). N-J phylogenetic tree was generated using 
the option available in CLUSTAL W program. Bootstrap values above 50 % from 1000 neighbour-
joining trees are indicated to the left of the nodes. Bar represents 10 amino acid changes per 100 
amino acids.  
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3.8.1.3. Muconate and 3-chloromuconate transformation rates by muconate cycloisomerases 
Amino acids conserved throughout muconate cycloisomerases but distinct in chloromuconate 
cycloisomerases  (marked in light grey in the alignment), and amino acids conserved throughout 
chloromuconate cycloisomerases, but distinct in muconate cycloisomerases (marked in dark grey)  
might indicate amino acids that are responsible for the functional differences between the two types 
of cycloisomerases (Fig. 18) (169). Various site-directed mutants of the P. putida PRS2000 
muconate cycloisomerase have been designed by the authors and analyzed for functional changes 
compared to the wild-type.  As described in chapter 3.4.1 MCI of Pseudomonas sp. strain MT1 
exhibited a higher activity against 3-chloromuconate than against the unchlorinated muconate and a 
comparison of kcat/Km- values indicated 3-chloromuconate to be even the preferred substrate for this 
enzyme. Such a behavior was unexpected for a MCI, specifically as previous reports on the 
archetype MCI of P. putida PRS2000 according to the studies of Vollmer et al. indicated muconate 
to be converted with 590 fold the velocity observed with 3-chloromuconate at 0.1 mM substrate 
concentrations and with a kcat/Km value more than 1000-fold that of 3-chloromuconate, muconate 
was assumed to be the by far preferred substrate (169) (Table 6, 12). Even though careful HPLC 
analysis revealed CatB of PRS2000 to be more active on 3-chloromuconate than previously 
reported, activity on 0.11 mM muconate was still 30-fold higher than the activity on 
3-chloromuconate, whereas MCI of MT1 exhibited higher activity on 3-chloromuconate compared 
to muconate (3.5.3).  
Out of the mutants described by Vollmer et al. two mutants showed increased activities against 
3-chloromuconate. In the I54V mutant the amino acid 54 (numbering according to protein sequence 
of MCI of PRS2000) was changed from Isoleucine to Valine  (both nonpolar residues), in mutant 
A271S amino acid 271 was changed from nonpolar alanine to uncharged, but polar serine. Mutant 
I54V showed an increased affinity and turnover of 3-chloromuconate, whereas mutant A271S only 
had a remarkably increased kcat compared to the wild type enzyme (Table 12). Remarkably, in 
contrast to all the other MCIs, but like the I54V mutants, MCI of MT1 carries a valine (V) at the 
respective position. As the obtained sequence of MCI of MT1 did not cover the full gene, we could 
not compare its sequence aligning with amino acid 271 of CatB of PRS2000. 
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Vollmer et al have used a questionable photometrical method to determine 3-chloromuconate 
transformation based on an initial decrease in absorption during 3-chloromuconate turnover (169) 
(3.5.3). Therefore, we re-evaluated the transformation rates of muconate and 3-chloromuconate at 
initial concentrations of 0.1 mM. The plasmids pCATB1, pCATB51 and pCATB54 (kindly 
provided from Schlömann and Kaschabeck) contained the wildtype gene catB of PRS2000, as well 
as the I54V and A271S mutated genes respectively. Enzymes were overexpressed in an E. coli 
BL21 derivative and formation of protoanemonin was evaluated by HPLC analysis as described 
above. Similar to the wild-type, both mutant enzymes converted 0.1 mM muconate with an activity 
17 – 34 fold that with 0.1 mM 3-chloromuconate. Thus, according to our study the introduced point 
mutations did not lead to any significant increase in the transformation rate of 3-chloromuconate to 
protoanemonin compared to their ability to transform muconate.  
 
Table 12. Relative activities of wildtype and  mutant MCI with muconate and 3-chloromuconate at initial substrate 
concentrations of 0.1 mM. 
Muconate 
cycloisomerases of  
Relative activity 
(activity with muconate : activity with 3-chloromuconate) 
 this study calculated from Vollmer et al. (169)
Pseudomonas sp. strain 
MT1 
0.29 ± 0.09 
 
 
P. putida PRS2000 
CATB1 (wildtype) 
30 ± 5 590 
P. putida PRS2000 
CATB51 (I54V mutant) 
34 ± 5 9.2 
P. putida PRS2000 
CATB54 (A271S mutant) 
17 ± 5 15 
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3.8.2 PCR to amplify gene sequences encoding MCIB 
PCR amplification with N-term3 and Is-D1 primers (Table 13) designed based on the determined 
MCIB protein sequence fragments, and MT1 DNA as template using an annealing temperature of 
48° C resulted in amplification of a dominant fragment of about 700 bp. In order to get amounts of 
the fragment sufficient for sequencing, amplification was repeated in 20 tubes in parallel, which 
were then combined and purified by gel purification. 30 µg/ml fragment were sent for sequencing 
with the N-term3 and Is-D1 primers, but unfortunately, sequences obtained were of very poor 
quality. Therefore the fragment was reamplified and cloned into pCR®4-TOPO. Two clones (named 
Cyclo1 and Cyclo2) both showing the integration of a 700 bp fragment when the plasmids were 
restricted with EcoRI, were used for further analysis. The plasmid containing the Cyclo1 insert was 
sent for sequencing using the M13-F and M13-R primer sites located on the vector. The sequences 
obtained were of good quality and were reverse compliment to each other. Sequence analysis 
identified the M13 primers and a fragment of expected size inserted into the vectors cloning site. 
However, when the insert was investigated for sequences of the degenerated primers, which should 
have been right next to the cloning site, the Is-D1 primer was found in reverse complement at both 
sides of the insert whereas the N-term3 primer sequence could not be localized in the sequence. 
Control experiments revealed that the 700 bp fragment could be amplified from genomic DNA or  
plasmid DNA as template in the presence of primer Is-D1 only. Database searches with the obtained 
sequences showed 88 % identity with the hypothetical protein Pflu4482 of P. fluorescens  and 79 % 
identity to the putative transcriptional regulator PP2884 of P. putida KT2440. It can be concluded, 
that the cloning was successful, but that the 700 bp fragment was not comprising MCIB encoding 
DNA sequence. Thus, the Is-D1 primer was not sufficiently specific. 
 
Table 13. Amino acid sequences of the N-terminal and internal tryptic peptides of Pseudomonas sp. 
strain MT1 MCIB used for the development of degenerated primers. Peptide sequences underlined 
were used for the primer design.  
Peptide  Amino acid sequence Name and sequence of degenerated 
primers 
N-terminal SQGFVIGRVLAQRLDIPFSQPIRM
SFGTLD 
N-term3 
ATGWSNTTYGGNACNYTNGA 
Is d MLFQENGGLEG Is-D1 
CGCCRCCRTTYTCYTG 
Is  c TLSTGSEGGDLAEGER  
Is b FGSGDPDAELLR  
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3.8.3 PCR to amplify gene sequences encoding trans-DLH 
A dominant 550 bp fragment could be amplified with the primers N-term2 and Is-C2 (designed 
based on known trans-DLH protein sequences of strain MT1, Table 14) and MT1 DNA as template. 
PCR-product at a concentration of 30 µg/ml was sent for direct sequencing. As only  very poor 
quality sequences were obtained, the fragment was cloned as described above. The resulting 
plasmid contained an insert of the expected size when excised with EcoRI and control PCRs 
performed with genomic DNA and plasmid DNA as template using only one primer each 
demonstrated that the fragment was amplified only when both degenerated primers were present. 
The insert of the plasmid was sequenced using M13-F and M13-R primers. Detailed investigations 
of the obtained sequences allowed identification of sequences of the vector adjacent to the M13 
primers and the cloning site, as well as sequences of both degenerated primers at the expected 
locations. However, the deduced amino acid sequence indicated amino acids adjacent to those used 
for primer design not matching information obtained by protein sequencing. Thus, even though both 
degenerative primers had annealed and lead to amplification of a 550 bp fragment in a preferred and 
reproducible manner, the amplified product does not comprise a part of the trans-DLH encoding 
gene. Database searches showed similarities ≥ 92 %  and identities ≥ 77 % to genes encoding 
proteins of the HlyD family of secretion proteins like the multidrug/solvent RND membrane fusion 
protein of P. putida KT2440 (NP_743545) (92 % similarity), the efflux transporter of Pseudomonas 
syringae  (NP_794059) (92 % similarity), the multidrug efflux membrane fusion protein MexA 
precursor of P. aeruginosa PAO1 (NP_249116) (85 % similarity). 
 
Table 14. Amino acid sequences of the N-terminal and internal tryptic peptides of Pseudomonas sp. 
strain MT1 trans-DLH used for the development of degenerated primers. Peptide sequences 
underlined were used for the primer design. 
Peptide  Amino acid sequence Name and sequence of degenerated 
primers 
N-terminal TDTSKSLPTYKQLLERKDAPPGS
SWGLFGK 
N-term2 
GCCTDCCDACYTAYAARCARCT 
Is c VSQGVTLEPGDAVLLR Is-C2 
GGYTCHAGRGTHACRCCYTG 
Is  d AFSLDLLATSLYALLAGPSL  
Is e KLDLDAGASGKALSAKVLEAAR  
Is f VDVNGAYSVDEAQALR  
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3.8.4 Southern Blot analysis of Pseudomonas sp. strain MT1 DNA for the presence of 
muconate cycloisomerase encoding genes 
About 600 ng of the 480 bp fragment comprising part of the MCI gene were used as template for 
DIG labeling according to the protocol of DIG DNA Labeling & Detection Kit (Boehringer 
Mannheim, Germany). The labeled probe was hybridized with genomic DNA restricted with four 
distinct restriction enzymes, respectively. In each case strong hybridization with two DNA 
fragments was observed. As the genome had been restricted at different recognition sites, the 
possibility that the two bands resulted from hybridization of the probe to a part of the MCI gene, 
localized on two restriction fragments is rather improbable. It can thus be assumed, that the probe 
not only hybridized to the MCI gene sequence, but also to a highly homologous sequence present 
on the genome. As biochemical experiments had shown the presence of a second cycloisomerase 
MCIB of unknown similarity to MCI in MT1, it can be reasoned that hybridization to a second gene 
fragment is due to high similarity of MCIB in the tested fragment (Fig. 20). 
 
 
Figure 20: Southern blot analysis of Pseudomonas 
sp. strain MT1 genome. Probe of MCI was 
hybridized to genomic DNA of MT1 digested with 
SmaI, EcoRV, PvuII and StuI. On the right and on the 
left bands of λ HindIII, EcoRI as genomic markers 
are indicated. 
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4. DISCUSSION 
4.1 The upper pathway 
Salicylate degradation can be initiated by either a salicylate 1-hydroxylase yielding catechol (50) or 
a salicylate 5-hydroxylase yielding gentisate (27, 47, 186). Whereas degradative routes involving 
chlorocatechols produced by 1-hydroxylation of salicylate have been described (82, 127), 
knowledge on the degradation of chlorogentisates is limited (172). However, in the present study 
degradation of salicylate and chlorosalicylates by MT1 via a chlorogentisate pathway can be 
excluded for various reasons. First, only catechol intradiol cleavage but no gentisate ring-cleavage 
activity was observed. Secondly, transformation of 3-chlorosalicylate results in the formation of 
3-chlorocatechol, evidencing the presence of a salicylate 1-hydroxylase activity in MT1. Slow 
transformation of 3-chlorocatechol by catechol 1,2-dioxygenase results in the formation of 
2-chloromuconate. The nearly quantitative accumulation of 3-chlorocatechol plus 
2-chloromuconate from 3-chlorosalicylate shows, that no 5-hydroxylating activity against this 
substrate is present. Third, during the transformation of 4- and 5-chlorosalicylate, 4-chlorocatechol, 
3-chloromuconate and maleylacetate were formed as intermediates. All those compounds can only 
be formed assuming a salicylate 1-hyroxylating activity and a catechol intradiol cleavage pathway.   
 
 
4.2 Degradation downstream of 4-chlorocatechol 
The aerobic degradation of chlorocatechols was until recently assumed to occur exclusively by 
enzymes of the chlorocatechol pathway involving chlorocatechol dioxygenase, chloromuconate 
cycloisomerase, dienelactone hydrolase, and maleylacetate reductase. However, recent studies have 
indicated that bacterial routes for channeling chlorocatechol into central metabolic pathways are 
more divers than previously thought. In 1995, Arensdorf and Focht (3) described the degradation of 
4-chlorobenzoate via 4-chlorocatechol and a meta-cleavage pathway, and similarly, Hollender et al. 
(61) proposed the degradation of 4-chlorophenol via meta-cleavage of 4-chlorocatechol to occur in 
a Comamonas isolate. Pseudomonas putida GJ31 grows on chlorobenzene via meta-cleavage of 
3-chlorocatechol (86). Another route of 3-chlorocatechol degradation has recently been reported for 
Rhodococcus opacus (91). It comprises, like all metabolic routes involving cleavage of 
chlorocatechols described so far, a special chlorocatechol dioxygenase with high activity against 
chlorocatechols (124). Chlorocatechol dioxygenases have thus far mainly been characterized from 
proteobacteria, and usually have similar relative maximal activities with catechol, 3-chloro- as well 
as 4-chlorocatechol (13). A similar specificity profile was observed for chlorocatechol 1,2-
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dioxygenase ClcA2 involved in 2-chlorophenol degradation by Rhodococcus opacus 1CP (89, 91). 
The only chlorocatechol dioxygenase differing in substrate specificity from above mentioned 
chlorocatechol dioxygenases is chlorocatechol dioxygenase ClcA1 of Rhodococcus opacus 1CP 
involved in 4-chlorophenol degradation, which exhibits similar maximal turnover rates for catechol 
and 4-chlorocatechol, but only 15 % of that activity with 3-chlorocatechol (84). In contrast to all 
chlorocatechol 1,2-dioxygenases described above, proteobacterial catechol dioxygenases are 
characterized by a very restricted substrate specificity and Vmax values with 4-chlorocatechol are 
usually in the range of 10 % that with catechol (13), and activity with 3-chlorocatechol is negligible 
(< 1 %, see (13)). 
The relative activities with catechol, 4-chloro- and 3-chlorocatechol and the absence of any 
significant 3-chlorocatechol transforming activity are thus indicative for the induction of catechol 
1,2-dioxygenase activity only, independent whether MT1 was growing on salicylate or 
chlorosalicylate. The negligible activity against 3-chlorocatechol is also the major reason for the 
failure of MT1 to grow on 3-chlorosalicylate.  
MT1 is thus obviously the first organism to be described capable to mineralize chloroaromatics via 
chlorocatechols in the absence of a specialized chlorocatechol dioxygenase. Such a capability is 
even more astonishing, as it was recently reported, that chlorocatechol ring-cleavage is a pathway 
bottleneck even in microorganisms harboring chlorocatechol genes. It has been shown that 
introduction of single copies of chlorocatechol genes into microorganisms capable to transform 
chloroaromatics into chlorocatechols is not sufficient to allow mineralization (75, 107). Later on it 
was proven, that accumulation of chlorocatechols impairs the growth of derivatives harboring single 
chlorocatechol gene copies and introduction of multiple copies of a chlorocatechol dioxygenase 
gene, and the consequent high expression of chlorocatechol 1,2-dioxygenase eliminated 
chlorocatechol accumulation and resulted in fast growing derivatives (108). Those results indicated 
that mineralization of chloroaromatics necessitates a delicate balance between chlorocatechol 
producing and chlorocatechol transforming activities. Therefore, the level of chlorocatechol 
transforming activities necessary to achieve growth depends significantly on the activity of 
peripheral enzymes. The above mentioned experiments have been performed using 
3-chlorobenzoate as model substrate. In case of chlorobenzene degradation it has been observed, 
that both peripheral enzymes (chlorobenzene dioxygenase and chlorobenzene dihydrodiol 
dehydrogenase) and chlorocatechol pathway enzymes are localized on the same catabolic plasmid 
(115, 165) and thus present in the same “gene dosage” inside the cell allowing growth. However, 
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the recruitment of catechol dioxygenase(s) for growth of MT1 on 4- and 5-chlorosalicylate easily 
explains the observed failure to grow on high concentrations of substrates (106), which was 
observed to result in the accumulation of chlorocatechol and cell death.  
 
Similarly, in the absence of a specialized chlorocatechol 1,2-dioxygenase (13), the presence of a 
typical proteobacterial chloromuconate cycloisomerase (usually active on 2-chloromuconate) (116, 
139, 150, 170) and of a cis-/trans-DLH (highly active on both cis- and trans-dienelactone) (85, 95, 
132, 133, 136, 137) were excluded as cell extracts showed no activity with 2-chloromuconate or cis-
dienelactone. In contrast, the high activity with muconate indicated the expression of a muconate 
cycloisomerase involved in the 3-oxoadipate pathway.  
Protoanemonin, a highly toxic intermediate, was recently shown to be the dominant product formed 
from 3-chloromuconate by such muconate cycloisomerases (8). As in Pseudomonas sp. strain MT1 
(as well as Pseudomonas sp. strain RW10), only enzymes of the 3-oxoadipate pathway have been 
observed and it has been suggested, that those organisms harbor a new route of 4-chlorocatechol 
degradation via protoanemonin as intermediate (106, 177). However, in none of these organisms, 
any protoanemonin hydrolyzing activity to form the postulated pathway intermediate cis-
acetylacrylate could be observed (14, 177, this study). 
When 4-chlorocatechol or the pathway intermediate 3-chloromuconate was incubated with cell 
extract, the substrates were transformed stoichiometrically into cis-dienelactone, protoanemonin 
and, surprisingly, maleylacetate.  
Thus, it was obvious that 3-chloromuconate is a central intermediate of the catabolic route in MT1 
from where the carbon flow is directed into cis-dienelactone, protoanemonin and maleylacetate. 
Only negligible activities with cis-dienelactone and protoanemonin were observed in either cell 
extracts or by whole cells, indicating cis-dienelactone and protoanemonin to be dead-end products 
of the pathway and therefore most likely to be leaking quantitatively out of the cells (10 ± 5 % cis-
dienelactone). The actual amount of protoanemonin formed will be higher than the one detected in 
the supernatant of culture (7 ± 5 %) as protoanemonin was reported to be relatively unstable even 
under physiological conditions (8). 
Therefore, maleylacetate is the dominant metabolite downstream of 3-chloromuconate which can be 
reduced by the highly expressed MAR. However, transformation of 3-chloromuconate to 
maleylacetate had to be elucidated and constitutes the core of the novel 4-chlorocatechol 
degradative pathway. 
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4.3 The new ortho-cleavage pathway of 4-chlorocatechol to maleylacetate 
In the present investigation it is shown that the amount of protoanemonin formed from 
3-chloromuconate depends on whether single purified cycloisomerases or combinations of enzymes 
are used for conversion. 3-Chloromuconate conversion by a purified muconate cycloisomerase of 
Pseudomonas sp. strain MT1 resulted in high concentrations of protoanemonin as shown for 
muconate cycloisomerases from Pseudomonas sp. strain B13 or RW10 (8). Simultaneous presence 
of MCI and trans-DLH of MT1, in contrast, yielded considerably smaller protoanemonin 
concentrations, but higher amounts of maleylacetate and thus, protoanemonin has to be considered 
not to be the major intermediate of the degradative pathway. Most interestingly, like MT1, also 
Pseudomonas sp. strain RW10 does not form quantitative amounts of protoanemonin when a cell-
free extract of chlorosalicylate-grown cells is exposed to 4-chlorocatechol (8) indicating that 
protoanemonin is not the only product.  
 
 
4.3.1 Mechanism of cycloisomerization 
Schmidt et al. have been the first ones to describe differences between muconate cycloisomerases 
involved in the 3-oxoadipate pathway and chloromuconate cycloisomerases of the chlorocatechol 
pathway. They postulated that the analyzed enzymes, derived from Pseudomonas sp. B13 differ 
from one another only by their substrate specificity, with chloromuconate cycloisomerases having 
an increased activity with chlorosubstituted muconates. They assumed that both muconate and 
chloromuconate cycloisomerases transform 2-chloro- and 3-chloromuconate, however at different 
rates, to 5-chloro- and 4-chloromuconolactone, respectively and that those muconolactones 
dehalogenate spontaneously to trans- and cis-dienenlactone, respectively. However, doubts on the 
spontaneous nature of dehalogenation arose when 5-chloro-3-methylmuconolactone, formed from 
2-chloro-4-methylmuconate, was reported as a stable compound, even under physiological 
conditions (113). A year later Vollmer et al. demonstrated the inability of MCI to cause 
dehalogenation during conversion of 2-chloromuconate. The authors showed that MCI instead 
catalyze the formation of an equilibrium between 2-chloromuconate and 2-chloro- and 
5-chloromuconolactone and proposed that chloromuconate cycloiomerases in contrast to muconate 
cycloisomerases have evolved the capability to cleave the carbon chloride bond (168). Thus 
dehalogenation of 5-chloromuconolactone was evidenced to be an enzymatic reaction. 
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Short time after, Blasco et al. observed that not cis-dienelactone, but protoanemonin is the product 
of 3-chloromuconate transformation by muconate cycloisomerases (8). Therefore they postulated 
that during 3-chloromuconate transformation muconate and chloromuconate cycloiosmerases 
catalyze different reactions and they postulated 4-chloromuconolactone as a common intermediate 
of both reactions. For chloromuconate cycloisomerases they postulated an active site which 
catalyzes fast elimination of the solvent-derived C5-proton and of the halide, thus generating cis-
dienelactone from 4-chloromuconolactone, whereas for muconate cycloisomerases they postulated 
an enzyme catalyzed decarboxylation and a dehalogenation of 4-chloromuconolatone leading to 
protoanemonin (8). 
According to studies on the reaction mechanisms of muconate cycloisomerase and mandelate 
racemase muconate (as well as 2-chloromuconate) cycloisomerization proceeds via an enol/enolate 
(Fig. 21 B), to which a proton is added to form muconolactone (Fig. 21 D) (42, 131). Similarly, the 
formation of protoanemonin from 3-chloro-cis,cis-muconate involves a protonation reaction, as two 
hydrogen atoms are present on the exocyclic carbon. In contrast, it was proposed that in the reaction 
leading to cis-dienelactone, the corresponding enol/enolate intermediate is not protonated but rather 
loses the negative charge by chloride abstraction (Fig. 21 C) (72). However, a direct enzyme-
catalyzed dehalogenation of 3-chloromuconate leading to cis-dienelactone (Fig. 21 A) cannot be 
excluded. To prove that protoanemonin formation involves a protonation reaction, Kaulmann et al. 
exchanged the Lys169 residue of Pseudomonas putida MCI, which is known to provide the proton 
for protonation reaction during muconate transformation (131), by alanine. As expected, substrates 
requiring protonation, such as muconate as well as 2-methyl, 3-methyl- or 2-chloromuconate were 
not converted at a significant rate by the variant. However, the variant was still active with 
3-chloro- and 2,4-dichloromuconate. Interestingly, cis-dienelactone and 2-chloro-cis-dienelactone 
were formed as products, whereas the wild-type forms protoanemonin and 2-chloroprotoanemonin, 
respectively. The authors assumed, thus, that chloromuconate cycloisomerases may avoid 
protoanemonin formation by increasing the rate of chloride abstraction from the enol/enolate 
intermediate compared to that of proton addition to it. 
More importantly, the study shows that protonation reaction to be definitely necessary for 
protoanemonin formation but not for cis-dienelactone formation and indicated that 
4-chloromuconolactone will be the intermediate of muconate cycloisomerase-catalyzed 
cycloisomerization, from which decarboxylation and chloride elimination to protoanemonin 
(Fig. 21 E) occurs, as proposed by Blasco et al. (8).  
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 The study presented here offers two new pieces of information that support Kaulmanns hypothesis: 
i) 3-Chloromuconate transformation by proteobacterial muconate cycloisomerases proceeds via a 
reaction intermediate which is used as a substrate for trans-dienelactone hydrolase. This hydrolase 
which is active with trans-dienelactone, 4-fluromuconolactone and enollactone, but not with cis-
dienelactone, 3-chloromuconate or protoanemonin, obviously acts on 4-chloromuconolactone. 
ii) Concomitant action of trans-DLH and MCI can prevent  protoanemonin formation in favor of  
maleylacetate formation, but it does not influence the formation of cis-dienelactone. Thus, the 
reaction intermediate, which serves as a substrate for trans-DLH (most probably 
4-chloromuconolactone) is not an intermediate in the formation of cis-dienelactone, but both 
reaction mechanisms diverge before, probably at the stage of enol/enolate intermediate. Similar 
observations were made during 3-chloromuconate transformation by concomitant action of  MCIB 
and trans-DLH. Figure 21 summarizes the reaction mechanisms we assume for 3-chloromuconate 
transformation by MCI and MCIB in the presence of trans-DLH.  
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Figure 21: Postulated mechanism for 3-chloromuconate transformation by combined action of a 3-chloromuconate 
cycloisomerizing enzyme and trans-DLH of Pseudomonas sp. MT1. Detailed description of steps are given in the text. 
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4-Chloromuconolactone is the intermediate of 3-chloromuconate cycloisomerization by muconate 
cycloisomerases, from which decarboxylation and chloride elimination to protoanemonin 
(Fig. 21 E) occurs (8). Whether this reaction is spontaneous or enzyme catalyzed has not been 
analyzed thus far.  
3-Chloromuconate transformation assays demonstrated that less protoanemonin but more 
maleylacetate were formed when cell extracts were applied in high compared to low concentration 
(Table 4). A similar product shift from protoanemonin to maleylacetate was observed when 
3-chloromuconate was incubated with increasing concentrations of purified MCI and  trans-DLH 
(see 3.5.1, 3.5.2 and below). The kinetic data presented clearly support the notion of protoanemonin 
formation from 4-chloromuconolactone to be a spontaneous reaction. Assuming that both 
protoanemonin and maleylacetate formation to be enzyme-catalyzed by muconate cycloisomerase 
or trans-dienelactone hydrolase, respectively, would exclude any effect of the total protein 
concentration on the product composition. However, if protoanemonin formation is spontaneous 
and competes with enzymatic hydrolyzation to maleylacetate, an increase in total protein 
concentration would lower the diffusion time for 4-chloromuconolactone to reach trans-DLH, 
which is in agreement with the observation of protoanemonin formation to be prevented by higher 
protein concentrations. Accordingly, out of various kinetic models established to describe the 
obtained kinetic data, only models assuming protoanemonin formation to be spontaneous were in 
good agreement with the measured data.  
Consequently, it can be concluded that cis-dienelactone is formed directly by MCI without 
involving the intermediate formation of 4-chloromuconolactone, whereas protoanemonin and 
maleylacetate formation necessitate the intermediate formation of this compound. The spontaneous 
decomposition of 4-chloromuconolactone to protoanemonin is prevented by trans-DLH which 
forms predominantly maleylacetate as reaction product. 
It can be further speculated whether trans-DLH and MCI or MCIB, respectively, form a loose 
multienzyme complex which falls apart during cell disruption (25, 110). Nevertheless, in whole 
cells, proteins will be packed much denser, compared the in-situ assays, such that spontaneous 
reactions and protoanemonin formation are prevented to a significant extent. This explains the low 
amounts of protoanemonin observed to accumulate in resting cell experiments and during growth of 
MT1 on chlorosalicylates.   
 
 
 Discussion 80 
Both cycloisomerases MCI and MCIB of MT1 have been tested for product formation in the 
presence of trans-DLH. In order to compare the influence of the enzyme ratio on the product 
formation, similar concentrations and ratio of the respective enzymes should be chosen and the 
amount of trans-DLH should be varied as performed for MCI of MT1. Figure 22 demonstrates that 
the effect of trans-DLH on 3-chloromuconate transformation by MCI and MCIB of Pseudomonas 
sp. strain MT1 is in the same order of magnitude. 
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Figure 22: Comparison of influence of trans-DLH on MCI and MCIB of 
Pseudomonas sp. strain MT1, respectively. Maleylacetate/protoanemonin ratio 
versus MCI/trans-DLH and MCIB/trans-DLH ratios. Curves as in Fig. 14 D and 
15, respectively. For better comparison, activities are given as mU/ml 
transformation of 3-chloromuconate for MCI and MCIB. 
 
 
4.3.2 Proposed function of trans-DLH - Mechanism of hydrolysis of a hypothesized 
cycloisomerization intermediate 
As reasoned above, we propose 4-chloromuconolactone as the reaction intermediate of 
3-chloromuconate cycloisomerization, which spontaneously decomposes to protoanemonin. We 
have further demonstrated that the formation of protoanemonin is reduced in favor of maleylacetate 
in the presence of trans-DLH (see 3.5.1 – 3.5.3). We assume that trans-DLH competes with 
dehalogenation and decarboxylation leading to protoanemonin and hydrolyzes 4-chloro-
muconolactone to maleylacetate. Schlömann et al. had previously shown, that 3-fluoromuconate, 
formed during 4-fluorobenzoate metabolism is transformed by muconate cycloisomerases to 
4-fluoromuconolactone without dehalogenation taking place. 4-Fluoromuconolactone was a rather 
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stable product and decomposed only slowly to maleylacetate with a half-life of 43 hours (135). 
During their studies on 4-fluorobenzoate metabolism, Schlömann et al. also could identify different 
types of dienelactone hydrolases, which were analyzed for their capability to transform 
4-fluoromuconolactone. Interestingly, trans-DLHs as well as cis-/trans-DLHs were observed to be 
capable to hydrolyze 4-fluoromuconolactone, whereas cis-DLH was not (133, 137). Dehalogenation 
of 4-chloromuconolactone by MT1 trans-DLH can be expected to resemble such 
4-fluoromuconolactone conversion to maleylacetate (132, 133). We could demonstrate that trans-
DLH of MT1 shares the ability to transform 4-fluoromuconolactone to maleylacetate with 
3-oxoadipate enol-lactone hydrolases of A. calcoaceticus and Pseudomonas putida, as well as trans- 
and cis-/trans-DLH of R. eutropha JMP134 and Pseudomonas sp. B13, respectively (132, 133). 
Tough the cis-/trans-DLH TfdEI of R. eutropha JMP134 (as the experiments  by Schlömann were 
performed in cell extracts, it is highly probable that the measured enzyme activity is due to activity 
of TfdEI, see (114)) was reported to be capable to transform 4-fluoromuconolactone, in the 
experiment performed by us, this enzyme was not capable to prevent protoanemonin formation 
from 3-chloromuconate by muconate cycloisomerase. Unfortunately, no detailed characterization of 
this enzymes capability to transform 4-fluoromuconolactone was available, and therefore it cannot 
be excluded, that it differed significantly from trans-DLH in turnover numbers for 
4-fluoromuconolactone. Thus, more detailed analysis will be necessary to evaluate to capabilities of 
cis-/trans-DLHs to transform 4-fluoro- and 4-chloromuconolactone.  
 
Additionally, it would be very interesting to screen various purified dienelactone hydrolases, 
especially trans-DLH of R. eutropha 335, Pseudomonas sp. RW10 and others induced in 
4-fluorobenzoate utilizing strains (137) for their ability to transform 4-chloromuconolactone 
generated in-situ by MCI or MCIB of MT1 in order to test if this functional phenotype could 
specifically be assigned to trans-dienelactone hydrolases.  
 
Figure 21 shows a possible reaction mechanism of maleylacetate formation from 
4-chloromuconolactone catalyzed by trans-DLH in analogy to reaction mechanism suggested by 
Chea et al. for dienelactone hydrolysis by cis-/trans-DLH of Pseudomonas sp. strain B13 (23). One 
may expect that the enzyme nucleophile attacks the lactone carbonyl group (Fig.  21, reaction F), 
giving rise to a halohydrin (Fig. 21, reaction G), which should spontaneously eliminate the 
halogenide ion (Fig. 21, reaction H). However, the relatedness of MT1 trans-DLH to other 
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hydrolytic enzymes, including the  cis-/trans-DLH family, is not known and trans-DLH differs in 
basic biochemical properties from cis-/trans-DLH eg. by its high susceptibility to chelators. Thus, 
this mechanism must be regarded as highly speculative. 
Inhibition of trans-DLH of MT1 by Hg2+, but not by 4-chloromercuribenzoate, both sulfhydryl-
selective agents (88), can be explained by the large molecular size of 4-chloromercuribenzoate 
which might not be able to access the active site pocket of trans-DLH, whereas the small ion can 
(136). Similarly other small reducing ions have a strong inhibitory effect on trans-DLH (Table 8). 
Unfortunately, there are no inhibition studies using ions on other DLH in the literature. However, 
not only trans-DLH of MT1 but also trans-DLH of Ralstonia eutropha 335 was shown to be 
susceptible to chelators, and it was suggested that trans-DLH of R. eutropha 335 might be Mn2+ 
dependant (132, 133). This observation could indicate a common reaction mechanism of both trans-
DLH of Pseudomonas sp. strain MT1 and R. eutropha 335. However, when protein sequence 
information obtained from MT1 and was compared with the almost complete protein sequence of 
trans-DLH of 335 (personal communication from Schlömann), no significant homology was 
observed. Against that, trans-DLH of 335 was similar to a sequence in R. metallidurans (ongoing 
sequencing project). Thus, the phylogenetic relationship between trans-DLHs of Pseudomonas and 
of Ralstonia still remain to be established. 
 
 
4.4 The novel cycloisomerase (MCIB) – product and substrate specificities of 
(chloro)muconate cycloisomerases 
The metabolism of 4-chlorocatechol by MT1 and reaction mechanisms leading to the formation of 
maleylacetate from 3-chloromuconate have been examined in detail using muconate cycloisomerase 
and trans-DLH of MT1. However, besides MCI, which is the dominant cycloisomerase during 
growth of MT1 on salicylate, we could identify a second cycloisomerase activity, termed MCIB  in 
MT1, which was specifically induced during growth on 5-chlorosalicylate. MCIB of Pseudomonas 
sp. strain MT1 catalyze 3-chloromuconate transformation to cis-dienelactone and protoanemonin in 
equal amounts and is thus assumed to be an enzyme with catalytical function intermediate to 
muconate and chloromuconate cycloisomerases of proteobacteria. However, our analysis has shown 
that even muconate cycloisomerases do (including the archetype enzyme of PRS2000) not 
exclusively catalyze protoanemonin formation but catalyze, though to a minor extent, 
dehalogenation to form cis-dienelactone (MCI of MT1 8 ± 5 % of the initial substrate concentration, 
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(see 3.4.1) and muconate cycloisomerase of P. putida PRS2000 17 ± 5 % (see 3.5.3)). Such a 
behavior, to the current knowledge, is however not astonishing. As described above, it is assumed 
that chloromuconate cycloisomerases avoid protoanemonin formation by increasing the rate of 
chloride abstraction from the enol/enolate intermediate compared to that of proton addition to it. 
Clearly, formation of protoanemonin and formation of cis-dienelactone require different active site 
structures, allowing at least theoretically all intermediate solutions. Thus, MCIB from the point of 
increasing halide elimination, is clearly intermediate to muconate and chloromuconate 
cycloisomerases.  
However, the product profile is not the only extraordinary property of MCIB. Similar to 
proteobacterial muconate cycloisomerases, MCIB has no significant activity with 
2-chloromuconate. This is in contrast to studies on proteobacterial chloromuconate 
cycloisomerases, which usually have relatively high turnover numbers for 2-chloromuconate. It 
should, however, be noted that even chloromuconate cycloisomerases analyzed in this aspect thus 
far (169) differed significantly  in their substrate specificity. Whereas the Pseudomonas sp. strain 
P51 and B13 derived enzymes transformed 2-chloromuconate and 3-chloromuconate with similar 
specificities (kcat/Km values), 3-chloromuconate was a by one order of magnitude preferred substrate 
for TfdDI of R. eutropha JMP134 (107). For all chloromuconate cycloisomerases, muconate is a 
relatively poor substrate (78, 139, 168, 169). Thus it seems, that MCIB exhibits just a slightly more 
restricted substrate specificity than above chloromuconate cycloisomerases. However, MCIB does 
not efficiently transform 2,4-dichloromuconate, which for all three chloromuconate 
cycloisomerases described in this respect, is the preferred substrate (78, 169). Two exceptional 
chloromuconate cycloisomerases are described in the  literature with substrate specificities similar 
to MCIB of MT1 - TfdDII of Ralstonia eutropha JMP134 (114) and ClcB of Rhodococcus opacus 
1CP (34, 151), both specifically dedicated to convert 3-chloromuconate.  The amino acid sequences 
of both proteins fall outside the clusters of muconate and chloromuconate cycloisomerases 
(Fig. 19). Alignment of the determined MCIB protein sequences with known muconate and 
chloromuconate cycloisomerases did not show any homology. However, careful inspection of the 
N-terminal sequence of MCIB showed the presence of motifs characteristic on one hand for 
muconate cycloisomerases of Pseudomonas (MSQXXVI) but also for chloromuconate 
cycloisomerases (PIXMSFXT). Further analysis of the MCIB protein sequence will reveal to which 
extend this protein actually is related to muconate and chloromuconate cycloisomerases and add 
more knowledge on sequence-function relationships among this important class of proteins.  
 Discussion 84 
On the first view, not only MCIB, but also MCI of MT1 has extraordinary properties, as it shows a 
higher specificity constant for 3-chloromuconate than for muconate (Table 6). Against that, 
transformation rates of 3-chloromuconate of MCI have generally been assumed to be significantly 
lower than of muconate, a fact that was first discussed for MCI of Pseudomonas sp. B13 (139) and 
later demonstrated for MCI of Pseudomonas putida PRS2000 (169). By site-directed mutagenesis, 
Vollmer et al. created two mutants I54V and A271S, which, according to the authors, were 
improved for 3-chloromuconate transformation (169). As MCI of MT1, in contrast to muconate 
cyloisomerases, but similar to chloromuconate cycloisomerases and like the I54V mutant, contains 
a valine at the respective position, it could be speculated that this amino acid is majorly responsible 
for the high turnover of 3-chloromuconate of MT1. However, reevaluation of 3-chloromuconate 
transformation by the PRS2000 muconate cycloisomerase and site-directed mutants showed, that 
they do not differ significantly in 3-chloromuconate transformation rates, and moreover, rates of the 
wildtype enzymes have been significantly underestimated. (Table 12). Therefore we suggest that the 
differences between muconate and chloromuconate cycloisomerases concerning 3-chloromuconate 
transformation rates are much less pronounced then previously assumed and that the major 
difference between these groups of enzymes is the reaction mechanism. 
 
In agreement with the hypothesized mechanism of cycloisomerization we speculate that the 
photometrical 3-chloromuconate activity test used by Vollmer et al. (169) does not determine the 
rate of substrate transformation into the final product protoanemonin, but determines slight 
differences in accumulation  of 4-chloromuconolactone (Fig. 21). If so, slight increases in 
3-chloromuconate transformation rates would result in accumulation of 4-chloromuconolactone, 
because spontaneous transformation of 4-chloromuconolactone would become rate limiting. This 
hypothesis can be tested by incubation of 3-chloromuconate with the wildtype or the mutant CatB 
together with trans-DLH of MT1. If 4-chloromuconolactone formation is in fact enhanced in the 
mutant enzymes, trans-DLH will have higher chances to encounter a 4-chloromuconolactone 
molecule and thus the shift from protoanemonin to maleylacetate production should be facilitated in 
the assays containing mutant CatB compared to assays containing the wildtype CatB. 
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4.5 The maleylacetate reductase (MAR) 
Maleylacetate as the product of transformation of 3-chloromuconate by muconate cycloisomerases 
and trans-dienelactone hydrolase of MT1 is converted to 3-oxoadipate by the action of a 
maleylacetate reductase. Most bacterial maleylacetate reductases, which are characterized in detail 
thus far, are encoded within the cluster of chlorocatechol pathway genes. However, as there was no 
indication for the induction of any other enzyme typical for chlorocatechol pathways, MAR of MT1 
is evidently not encoded in such a gene cluster.  
Concerning kinetic parameters, MAR of MT1 differs from previously described maleylacetate 
reductases in two aspects. Firstly, the Km of MAR of MT1 was significantly lower compared to 
proteobacterial MARs of the chlorocatechol pathway (Pseudomonas sp. strain B13 Km = 58 µM 
(71); P. aeruginosa RHO1 Km =65 µM (92); R. eutropha JMP134 TfdFII Km = 50 µM (92)).  
Secondly, the enzyme was efficient in the reduction of cis-acetylacrylate to laevulinate, a reaction 
analogues to maleylacetate reduction.  Though MT1 MAR has a very high Km-value  for cis-
acetylacrylate (640 µM ± 135 µM), its maximal turnover number with cis-acetylacrylate is 34 % 
that with maleylacetate (see 3.7.1). This activity contrasts that of the TfdFI maleylacetate reductase 
of R. eutropha JMP134 MAR which exhibits only negligible activity with cis-acetylacrylate. In fact 
the side activity of MAR of MT1 with cis-acetylacrylate could explain the capability of MT1 to 
grow on that substrate (106). However, if MT1 actually does grow on cis-acetylacrylate via an 
initial MAR catalyzed reduction with laevulinate as intermediate remains to be elucidated.  
 
 
4.6 Regulation and genetic organization of the novel pathway 
All enzyme activities measured in cell extracts of 5-chlorosalicylate grown MT1 could also be 
detected in extracts of salicylate, but not in succinate grown cells (Table 2). Thus all those activities 
are inducible. MCI and muconolactone isomerase were induced to higher levels in cells grown on 
salicylate, as expected for enzymes of the 3-oxoadipate pathway (50, 102), whereas salicylate 
1-hydroxylase, catechol 1,2-dioxygenase, MCIB, trans-DLH and MAR were significantly higher 
expressed when cells were grown on 5-chlorosalicylate compared to salicylate.  
On the first view, the induction pattern of catechol 1,2-dioxygenase is surprising, as catechol 1,2-
dioxygenase is commonly known to be part of the 3-oxoadipate pathway and to be encoded within 
one operon with MCI and muconolactone isomerase (50). 
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 There are growing evidence that catabolic genes of the 3-oxoadipate pathway can be encoded 
several times throughout a bacterial genome, so that they can underlay different mechanisms of 
regulation (see 4.8) (62, 144). Similar bacterial genome sequencing projects reveal increasing 
examples of strains, that harbor more than one catechol 1,2-dioxygenase gene or complete cat gene 
clusters. Jiménez et al. (62) summarized cases where several catechol 1,2-dioxygenases are encoded 
within a bacterial genome, either as duplicates of the full (93, 158) or partial 3-oxoadipate cluster 
(20, 62, 64, 73, 74, 94). The recent comparison genome sequences of Pseudomonas putida KT2440 
with other Pseudomonas strains, demonstrated that P. fluorenscens Pf0-1 harbors two copies of the 
cat gene clusters, whereas P. putida KT2440 codes for one cluster and one additional catechol 1,2-
dioxygenase which is located within the benzoate degrading cluster (ben cluster). The ben clusters 
of P. putida PRS2000, P. aeruginosa and fluorescens, in contrast, do not harbor a catechol 1,2-
dioxygenase encoding gene. Ralstonia metallidurans CH34 encodes two non-identical cat clusters 
and one additional catechol 1,2-dioxygenase gene adjacent to its ben gene cluster. In contrast, some 
strains like Pseudomonas aeruginosa PAO1, Burkholderia pseudomallei (ongoing genome project) 
and Novosphingobium aromaticivorans (ongoing) contain only one 3-oxoadipate cluster or no such 
cluster or genes at all like P. syringae pv. tomato DC3000.  
Hence occurrence, genetic location, and regulation of such isoenzymes is highly diverse.  Our 
observation of a higher induction of catechol 1,2-dioxygenases activity in 5-chlorosalicylate cells 
concomitant with a reduction in level of muconate cycloisomerase and muconolacton isomerase 
indicate that MT1 should contain at least one independently regulated catechol 1,2-dioxygenase. 
Recent experiments (Camara, personal communication) indicate that MT1 harbors at least two 
catechol 1,2-dioxygenases. Thus it can be speculated, that one of the respective encoding genes is 
located inside a cat gene cluster, whereas the second one is independently regulated.   
As stated above, mineralization of chloroaromatics necessitates a delicate balance between 
chlorocatechol producing and chlorocatechol transforming activities. In this context, the high levels 
of catechol 1,2-dioxygenase observed during growth on chlorosalicylate are most probably due to a 
catechol 1,2-dioxygenase independently regulated from the 3-oxoadipate pathway gene cluster and 
is possibly absolutely necessary to allow growth of MT1 on chlorosalicylates.  
 
According to separation of MT1 cell extracts using different principles of protein chromatography 
only one MCI should be present in MT1. Nevertheless, in southern blots with a fragment of MCI 
encoding gene of MT1 applied as probe, two distinct genome fragments hybridized resulting in two 
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major bands (Fig. 20) and it can be assumed that hybridization is due to sequence homology 
between the MCIB and the MCI encoding gene sequences. The inverse induction patterns of MCI 
and MCIB suggest that their genes are not located within one operon, neither does the southern blot 
show a genetic connection of MCI and MCIB.  
 
Salicylate hydroxylase (Fig. 7) is a flavoprotein monooxygenase that catalyzes the conversion of 
salicylate to catechol. The enzyme was first purified from P. putida S1 (181) and later from various 
other Pseudomonas and Burkholderia strains, and cloned and sequenced from various sources (9, 
66, 81, 183), dominantly Pseudomonas spp.. Usually, salicylate hydroxylase is included in the 
naphthalene pathway, and the gene encoding salicylate hydroxylase is followed by genes encoding 
a meta-cleavage pathway. Different so-called NAH plasmids harboring these genes have been 
described from Pseudomonas strains (19, 182). In contrast, P. stutzeri AN10 harbors 
chromosomally located nah genes (126). Moreover, variations in gene organization have been 
observed. P. stutzeri AN10, besides nahG encoding salicylate hydroxylase located in one 
transcriptional unit with the meta-cleavage pathway genes, contains a second gene encoding 
salicylate hydroxylase, nahW, which is situated outside but in close proximity to this transcriptional 
unit. Both, the nahG and nahW genes of P. stutzeri AN10 are induced and expressed upon 
incubation with salicylate. Such a gene organization seems to be common to naphthalene degrading 
P. stutzeri strains (10). Despite differences in gene organization and partially low homology (NahW 
shares 23 – 25 % amino acid sequence identity to other salicylate hydroxylases), most salicylate 
hydroxylases described thus far exhibit similar substrate ranges with significant activities with 
salicylate,  4-chloro- and 5-chlorosalicylate, and a lower activity against 3-chlorosalicylate (10, 66, 
82, 127). Given the broad substrate specificity of salicylate 1-hydroxylases it is not surprising that 
chlorosalicylate mineralizing Pseudomonas strains could easily be obtained by combining a 
salicylate 1-hydroxylase with a functioning chlorocatechol pathway (82, 127).  Genes similar to 
those encoding salicylate hydroxylase (approx 25 – 30 % amino acid sequence identity) have been 
localized in the genome of P. aeruginosa PAO1 and P. putida KT2440, however, KT2440 is 
reported not to grow on salicylate (63). The analysis of strain collections has shown, that only a few 
Pseudomonas strains are capable to mineralize salicylate, whereas such a capability seems to be 
frequent in Burkholderia cepacia (155), however, as outlined above, identification of the encoding 
regions as well as information on the regulation of salicylate hydroxylases independent of those 
involved in naphthalene degradation is rare. Interestingly, salicylate 1-hydroxylase is more 
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efficiently induced in MT1 during growth on 5-chlorosalicylate compared to salicylate, and thus 
shows induction pattern similar to those of catechol 1,2-dioxygenase, MCIB, trans-DLH and MAR. 
However, if those genes are localized in one and the same gene cluster remains speculative.   
 
Extracts of MT1 were highly active with trans-dienelactone and maleylacetate. Similarly, 
concomitant expression of different types of DLH and MAR in the absence of chlorocatechol 1,2-
dioxygenase and chloromuconate cycloisomerase of the chlorocatechol pathway were previously 
described for bacteria growing on 4-fluorobenzoate as only source of carbon and energy (137). The 
authors had speculated on a novel pathway via ortho-cleavage of 4-fluorocatechol, 
3-fluoromuconate and 4-fluoromuconolactone. 
In R. eutropha 335 a trans-DLH has been reported as crucial enzyme and shown to be induced 
during growth of the strain with 4–fluorobenzoate (137). The enzyme may play a dual role in the 
degradation and be responsible for direct conversion of 4-fluoromuconolactone as well as 
conversion of trans-dienelactone formed from 4-fluoromuconolactone as by-product by 
3-oxoadipate enol-lactone hydrolase (132). The natural function of the R. eutropha trans-DLH so 
far is unclear. It is highly unlikely to have been selected especially for 4-fluorobenzoate catabolism 
and thus seems to be recruited for it by accidental induction. In Pseudomonas sp. strain MT1 trans-
DLH may also be recruited by chance induction. However, it may also be coinduced with MCIB. If 
this was true, then these enzymes might constitute the core elements of another highly unusual 
chlorocatechol degradative pathway. Future studies into the genetic background of MT1 
cycloisomerase and trans-DLH should help to solve this question. 
 
In MT1, MAR is responsible for channeling the substrate into the Krebs cycle. While many 
chlorocatechol operons do comprise MAR encoding genes (38, 67, 68, 79, 109, 114, 143, 163), 
some recently characterized chlorocatechol gene clusters did not appear to contain such genes (34, 
91, 144) and thus maleylacetate reductases have to be recruited from other metabolic routes.  
Maleylacetate reductases have also been shown to contribute to the bacterial catabolism of natural 
aromatic compounds like quinol, resorcinol, tyrosine and vanillate (15, 142, 153), as well as more 
complex structures, such as hydroxylated biarylethers (4). Though MAR tends to be encoded within 
specialized gene clusters for degradation of hydroxylated biarylethers (4), dinitrotoluene 
(Burkholderia cepacia R34 (65)), 2,4,5.trichlorophenoxyacetate (B. cepacia AC1100 (26)), 
pentachlorophenol (Sphingomonas chlorophenolica ATCC 39723 (17)) recent bacterial genome 
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projects, including that of Ralstonia metallidurans (acc. no. NZ_AAAI01000075), have revealed 
that MAR encoding genes are localized in chromosomal regions with unknown functions outside 
catabolic gene clusters (144) and more such information might be coming up with ongoing and 
future genome projects. Similarly, in Rhodococcus opacus 1CP, a MAR encoding gene of unknown 
metabolic function , which is only distantly related to proteobacterial MAR of the chlorocatechol 
pathway (142) and not located within a chlorocatechol cluster has been observed.   
A maleylacetate reductase of an obvious function similar to that in MT1, more precisely an enzyme 
responsible for channeling maleylacetate formed from 4-halomuconolactone by a trans-
dienelactone hydrolase, into the Krebs cycle, was recently described from R. eutropha 335 (MacA, 
accession number AF130250), as not being part of a specialized gene cluster (137, 141, 144). 
Recent analysis showed, that the macA gene is localized in a small gene cluster comprising, in 
addition to macA a gene for a hypothetical membrane transport protein, macB, possibly 
cotranscribed with macA, and a presumed regulatory gene, macR, divergently transcribed from 
macAB. MacA shared only 50 - 57 % identity with maleylacetate reductases of the chlorocatechol 
pathway, whereas it turned out to be most similar to TftE, the MAR of 2,4,5-dinitrophenoxyacetate 
degrading B. cepacia AC1100 (62 % identity) (26) and to the putative MAR of the 
2,4-dinitrotoluene degrading B. cepacia R34 (61 % identity) (65, 144).  It was speculated, that 
maleylacetate itself is the inducer of the macA gene, such that the mac cluster of R. eutropha 
JMP335 serves as a bridge between maleylacetate forming pathways and the 3-oxoadipate pathway 
funneling 3-oxoadipate to Krebs-cycle intermediates in a more general way than just for the 
degradation of the presumably non-natural compound 4-fluorobenzoate. 
However, in contrast to the situation in 335, where maleylacetate reductase was induced exclusively 
during growth on fluorobenzoate, but not on benzoate, significant induction of maleylacetate 
reductase activity was observed in MT1 even during growth on salicylate, with increased expression 
levels during growth on chlorosalicylate suggesting a regulation and/or gene organization 
completely different from that in 335.  
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4.7 Strain MT1 with its novel pathway in the 4-strain carbon sharing community 
Pseudomonas sp. strain MT1 was isolated by continuous culture enrichment as a member of a 
4-strain community growing in  very stable community composition on 4-chlorosalicylate (MT1, 84 
± 5 %; Achromobacter xylosoxidans MT3 and Pseudomonas veronii strain MT4, 8 ± 4 %;  
Empedobacter brevis MT2, 1 %). Interestingly, though MT1 can also grow in monoculture on  
4-chlorosalicylate, when inoculated together with MT2, MT3 and MT4, it never outcompetes the 
other strains. Thus, there must be an advantage to exist in a community compared to growing as a 
monoculture. 
Bacteria metabolize substrates in order to obtain energy and carbon for biosynthesis and growth. 
The chlorosalicylate degrading community can be regarded as an example of carbon sharing 
between community members. Much simpler examples of carbon sharing for mineralization of a 
substrate have been described in the literature. The most simple example are two-membered 
communities mineralizing bicyclic aromatics. In communities mineralizing eg. chlorodibenzofuran, 
one community member is responsible for the initial attack and grows on the expense of the hereby 
activated aromatic ring. As the microorganism does not harbor a pathway for mineralizing the 
intermediary formed chlorinated single-ring aromatic, chlorosalicylate in the case of dibenzofuran 
degradation, a second community member can gain its energy by mineralizing that intermediate 
(177). A similar carbon sharing has been reported for the growth of two species cultures on 
chlorinated biphenyls or aminonaphthalenesulfonates (1, 51, 97). Nonetheless, collaboration 
between microorganisms has generally been acknowledged when regarding anaerobic metabolism 
and has not, yet, been received the respective attention in aerobic metabolism. Additionally, 
investigations were mainly restricted to above mentioned simple kind of carbon sharing. Feigel et 
al. were among the first to observe synthrophic interaction between community members during the 
aerobic degradation of aminobenzenesulfonate (35). Even though one community member harbors 
all enzymes for mineralization, its growth in monoculture is inhibited by a toxic intermediate, the 
degradation of which is supported by the second community member. Such interactions between 
microorganisms, evidently of high importance under environmental conditions, was neglected, as 
nearly all enrichment to isolate microorganisms for xenobiotic degradation had been performed in 
batch culture, enriching single species with high growth rates. However, growth in continuous 
culture under low substrate concentrations resembles more the actual environmental conditions. 
Nevertheless, it was initially surprising that continuous culture enrichment on a simple carbon 
source like chlorosalicylate resulted in a stable four-membered community.  
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Strain MT1 was assumed to degrade 4-chlorosalicylate via 4-chlorocatechol and protoanemonin as 
intermediates. As MT2, MT3 and MT4 are not capable of growth on 4-chlorosalicylate, but can 
grow in commensal relationship with MT1, it was assumed that they harbor pathways for 
mineralization of metabolites excreted by MT1. 
The analysis by Pelz using 13C-labelled metabolites and isotopic ratio mass spectrometric analysis 
of label enrichment in immunocaptured members of the community revealed a complex pathway 
network of carbon sharing (106). In fact, strain MT3 was rapidly incorporating labeled 
4-chlorocatechol, whereas MT4 was rapidly incorporating labeled protoanemonin. In contrast to the 
assumed identity of protoanemonin as pathway intermediate, MT1 was only very slowly 
incorporating protoanemonin. The metabolic pathway of 4-and 5-chlorosalicylate degradation has 
now been elucidated for Pseudomonas sp. strain MT1 and the results more clearly evidence the 
metabolic flux in the 4-membered community. Figure 23 summarizes probable and demonstrated 
steps of 4-chlorosalicylate degradation in the community.  
  
Cycloisomerization of 3-chloromuconate and hydrolysis of 4-chloromuconolactone are the key 
reactions in the degradation of 4- and 5-chlorosalicylate by MT1. During this reaction, 
protoanemonin will be formed by chemical decomposition of 4-chloromuconolactone, a reaction 
not completely avoidable. Pelz et al. demonstrated that MT4 can take up and metabolize significant 
protoanemonin (106), thus indicating that this strain harbors a metabolic activity with 
protoanemonin. Thus, as Pelz indicated, MT4 fulfills its function in detoxifying any protoanemonin 
accumulating in the culture. However, in contrast to previous assumptions, MT4 seems to be the 
only community member capable to do so.  
cis-Dienelactone is formed as a side product by MCI of MT1, and will be formed in higher amounts 
when MCIB is simultaneously expressed. Thus, cis-dienelactone will be formed during 
chlorosalicylate degradation by MT1. Pelz et al. had shown, that 4-chlorocatechol is dominantly 
incorporated by MT3. This rapid incorporation can be due to a functional chlorocatechol pathway in 
this strain, which is also evidenced by a high 4-chlorocatechol transforming activity, indicative for a 
chlorocatechol 1,2-dioxygenase in the consortium, and probably in MT3 (106). If MT3 harbors a 
chlorocatechol pathway it should be capable to metabolize cis-dienelactone.  
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Fig. 23: Modified after Pelz et al. (106). Metabolic pathways in the strain bacterial community. 
Speculated excretion and uptake of metabolites are marked with ?. Thickness of arrows is 
chosen according to assumed importance of the catalytical step. Metabolism of Pseudomonas 
veronii MT4 Achromobacter xylosoxidans MT3 and Empedobacter brevis MT2 are 
hypothetical. TCC, tricarboxylic acid cycle. 
 
In fact, the relative abundance of MT3 in the community (8 %) agrees well with the proportion of 
cis-dienelactone accumulating during growth of MT1 in pure culture or during resting cell 
experiments. In contrast, the amounts of protoanemonin accumulation during pure culture growth or 
during transformation experiments were always slightly lower (4 %) than the relative abundance of 
MT4. However, the fluxes from 3-chloromuconate to maleylacetate, protoanemonin and cis-
dienelactone, within the intact cell of MT1, especially under chemostat conditions, are still 
unknown as they depend on a very fine-tuned interplay of the respective enzymes. However, the 
stable relative abundances of the strains indicate that most of the substrate is metabolized via the 
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novel pathway in MT1 and that similar amounts of leaking side-products are degraded by MT3 and 
MT4. However, it would not be possible to conclude on any detailed fluxes – first of all, because 
the amounts of leaking metabolites are not quantified and, secondly, because the strains might 
invest different amounts of energy for the metabolic break-down by enzyme synthesis or other 
burdens such as synthesis of stress factors. It would be interesting to test whether it was only MT3 
taking up cis-dienelactone with a pulse feed experiment applying 13C-labeled cis-dienelactone.  
 
However, the picture of a simple carbon sharing model based on kinetic properties of the MT1 
enzyme system for transformation of 3-chloromuconate to maleylacetate, protoanemonin and cis-
dienelactone is for sure an oversimplification. First of all, cis-dienelactone will not be freely 
permeable and thus, MT3 would probably need an appropriate transporter system, and secondly, 
chloromuconates and not dienelactones are the known inducers of the chlorocatechol pathway.  
It has been shown, that specifically at higher substrate concentrations, 4-chlorocatechol is leaking 
out of MT1 and that accumulation of 4-chlorocatechol prevents growth. In fact, the ring cleavage of 
4-chlorocatechol by (chloro)catechol 1,2-dioxygenase is crucial for a healthy growth of the bacteria, 
as 4-chlorocatechol was shown to have a MIC-value of 40 – 200 µM and to negatively effect the 
viability of different Ralstonia strains (108).  Pelz et al. speculated that the major function of MT3 
is to protect MT1 from the toxicity that would otherwise occur from the accumulation of 
4-chlorocatechol. Actually, the take up by MT3 of even small amounts of 4-chlorocatechol excreted 
by MT1 under chemostat growth would allow the formation  3-chloromuconate and thus, the 
inducer of the whole chlorocatechol pathway genes.  
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4.8 Outlook 
In the present study a novel metabolic pathway for 4-chlorocatechol degradation was elucidated.  
Extensive work on substrate transformation by the concomitant action of a cycloisomerase and a 
trans-DLH, revealed that the influence of the second enzyme on product formation was not only 
dependent on its relative amount, but that the total protein concentration was also highly important. 
The general  kinetics can be explained by trans-DLH to act on 4-chloromuconolactone as reaction 
intermediate and by 4-chloromuconolactone to decompose spontaneously to form protoanemonin. 
Future experiments should focus on (i) detailed analysis of the influence of trans-DLH on products 
formed by different cycloisomerases to finally obtain a detailed kinetic model on the overall 
reaction, (ii) analyzing in detail kinetic alterations that have occurred in site-directed CatB variants 
of PRS2000. Furthermore, it would now be very interesting to investigate how important this 
pathway is in the environment and how far this pathway is spread among bacteria. Strains isolated 
by growth on 4-fluorobenzoate (137) might be good candidates for harboring the novel pathway as 
well. 
 
As the work was focused on the biochemical characterization (metabolites and enzymes) of the 
pathway, it would be of benefit to explore the genetics of the pathway. Having the gene sequences 
of the key enzymes will not only allow faster screening of bacteria for the novel pathway, but also 
to compare the genes with sequences in the databases and thereby investigating the pathway from 
an evolutionary point of view. Such comparisons will also allow to move forward in the 
identification of crucial amino acid residues determining selectivity of (chloro)muconate 
cycloisomerases. 
  
Increasing accumulation of sequence data, including whole bacterial genomes, open up the door to 
understand enzyme recruitment for catabolic pathways and gene recruitment from different location 
throughout a bacterial genome. Those mechanisms are considered crucial for bacterial adaptation 
and evolution of metabolic networks. Localization of the pathway encoding genes in the MT1 
genome will form a solid basis for discussing recruitment of enzymes of the novel pathway. More 
detailed DNA sequence analysis will allow also to characterize the regulation of this new pathway 
and the manipulation of the pathway. Such manipulation will allow to investigate in more detail the 
collaboration between different community members of the chemostat community. 
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